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Abstract 
 
B cells contribute to chronic allograft deterioration, negatively impacting graft 
survival, and curtailing the lifespan of a resource already in short supply. Given this, 
identifying alloreactive B cells could generate an important target in the battle 
against rejection.  This study described an IgG-detecting ELISPOT used to determine 
if the risk of developing antibody-mediated rejection (AMR) could be predicted pre-
transplantation by in vitro analysis of allospecific B cells. This method failed to 
discriminate accurately B-cell responses to donor antigen. An alternative approach 
used was to detect peripheral HLA-specific B cells. Circulating HLA–A*0201 and –
DQB1*0301 B cells were identified at higher frequency in sensitised patients, and 
this correlated with the level of serum alloantibody. Expression of HLA-DQB1*0301 
B cells were at a higher frequency than HLA-A*0201 B cells in those with serum de 
novo donor-specific antibody (dnDSA). Next, levels of B-cell activating factor (BAFF) 
were investigated. Excess BAFF has been related to rejection
 
and the development 
of DSA. Here elevated serum BAFF, low BAFF-receptor
 
and
 
DSA were all associated 
with deteriorating graft function. In addition intrarenal CD19
+
 cells, BAFF and BAFF-
receptor identified with acute AMR.   
In contrast to a pathogenic role of B cells, a small population may be protective. The 
presence of regulatory B cells, defined by IL-10 production were higher in those 
with stable graft function, and identified with naïve B cells rather than memory B 
cells when compared to those with deteriorating grafts. The CD19
+
CD24
high
CD38
high
 
subset was also elevated in stable patients, and the ability to supress T-cell 
activation and secretion of the Th1 cell pro-inflammatory cytokine, IFN-γ was 
altered as a function of allograft stability. 
These data demonstrated characteristics within the B-cell compartment associated 
with stable graft function. The ability to monitor these cells may have clinical 
implications for predicating the risk of rejection, to dictate immunosuppressive 
therapy and promote allograft survival. 
 
Approved by the Central London Research Ethics Committee (REC1: 07/H0707/10) 
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1.0 Introduction 
 
Renal transplantation is the preferred therapeutic modality to treat end stage renal 
failure (ESRF), improving quality of life, increasing life expectancy and being cost-
effective (Wolfe et al., 1999, Howard et al., 2009). To receive these benefits, every 
transplant must be optimised to maximise long-term allograft survival, not least 
because the demand for organs cannot be satisfied by the supply donated. However, 
despite advances in organ preservation and immunosuppression, rejection is a major 
obstacle governing the success of transplantation. Allograft rejection occurs following 
the transplantation of an organ into a genetically disparate recipient, evoking an 
immune response directed against recognition of alloantigens leading to destruction.   
 
Vast improvements over the past two decades in our understanding of the molecular 
mechanisms of rejection, together with immunosuppression management and 
immunological assessment of a recipient–donor pairing, have contributed towards 
attaining excellent short-term allograft survival; surpassing 90% during the first-year. 
However, in the long-term this impact is not conveyed as demonstrated by data 
reporting allograft half-life survival. In the United States, a deceased-donor transplant 
survived 6.6 years in 1989; in 1995, 8 years and by 2005, 8.8 years. Following a living-
donor transplant, the change was minimal from 11.4 years in 1989 to only 11.9 years in 
2005 (Lamb et al., 2011). These data reflect relative stagnation in attrition rate beyond 
the first-year of transplant. 
 
In the early period post-transplant, T cells are the principal mediators of acute 
rejection. This immune response follows recognition of donor alloantigens presented 
to recipient T cells most commonly by donor antigen-presenting cells (APCs). Donor 
APCs can travel from the graft to lymphoid organs rich in T cells, presenting alloantigen 
and allowing differentiation of T cells into various subsets. These return to invade and 
destroy the graft, producing inflammatory cytokines to attract further T cells, 
ultimately leading to necrosis, basement-membrane rupture and tubular atrophy 
(Robertson and Kirby, 2003, Bonsib et al., 2000). Current therapies target the initial 
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stages of T-cell activation, and these strategies successfully control acute T-cell-
mediated rejection. 
 
In the long-term, allografts fail due to a combination of immunological and non-
immunological factors. The latter include delayed graft function, prolonged cold 
ischaemia time, inadequate immunosuppression, recurrence of disease, infection and 
complications due to pre-existing donor-related factors. Thus there is complexity 
beyond preventing initial rejection and the potential for effective intervention can be 
limited. Therefore targeting the immunological response, specifically HLA antibody 
directed against the allograft, may hold the most effective strategy towards improving 
allograft longevity. 
 
B cells produce antibody and their contribution as important mediators in humoral 
allograft rejection is well established. Specifically, the presence of B cells specific for 
donor HLA expressed on the allograft can cause immediate or hyperacute antibody-
mediated rejection (AMR). The deposition of anti-HLA antibodies on allograft 
endothelium activates the complement pathway within the graft, causing endothelial 
necrosis, platelet deposition, local coagulation and ultimate graft loss (Colvin, 2007). 
Accordingly, technology affording their detection has greatly improved and has led to 
avoidance of high-risk situations. Post-transplantation, the detection of HLA antibodies 
formed against the allograft are incontrovertibly associated with poorer long-term 
graft survival (Hidalgo et al., 2009, Loupy et al., 2012, Einecke et al., 2009, Cornell et 
al., 2008).  
 
A limitation in defining sensitisation status through analysis of patient serum is that 
this reflects plasma cells actively secreting antibody and not the B-cell compartment as 
a whole. This is particularly relevant in the case of acute antibody-mediated rejection 
(AAMR). Although not as immediate as hyperacute rejection, AAMR can cause major 
graft dysfunction by the rapid generation of complement-fixing antibodies (Terasaki, 
2003). This response is most commonly engendered by previous exposure to HLA 
expressed by the allograft. Since, the presence of donor-specific HLA antibodies (DSA) 
pre-transplantation are, in general, a contraindication to proceeding with the 
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transplant, AAMR may be attributed to activation of a secondary immune response as 
a result of memory B cells. Equally, in chronic AMR (CAMR), undetected pre-existing 
DSA or those developed in the post-transplantation period are implicated in antibody-
mediated allograft damage as demonstrated by histological evidence (Colvin, 2007). 
Thus more detailed characterisation of B cells beyond their secreted products could 
provide valuable information to anticipate graft dysfunction, aid prediction of both 
acute and chronic rejection, and allow treatment prior to the development of 
irreversible graft lesions. 
 
The questions central to this thesis relate to the ability to detect and characterise B 
cells in renal transplant recipients with differing levels of allograft stability. This 
introduction provides an overview of the origin, development and functions of B cells, 
with emphasis on the role of B-cell activating factor (BAFF) and regulatory B cells in the 
context of renal transplantation. The introduction concludes by describing the 
principle aim and objectives of this thesis. 
 
1.1 The origin and development of B cells 
 
B cells provide both specific and long-term immunity and are a critical component of 
the adaptive immune response. First, in response to antigen, B cells undergo a series of 
genetic rearrangements generating high-affinity antibody-producing plasma cells. 
Second, immunological memory which imparts long-lived immune protection against a 
vast range of foreign antigens is generated. To achieve this requires co-operation with 
T cells. Following capture of antigen, B cells process and present antigenic peptides to 
CD4
+
 T cells. This interaction not only provides B cells with the help they require for 
activation into plasma or memory B cells but also drives CD4
+
 T-cell activation. This 
third role as antigen-presenting cells (APCs) is important during the development of an 
immune response. 
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In detail, during embryonic life B cells originate in the bone marrow from pluripotent 
haematopoietic stem cells seeded by the developing foetal liver (Muller et al., 1994). 
Early B-cell development occurs with differentiation of a pluripotent haematopoietic 
precursor to a multipotent progenitor cell expressing a tyrosine kinase receptor, FLT3 
(Hardy et al., 2007). This binds to its ligand on stromal cells allowing the next 
differentiation stage giving rise to the common lymphocyte progenitor; this includes T- 
and B-cell progenitors. With regard to B cells, the pro-B-cell is formed first and is 
characterised by the cell surface marker CD22. The generation of antibody diversity 
begins at this pro-B-cell stage with functional rearrangement of gene segments 
comprising variable (V), diversity (D), joining (J) of the heavy (H) chain (VH, DH, JH) 
together with V & J of the light (L) chain (VL, JL). The H chain is part of the core antibody 
structure. Five types of H chain exist: γ, μ, δ, α and ε which confer the class of antibody 
as IgG, IgM, IgD, IgA and IgE. Antibodies have two identical H chains containing several 
constant domains and a single variable domain and two L chains containing one 
variable domain and one constant domain. The antigen-binding site of an antibody 
contains the variable region of one H chain and one L chain.  There are three stages in 
the H and L chain gene rearrangements that depend on two enzymes; recombinase-
activating gene (RAG) 1 and RAG2. First, pro-B cells rearrange the D & J segments of 
the H chain. Second, joining the rearranged DJ segment with an upstream V region. 
This requires the stromal cell-derived cytokine, IL-7 (Milne and Paige, 2006). The third 
is the functional rearrangement of VDJ leading to μ-H chain at the cell surface to form 
part of the pre-B-cell receptor (BCR). The pre-BCR must be functional for B cells to 
develop further and enter the pre-B-cell stage defined by expression of CD19 and CD20 
at the pre-B-cell stage. 
  
The immature B-cell stage is completed by expression of IgM on the cell surface, 
defined by the μ-H chain, and is followed by antigen-specific negative selection. B cells 
reacting with self-antigens present in the bone marrow are eliminated by central 
tolerance mechanisms which include anergy (Hartley et al., 1991), clonal deletion 
(Nemazee and Burki, 1989) and receptor-editing (Gay et al., 1993). Only a small 
percentage, approximately 5%, of the B-cell pool will survive past the first selection 
stage and enter the periphery (Anolik, 2013). These immature B cells, now 
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independent of stromal factors migrate from the bone marrow, via the blood stream 
to the secondary lymphoid organs and begin to express IgD, defined by δ-H chain along 
with IgM and CD21. 
 
Transitional B cells are the intermediate stage between immature B cells derived from 
the bone marrow to mature B cells in the periphery. In mice, immature B cells 
differentiate to transitional type 1 (T1), type 2 (T2) (Loder et al., 1999) and/or type 3 
(T3) (Allman et al., 2004). The classification is dependent on expression of IgD and 
CD21 (Carsetti et al., 1995). T1 cells are found in the bone marrow, spleen and blood. 
T2 are thought to be derived from T1 and are present in the spleen. T3 are proposed as 
an anergic splenic population failing to reach maturity (Merrell et al., 2006, Srivastava 
et al., 2005). T1 and T2 cells progress to become a mature follicular or marginal zone 
(MZ) B-cell (Allman et al., 2004). The fate of this occurs at the T1 or T2 stage and is 
dependent on the nature of the BCR (Pillai et al., 2005, Meyer-Bahlburg et al., 2008).  
 
The BCR consists of a surface antigen-binding immunoglobulin plus Igα (CD79a) and Igβ 
(CD79b) chains; B cells deficient in the Igα cytoplasmic tail are unable to develop 
beyond the T1 stage (Torres et al., 1996). In addition, signalling via B-cell activating 
factor (BAFF) to BAFF receptor (BAFF-R) regulates B-cell expansion and survival and is 
proposed to control development of T1 to T2 to mature B cells. Their critical role is 
demonstrated by their deficiency in mice that are unable to develop beyond T1 cells 
and lack both T2 and mature B cells (Schiemann et al., 2001, Mackay et al., 2003).  
 
Both follicular and MZ B cells represent mature naïve populations with differing 
functions. Follicular B cells generate a conventional T-cell-dependent response and MZ 
B cells react to T-cell independent antigens, contributing to an innate response; these 
routes of B-cell response are described in detail in the next section, ‘The B-cell 
response to antigen’.  
 
In humans, B-cell maturation upon exit from the bone marrow is less understood. 
Transitional B cells have been identified as early emigrant cells previously selected for 
self-tolerance (Sims et al., 2005). Evidence from studies of autoimmunity indicates a 
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check point is lost at this stage in patients with systemic lupus erythematosus (SLE) 
where elevated levels of immature B cells, both polyspecific and autoreactive cells are 
present within the circulating B-cell compartment having failed deletion (Yurasov et 
al., 2005, Meffre and Wardemann, 2008). Expansion of transitional cells, identified 
through high expression of CD24 and CD38, are also reported in infection and more 
recently in transplantation (Blair et al., 2010, Sims et al., 2005, Das et al., 2012, Newell 
et al., 2010). Moreover, in vitro these cells are capable of producing IL-10, mediating 
immune suppression of T cells (Blair et al., 2010). The regulatory capacity identified in 
the transitional B-cell subset has important implications for immune competence and 
tolerance and accordingly there is active interest in further characterising these cells in 
humans. This is discussed in more detail under the section ‘Regulatory B cells’.  
 
Transitional B cells that survive selection to avoid auto-reactivity develop into naïve B 
cells (Palanichamy et al., 2009, Suryani et al., 2010). It is not clear in humans whether, 
as with mice, MZ B cells directly develop from transitional cells. Evidence suggests 
murine MZ B cells develop as a separate lineage of naïve B cells from those that occupy 
the follicles (Vossenkamper et al., 2012). However, in humans, MZ B cells have features 
of memory B cells and somatic mutations indicative of involvement in a germinal 
centre (GC) response (Weill et al., 2009). The GC reaction is described in more detail in 
the next section. 
 
1.1.1 Mature B cells – The B-cell response to antigen 
 
The further maturity of B cells occurs following encounter with antigen. Unlike T cells, 
they can recognise antigen in a native or unprocessed form as it circulates through B-
cell-rich areas of the secondary lymphoid organs (Tarlinton and Lew, 2007). Antigen 
can also activate B cells by travelling on the cell surface of dendritic cells into follicular 
areas of the lymph nodes or spleen (Qi et al., 2006). The B-cell response is initiated 
following engagement of the BCR by antigen; however the BCR itself has no intrinsic 
signalling capacity and, to transduce signal, must be associated with CD79a and CD79b 
which do. Both have immune-receptor tyrosine-based activation motifs (ITAMs) in 
their cytoplasmic domains (Clark et al., 1992). Phosphorylation of the ITAM tyrosines 
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by src kinases initiates a signalling cascade generating intermediates such as 
phosphatidylinositol-(3-4-5)-triphosphate (PIP3) and phosphatidylinositol-3 kinase 
(PI3K) (Gold et al., 1990). The expression of cell surface receptors, for example CD19, 
can lower the threshold for B-cell activation by augmenting signals through the BCR. 
Moreover, CD19 expresses tyrosine residues on its cytoplasmic domain and following 
phosphorylation can allow binding of other proteins such as PI3K (Carter and Fearon, 
1992). Other pro-activation signals are provided by BAFF (Scholz et al., 2008) and are 
discussed in detail later in this chapter. BCR signalling is also negatively regulated by 
inhibitory cell surface receptors, CD22, CD72 and FcγRIIB, which express immune-
receptor tyrosine-based inhibitory motifs (ITIMs). Ligation of these receptors results in 
phosphorylation of ITIMs and employment of phosphatases such as SHIP, SHP-1 and 
SHP-2 to degrade PIP3 thus terminating activation signalling (Pritchard and Smith, 
2003). The progression of B-cell activation following successful aggregation of the BCR 
can be either T-cell-dependent or T-cell-independent. 
 
1.1.1.1 T-cell-independent B-cell response to antigen 
 
B cells can be induced to produce antibody in the absence of T-cell help, as the second 
activating signal usually delivered by the T-cell can be provided by the antigen itself. 
These antigens are derived from microbial constituents and activate B cells by cross-
linking the BCR, inducing polyclonal activation of B cells regardless of antigen 
specificity.  
 
Two main classes of T-cell-independent (TI) antigens exist and are broadly classified as 
either TI-1 or TI-2. TI-1 antigens are intrinsically mitogenic, inducing polyclonal B-cell 
activation through toll-like receptors (TLRs). TLRs are a class of pattern recognition 
receptors (PRR), which recognise conserved microbial structures such as the bacterial 
polysaccharide, lipopolysaccharide (LPS) or unmethylated single-stranded DNA motifs 
for example, CpG oligonucleotides (Manicassamy and Pulendran, 2009). Many cells of 
the immune system express TLRs and respond to stimulation via TLR agonists, such as 
LPS or CpG. These include dendritic cells, macrophages, mast cells, T cells and B cells 
and non-immune cells, including fibroblasts and epithelial cells. B cells, in particular, 
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express many TLRs, for example, TLR2, TLR3, TLR5, TLR7, TLR9, and can respond to a 
variety of ligands (Barr et al., 2007). The response is to proliferate, secrete antibody 
and cytokines or act as APCs. 
 
TI-2 antigens are not intrinsically mitogenic and are characterised by their repetitive 
polysaccharide structure in the form of glycoproteins, glycolipids or capsules expressed 
on the surface of pathogens such as Streptococcus pneumoniae and Nisseria 
meningitidis (Satterthwaite et al., 1998). With an organised and repetitive form, 
epitopes of TI-2 antigens simultaneously engage and cross-link multiple BCRs to induce 
rapid IgM responses (Dintzis et al., 1983).   
 
1.1.1.2 T-cell-dependent B-cell response to antigen 
 
In response to T-cell-dependent antigen, naïve follicular B cells are activated in the T-
cell-rich extra-follicular areas of secondary lymphoid tissue, including spleen, lymph 
nodes and Peyer’s patches in the gut or tonsil. B-cell activation occurs via two signals, 
the first is delivered through the BCR, and the second, required for proliferation and 
differentiation, is delivered by helper T (Th) cells that recognise the processed 
antigenic peptides, presented in the context of HLA class II molecules, on the B-cell 
surface. In addition, the interaction between CD40 ligand (CD40L) expressed on the 
Th cell and CD40 receptor expressed on the B-cell are essential for efficient activation 
of naïve B cells (Gray et al., 1996, Tarlinton, 2006).  
 
Activated B cells have two destinations; either they migrate to the T-zone: red pulp 
border, marginal sinus-bridging channel and into the red pulp of the spleen to form 
extra-follicular plasmablasts, (MacLennan et al., 2003) or they continue to interact 
with T cells at the T–B border of the spleen or interfollicular region of the lymph node, 
migrate into the follicle and proliferate to form a germinal centre (GC) (Kerfoot et al., 
2011). Evidence suggests the initial response to antigen is dictated by B cells with the 
greatest specificity for antigen; these quickly differentiate into short-lived antibody-
secreting plasma cells whereas those with low affinity encounter the GC reaction (Paus 
et al., 2006). Here B cells undergo rapid proliferation and form B-cell concentrated 
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follicles, the GC. This also contains specialised subsets of cells, follicular helper T (Tfh) 
cells and follicular dendritic cells (FDC). Both are important in maintaining the GC, Tfh 
cells through the secretion of IL-21 and high-level expression of ICOS and CXCR5 
(Vinuesa et al., 2005) and FDC by localising the antigen on their surface within the 
follicles (Tarlinton et al., 2008b). The GC reaction results in clonal expansion, class-
switch recombination (CSR) of the heavy chain, somatic hypermutation (SHM) of VH 
genes and affinity maturation where there is selection of cells carrying a BCR with the 
highest affinity for the antigen. This modification of the BCR achieves greater affinity 
for antigen. The final progeny of B cells can migrate as antibody-secreting plasma cells, 
usually to the bone marrow or leave the GC as a long-lived population of memory B 
cells. These events are summarised in Figure 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Human B-cell development 
B cells originate in the bone marrow, as they progress to maturity, a number of 
differentiation stages occur. First formed is the pro-B cell where generation of antigen 
diversity begins. The pre-B cell stage is defined by possession of a functional BCR and 
expression of CD19 & CD20. Further selection processes occur at the immature B-cell 
stage by central tolerance mechanisms; those which survive enter the periphery as 
transitional B cells. Transitional B cells (T1 & T2) are an intermediate of immature and 
mature B cells. T3 cells may represent an anergic splenic population that fail to mature. 
Transition to maturity occurs following engagement with antigen by the BCR and 
associated signalling pathways. B cells proliferate to form a B-cell rich follicle, the 
germinal centre (GC). The final progeny of B cells can migrate as antibody-secreting 
plasma cells or a long-lived population of memory B cells. 
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1.1.1 The development of humoral immunity 
 
1.1.2.1  Memory B cells  
 
B-cell memory is responsible for providing long-term humoral immunity through both 
long-lived antibody-secreting plasma cells in the bone marrow and memory B cells 
circulating through the lymphatic system, driving the rapid secondary immune 
response. These latter cells do not themselves secrete antibody rather, following re-
exposure to antigen, they can elicit an immune response capable of generating and 
replenishing the plasma cell compartment. In addition, antibody production is of both 
greater magnitude and higher affinity for the antigen than the primary response (Slifka 
and Ahmed, 1998). Their ability to respond rapidly to antigenic re-stimulation can be 
attributed to the precursor frequency of antigen-specific B cells being greater than that 
of antigen-binding naïve cells (McHeyzer-Williams and McHeyzer-Williams, 2005). In 
addition, memory B cells are more optimally placed to encounter antigen at sites of 
antigen drainage (McHeyzer-Williams and McHeyzer-Williams, 2005). They have also 
been located in the splenic marginal zone, mucosal epithelium and next to GC within 
secondary lymphoid organs (Aiba et al., 2010, Ehrhardt et al., 2005). Recently, murine 
memory B cells were located in the lung and draining lymph nodes following influenza 
infection (Onodera et al., 2012). In addition to differential localisation, other subsets of 
memory B cells exist together with the classical IgG-type, identified by expression of 
IgA and IgM, commonly involved in intestinal immune responses (Benckert et al., 2011, 
Pape et al., 2011).  
 
Why an individual B-cell becomes a memory or plasma cell following a GC reaction (or 
vice versa) is not clear. A temporal switch model has been proposed whereby in early 
GC reactions memory cells are produced and conversely in late reactions plasma cells  
are produced (Shlomchik and Weisel, 2012). Evidence in animal models demonstrates 
early failure of the GC has minimal impact on memory but not plasma cell constitution 
(Wang and Carter, 2005, Inamine et al., 2005). Taken together with the uncertainty of 
function roles, differential localisation and subsets of memory B cells, these factors 
may have important implications in disease progression or resistance, and for 
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designing potential therapy to target memory B cells during infection or to diminish 
the alloresponse following transplantation. 
 
1.1.2.2 Plasma cells  
 
Plasma cells predominantly reside in the bone marrow. These cells are terminally 
differentiated and responsible for antibody secretion, although generally short-lived; 
are capable of persisting for many years (DiLillo et al., 2008, Slifka et al., 1998). The 
signals that enable long-term plasma cell survival may be mediated by up-regulation of 
anti-apoptotic molecules such as Bcl2 and Mc11 (Spets et al., 2002, Peperzak et al., 
2013). Mc11, in particular, has been shown to be critical for plasma cell survival. There 
is also dependence on access to specialised niches formed by stromal elements in 
normal and inflamed tissue (Tarlinton et al., 2008a). This migration towards niches is 
reliant on expression of survival factors such as APRIL, IL-6 and CXCL12 (Tarlinton et al., 
2008a, Chu and Berek, 2013). CXCL12 was the first of these to demonstrate function 
during migration: under its influence immature plasma cells migrate into the blood 
stream and enter the bone marrow (Radbruch et al., 2006). Furthermore, in synovial 
tissue from patients with rheumatoid arthritis (RA), infiltrating plasma cells 
consistently express CXCR3, while synovial fibroblasts produce its ligand, CXCL9, 
possibly providing a mechanism for retaining these cells in the inflammatory 
environment (Tsubaki et al., 2005). However, it remains to be determined how plasma 
cell homeostasis is maintained with the continual addition of new specificities without 
any loss of the existing population. 
 
1.1.2.3 Longevity of B-cell memory  
 
The memory response to antigen can be elicited many years after immunisation or 
infection and a number of mechanisms for this are proposed. First, that a population of 
long-lived plasma cells exist or that antigen persists providing constant antigenic 
stimulation (Lanzavecchia and Sallusto, 2009). However, it is unclear how these 
memory cells are maintained in the absence of persistent antigenic stimulus. For 
example, serum antibodies to the vaccinia virus have been detected more than half a 
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century post-vaccination with no further exposure to antigen. In humans, evidence 
suggests memory B cells are maintained through homeostatic proliferation (Bernasconi 
et al., 2002). By measuring memory B-cell responsiveness to polyclonal stimuli in the 
absence of specific antigen, memory cells will generate plasma cells maintaining 
constant serum antibody levels (Lanzavecchia et al., 2006). Alternatively a ‘bystander 
effect’ may exist where memory B cells respond to non-specific T cell signals as a result 
of an immune response to antigen of unrelated specificity (Banchereau et al., 1994).  
However, this hypothesis is undermined by data demonstrating memory B-cell 
proliferation is dependent on antigen specificity (Benson et al., 2009). In summary, the 
mechanism underlying the maintenance of B-cell memory is unclear.  
 
Memory B cells can up-regulate survival molecules such as Bcl2 (Good et al., 2009). In 
addition, BAFF is implicated in maintaining memory B-cell survival as mutational 
studies in a BAFF receptor, TAC1, result in reduced frequency of memory B cells (Salzer 
et al., 2009). The direct contribution of these factors to the overall persistence of 
memory B-cell populations remains to be established. 
 
1.1.3 The B-cell lineage 
 
The process of B-cell development described does not apply to all B cells. In mice, it 
has long been established that two populations exist, B1 and B2 (Kantor and 
Herzenberg, 1993, Montecino-Rodriguez and Dorshkind, 2012). Unlike standard B cells, 
referred to as B2 cells, B1 cells develop during foetal and perinatal life and reside in 
the peritoneal and plural cavities; they are self-renewing and important in the innate 
immune system. Independent of T-cell help, they produce low-affinity, polyreactive, 
IgM antibodies and can be the first cells to respond to antigen (Martin and Kearney, 
2001, Griffin et al., 2011). B1 cells can be identified by differential expression of C5. C5
+
 
cells are classed as B1a and produce broadly reactive IgM. B1b cells lack C5 expression 
and generate long-lasting memory-type IgM response independent of T cells 
(Baumgarth, 2011). 
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Given the location of B1 cells in foetal/neonatal peritoneal and pleural cavities, human 
B1 cells are difficult to isolate and characterise and an equivalent population has yet to 
be identified. C5-expressing human B cells in cord blood are assumed to be the murine 
equivalent (Montecino-Rodriguez and Dorshkind, 2012). Recently, an alternative B1 
cell phenotype, CD20
+
CD27
+
CD43
+
 was postulated to share common features with 
murine B1 cells (Verbinnen et al., 2012). However, more detailed analysis indicated 
this phenotype included pre-plasmablasts since secretion of IgG can be induced, a 
feature which would preclude them from being pure innate B1 type cells (Covens et 
al., 2013). 
 
In contrast to B1 cells, B2 cells develop in the post-natal period in the conventional 
way described in mice and humans. They are continuously replaced throughout life 
from bone marrow precursors. Circulating in the blood and secondary lymphoid 
organs, they can respond to T-dependent and T-independent antigen. A number of 
subsets exist corresponding to the level of activation, maturation and differentiation.  
 
1.1.3.1  Defining human B-cell subsets in peripheral blood 
 
Until the advent of monoclonal antibody technology, descriptions of cellular 
characteristics were very primitive. The ability to identity cell surface receptors, known 
by cluster of differentiation (CD) molecules allowed for detailed examination of B cells, 
indeed all cells and their associated subsets. In 1980, five years after monoclonal 
antibodies were first described (Kohler and Milstein, 1975), Nadler and colleagues 
reported B1, now known as CD20, as the first B-cell-specific surface molecule 
(Stashenko et al., 1980). The introduction of immunophenotyping cells by flow 
cytometry has allowed classification of a number of B-cell subsets based on expression 
of cell surface markers; these include a variety of CD molecules and immunoglobulin 
isotypes. Universal to all B-cell subsets is expression of CD19 and in the peripheral 
blood there are three major populations of circulating B cells; transitional, mature 
naïve and memory B cells, each identifiable through cell surface markers. 
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1.1.3.2 Transitional B cells 
 
Human transitional B cells are found in bone marrow, spleen and peripheral blood and 
were first identified by high expression of CD24 and CD38 (Sims et al., 2005, Cuss et al., 
2006, Carsetti et al., 2004). In the periphery, three populations of CD19
+
 cells can be 
discriminated using CD24 and CD38. The smallest population expresses high levels of 
both CD24 and CD38 and in healthy individuals represents from 2-4% of peripheral B 
cells (Sims et al., 2005, Carsetti, 2004, Marie-Cardine et al., 2008). (Incidentally, in the 
bone marrow this population can comprise up to 50% (Marie-Cardine et al., 2008).) 
Additional analysis of CD27 expression differentiates mature from memory cells: 
CD24
high
CD38
- 
are memory cells and CD24
low
CD38
+ 
are mature naive B cells. CD27 is 
absent on CD24
high
CD38
high 
cells (Carsetti, 2004, Cuss et al., 2006, Tangye et al., 1998). 
 
In contrast to mice, T1 and T2 populations are not as clear and the distinction between 
subsets is rather subjective. Some studies have reserved the brightest expression of 
both CD24 and CD38 for T1 cells (Palanichamy et al., 2009, Vossenkamper et al., 2013).  
 
Recently, CD21 and IgD have also been employed, with high expression of both 
identifying with T2 cells (Suryani et al., 2010). Furthermore, in vitro studies showed 
CD21
high
 T2 cells to be more mature by exhibiting greater proliferation and IgG 
secretion. In addition, analysis of these subsets following hematopoietic stem-cell 
transplantation (HSCT) demonstrated T1 as the primary emigrants from the bone 
marrow, repopulating peripheral blood prior to T2. Significantly higher expression of 
CD21 on T2 cells compared to T1 cells has also been reported in human bone marrow 
samples suggesting differentiation may also occur here (Agrawal et al., 2013). 
 
1.1.3.3 Mature naïve B cells  
 
Naïve B cells reside in lymphoid follicles and represent approximately 60-70% of total B 
cells. They are characterised by co-expressing both IgM
 
and IgD, while having no CD27 
(Weill et al., 2009). As noted above, the CD19
+ 
CD24
low
CD38
+ 
phenotype is also used to 
define mature naïve B cells. 
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 1.1.3.4  Memory B cells  
 
Early investigations determined that memory B cells expressed CD27 defined their 
expression using CD27; this population represents approximately 25% of circulating B 
cells (Maurer et al., 1990, Agematsu et al., 1997). In addition to CD27, the identity of 
IgG
+
 switched memory cells was confirmed by their loss of IgD expression. IgD
-
 cells 
signify the accumulation of somatic mutations in Ig V region genes, a defining feature 
of isotype class-switched memory cells (Tangye and Tarlinton, 2009, Klein et al., 1998). 
Memory B cells expressing IgM and/or IgD phenotypically resemble the classical Ig 
class-switched memory cells but without having undergone isotype switching. The 
introduction of IgD allowed identification of three populations, CD19
+
CD27
-
IgD
+
, naïve 
B cells; CD19
+
CD27
+
IgD
+
, un-switched memory B cells and CD19
+
CD27
+
IgD
-
, memory B 
cells (Agematsu et al., 1997, Maurer et al., 1992). 
 
CD27 and IgD were regarded as unique markers of all memory B cells (Klein et al., 
1998) until minor populations of CD27
-
 memory B cells were identified (Sanz et al., 
2008, Fecteau et al., 2006, Ma et al., 2006, Wei et al., 2007). Further analysis of this 
population revealed IgM expression rather than IgD (Wu et al., 2011). While both 
CD27
+
 and CD27
-
 populations could elicit antibody secretion in response to viral 
antigen (Wirths and Lanzavecchia, 2005), fewer CD27
- 
cells have somatic mutations 
suggesting an heterogeneous memory population (Wu et al., 2011). 
 
Advances in flow cytometry have allowed multiple cell surface and intracellular 
markers to be explored simultaneously, allowing detailed characterisation of cellular 
subsets and importantly enables identification of changes within disease settings. 
 
1.1.4 Effector functions of B cells 
 
B cells are classically associated with antibody production. However, accumulating 
evidence demonstrates their functional versatility with important antibody-
independent functions exerted via secretion of cytokines and antigen presentation to 
either promote or suppress the immune response. 
CHAPTER 1 
35 
1.1.4.1 Cytokine production  
 
B cells are highly plastic in their capacity to produce cytokines, modulating both the 
humoral and cellular immune response. Activated B cells produce a wide range of 
cytokines and are classified as B-effector 1 (Be1) or B-effector 2 (Be2). Analogous to 
Th1 and Th2 cells, Be1 cytokines include pro-inflammatory cytokines targeting effector 
T-cell subsets, while Be2 cells produce cytokines which favour regulatory T-cell (Treg) 
expansion (Harris et al., 2000, Zhong et al., 2007). The production of cytokines can be 
elicited by stimuli such as TLR agonists or Th cells. TLR agonists are particularly potent 
mediators of cytokine secretion and this function is augmented by ligation of CD40 
(Barr et al., 2007).  Moreover, the stimulant can dictate both type and amount of 
cytokine produced. For example, engagement with different TLRs gives rise to different 
cytokines: IL-13 is produced in response TLR1 and TLR2 stimulation, while TLR7 and 
TLR9 engagement induced production of IL-10 (Agrawal and Gupta, 2011). Similarly, 
stimulation with CD40L can drive B cells to produce IL-10 and not lymphotoxin (LT); 
however a combination of CD40L and antigen (anti-immunoglobulin) and B cells 
secrete elevated levels of LT and less IL-10 (Duddy et al., 2007). The level of B-cell 
maturation can also determine cytokine production. For example, both naïve and 
memory B cells produce IL-13 in response to TLR1 and TLR2 ligation; however only 
memory B cells produce IL-6 and TNF-α (Agrawal and Gupta, 2011). Moreover, the 
production of pro-inflammatory cytokines such TNF-α and LT is most prominent from 
memory B cells (Duddy et al., 2007). 
 
In the disease setting, altered capacity of B cells to produce cytokine can be measured 
as an indicator of dysregulation within the immune system. In autoimmunity, B cells 
isolated from patients with muscular sclerosis (MS) and activated with CD40L and TLR9 
showed reduced secretion of IL-10 and elevated levels of LT compared to healthy 
controls (Bar-Or et al., 2010). Similarly, in patients infected with Porphyromonas 
gingivalis, B cells produced large quantities of IL-8 and TNF-α in response to 
stimulation with TLR4, unlike healthy controls who were essentially unresponsive 
(Jagannathan et al., 2009). These studies highlight how the microenvironment during 
disease can alter expression of cytokines – which could have both positive and 
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negative effects. For example, the secretion IL-10 by B cells has a protective or 
suppressive role in autoimmune disease as demonstrated in animal models where 
depletion directly impacted the severity of disease (Mauri et al., 2003, Yanaba et al., 
2009, Mizoguchi et al., 2002, Fillatreau et al., 2002).  
 
IL-10-producing B cells can also induce Treg expansion or suppress Th1 or Th17 
responses (Fillatreau et al., 2008, Zhong et al., 2007). These cells are referred to as 
regulatory B cells (Bregs) and are described in more detail later in this chapter. 
Conversely, cytokine production by B cells could be pathogenic, enhancing disease 
progression. This is evident in CD27
+
 Be1 cells which are elevated in the salivary glands 
of patients with primary Sjögren’s syndrome (Youinou et al., 2007). Similarly, B cells 
stimulating the production of  TNF-α and IFN-γ by CD4
+ 
T cells have been associated 
with development of MS (Duddy et al., 2007, Harp et al., 2010). Furthermore, B cells 
secreting TNF-α and LT could exacerbate inflammatory T-cell responses in MS. 
Importantly, depletion of B cells decreased CD4 and CD8 pro-inflammatory responses 
and also attenuated disease (Bar-Or et al., 2010).  
 
Cytokine-producing B cells are implicated in the formation and maintenance of 
lymphoid tissue.  Within the ectopic lymphoid tissues are B cells producing IFN-γ, IL-6, 
TNF-α and LT (Daridon et al., 2007). Ectopic lymphoid tissues develop at areas of 
inflammation or infection in peripheral, non-lymphoid organs. It is not understood if 
these tissues lead or are produced in response to disease, but B cells contribute to 
their formation as shown by B-cell-deficient mice failing to develop successful tertiary 
lymphoid tissue (Weyand and Goronzy, 2003). Moreover LT derived from B cells was 
important in creating successful lymphoid tissue architecture (Fu et al., 1998). In the 
setting of autoimmunity, B-cell ectopic lymphoid structures have been identified in 
patients with lupus nephritis (Chang et al., 2011). Furthermore, depleting B cells 
altered the lymphoid architecture through elimination of TNF-α- and LT-secreting cells 
(Duddy et al., 2004, Ansel et al., 2000). Similarly, depleting B cells in synovial biopsies 
from patients with RA failed to develop ectopic follicles and reduced autoreactive T 
cells (Takemura et al., 2001). Together these studies suggest cytokine-producing B cells 
contribute to exacerbated disease through maintaining ectopic lymphoid tissues. For 
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therapeutic purposes, a potentially effective strategy would target cytokines involved 
in a pathogenic response while sparing suppressive or regulatory cytokines having a 
positive impact on disease progression. 
 
1.1.4.2 Antigen presentation 
 
In vivo, activated B cells represent the largest population of antigen-presenting cells 
and are particularly efficient due to their specificity and high affinity of the BCR for 
antigen (Balin et al., 2008, Lund and Randall, 2010). In addition, their capacity to 
clonally expand allows them to become the principal APCs during an immune response 
(Tarlinton et al., 2008b). The capability of B cells to act as APCs was first demonstrated 
using EBV-transformed B cells that effectively presented and processed an exogenous 
antigen, tetanus toxoid, resulting in antigen-specific T-cell proliferation (Lombardi et 
al., 1987). Similarly, B cells isolated from healthy donors stimulated with CD40L acted 
as APC to generate antigen-specific CD4
+
 T-cell lines (Lanzavecchia, 1985, Lapointe et 
al., 2003).  
 
The mechanisms for effective antigen presentation are believed to be reliant on 
formation of the immunological synapse following encounter with specific antigen and 
reorganisation of the B-cell membrane (Grakoui et al., 1999). In the immunological 
synapse, BCR and antigen become aggregated and subsequently internalised allowing 
antigen degradation and presentation on the B cell’s surface in association with HLA 
class II molecule to CD4
+ 
T cells (Batista et al., 2001). This establishes a cognate link 
between B and T cells due to the specificity of the antigen presented to the T-cell 
receptor (TCR) (Lanzavecchia, 1985). Activation of T cells by B cells is distinct from 
other APC that bind antigen non-specifically as B cells process and present antigen that 
binds specifically to the BCR therefore the peptides presented will be enriched for the 
specific antigen and facilitate engagement with the T-cell receptor (Clark et al., 2004).  
This cognate interaction provides the T-cell help required for B-cell activation while 
allowing the B-cell to drive T-cell activation. Evidence suggest this can both amplify and 
co-regulate, promoting B- and T-cell clonal expansion and memory (Ron and Sprent, 
1987, Ahmed and Gray, 1996, Shimoda and Koni, 2007, Linton et al., 2000). The 
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importance of this interaction is highlighted by a study of allograft rejection where 
MHC class II-deficient B cells prevented T-cell activation (Crawford et al., 2006). 
Similarly, chimeric mice with defective MHC-class II had prolonged cardiac survival 
(Noorchashm et al., 2006). In patients with MS, memory and naïve B cells had the 
ability to induce CD4
+
 T-cell proliferation to neuro-antigens which was almost absent in 
healthy controls (Harp et al., 2010). In addition, B cells induced IFN-γ secretion by 
autologous CD4
+
 T cells suggesting a contribution in the Th1 response.  
 
These studies show B cells can effectively process and present antigen to T cells, 
priming and initiating effector responses allowing T-cell mediated responses 
independent of antibody. 
 
1.1.5 Summarising B-cell development  
 
The process of B-cell development described begins in primary lymphoid tissue and 
progresses to maturation in secondary lymphoid tissue resulting in a population of 
cells expressing a hugely diverse range of BCRs capable of recognising an enormous 
variety of antigenic specificities. The differentiation of activated B cells into antibody-
secreting cells forms the cellular basis of humoral immunity, providing both specific 
and long-term immunity. In addition, B cells have the inherent apparatus to effectively 
present antigen to T cells, and this coupled with secretion of cytokines can potentially 
exacerbate disease progression. In contrast, a small population of IL-10-producing B 
cells can exert immune suppression. A greater understanding of the B-cell 
compartment as a whole is emerging and will aid in designing strategies of how best to 
abolish or exploit these cells in disease. 
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1.2 The role of BAFF in the immune system 
 
The B-cell activating factor (BAFF), a member of the tumour necrosis factor (TNF) 
superfamily is essential for B-cell selection, differentiation and survival (Batten et al., 
2000, Mackay et al., 2010, Mackay and Schneider, 2009). Also known as TALL-1 (Shu et 
al., 1999), THANK (Mukhopadhyay et al., 1999), BLyS (Moore et al., 1999)and zTNF4 
(Gross et al., 2000), it exists as a homotrimeric type II transmembrane protein until 
proteolytic cleavage by a furin protease releases the soluble cytokine (Moore et al., 
1999, Mackay et al., 1999). Soluble BAFF can remain as a homotrimer or a capsid-like 
assembly of 20 trimers and can bind to one of three receptors: BCMA (B-cell 
maturation antigen), TACI (transmembrane activator) and CAML (calcium-signal 
modulating cyclophilin ligand) and BAFF receptor (BAFF-R), all are predominantly 
expressed on B cells (Mackay and Browning, 2002). 
 
1.2.1 BAFF and its receptors 
 
BAFF is principally expressed by cells of the innate immune system including 
monocytes, macrophages, neutrophils, dendritic cells & follicular dendritic cells 
(Mackay et al., 2003) and to a lesser extent T cells and activated B cells (Mackay and 
Leung, 2006, Chu et al., 2007).  Expression is also described by non-haematopoietic 
cells. Some examples are fibroblast-like synoviocytes in the synovium in patients with 
RA (Alsaleh et al., 2007), astrocytes in patients with MS (Krumbholz et al., 2005) and 
osteoclasts in patients with multiple myeloma (Abe et al., 2006). This suggests possible 
niches exist, promoting the survival and function of B cells and influencing disease 
progression. 
 
The production of BAFF can be stimulated by cytokines such as IFN-γ, IL-10, 
granulocyte colony-stimulating factor (G-CSF) (Mackay et al., 2003) and by 
engagement of TLR4 and TLR9 (Mackay et al., 2003, Boule et al., 2004). 
 
Although BAFF binds all three receptors; there is higher affinity for BAFF-R and TACI 
(Mackay et al., 2003). The expression of these receptors on B cells varies according to 
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the stage of maturation. TACI is expressed on mature B cells such as marginal zone 
(MZ) and B1 cells (Ozcan et al., 2009) and BCMA is restricted to plasmablasts and 
plasma cells (O'Connor et al., 2004).  
 
BAFF-R is the dominant receptor for BAFF and is expressed at low levels by immature B 
cells, increasing as B cells reach maturity such that expression is found on all mature B 
cells with the exception of plasmablasts and plasma cells (Ng et al., 2004, Darce et al., 
2007). In addition, constitutive expression is found on regulatory T cells and is 
upregulated on activated T cells (Mackay and Leung, 2006). BAFF-R has a key role for 
inducing B-cell survival as demonstrated using BAFF-R-, BCMA- and TACI-deficient mice 
to show that BAFF differentiation and survival signal in transitional and mature B cells 
is critically dependent on BAFF-R only (Mackay et al., 2003). 
 
The ligation of BAFF to its receptors activates specific TNF-associated factors (TRAFs) to 
regulate signal transduction in B cells (Figure 1.2). These TRAFs induce the (nuclear 
factor) NF-κB-signalling pathways which have pivotal roles in a range of immune 
responses, (Miller et al., 2006, Morrison et al., 2005) and can also promote regulation 
of Bcl-2 proteins important in cell proliferation and survival (Do et al., 2000). Ligation 
of BAFF with BAFF-R primarily results in activating the non-classical NF-κB2 pathway 
whereas binding BCMA or TACI leads to activation of the classical NF-κB1 pathway. 
This signalling initiates a cascade of events to promote B-cell survival and growth 
(Mackay and Schneider, 2009, Rickert et al., 2011). 
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1.2.2 Biological functions of BAFF and BAFF receptor 
 
B-cell survival is dependent on both the nature of BCR engagement and the availability 
of cytokines, namely BAFF (Anderson et al., 2007, Goodnow et al., 2005). Firstly, 
differentiation of B cells from immature to mature or MZ B cells requires a functional 
BCR consisting of a surface immunoglobulin molecule plus Igα and Igβ chains. In a 
murine model, B cells are unable to develop beyond the immature stage following 
deletion of the Igβ cytoplasmic tail (Reichlin et al., 2001). Secondly, signalling via BAFF 
is required, as its absence is associated with almost complete failure to proceed to 
maturity (Schiemann et al., 2001, Gross et al., 2001). It is now well established that 
maturation of transitional B cells into mature B cells is critically dependent on BAFF 
Figure 1.2  BAFF signalling through BAFF-receptor mediates B-cell growth 
and survival 
B-cell activating factor (BAFF) is predominantly produced by innate immune cells 
such as macrophages, monocytes, neutrophils, dendritic cells, and follicular dendritic 
cells. BAFF is proteolytically cleaved at the cell surface to produce soluble cytokines 
which exist in the common trimeric form of TNF-family ligands. Upon binding to 
BAFF-receptor (BAFF-R), TNF receptor-associated factors (TRAFs) are recruited 
resulting in the activation of the non-classical NF-κB2 pathway promoting B-cell 
maturation and survival.  
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(Waldschmidt and Noelle, 2001) (Kalled, 2006, Woodland et al., 2006). In a murine 
model, deficiency of BAFF and B cells fail to mature beyond the T1 stage to B2 or MZ B 
cells (Mackay et al., 2003). However, B1 and memory cells remain unaffected (Benson 
et al., 2008). In addition, BAFF-R is necessary to support survival signals as deletion 
results in the loss of mature B cells (Shulga-Morskaya et al., 2004).  
 
There is direct interplay between BAFF/BAFF-R signalling and the BCR directly 
influencing B-cell maturation and survival. When BAFF is limited, ligation of the BCR by 
antigen results in anergy and reduced survival of immature transitional B cells (Mackay 
et al., 2010). Equally, during excessive production of BAFF, improper B cell maturation 
of splenic B cells occurs, affecting transitional T2 B cells, MZ B cells and a vastly 
expanded B-cell compartment (Gross et al., 2000). Furthermore, recombinant BAFF 
can induce survival and maturation of immature B cells (Batten et al., 2000, Rolink et 
al., 2002).  
 
In addition to promoting B-cell survival, BAFF is also implicated in inducing protein 
synthesis, cell growth and glycolysis through activating a protein kinase pathway, 
mTORC1 (mammalian target of rapamycin complex 1). Cellular growth and survival 
effects of BAFF on B cells are mediated by the kinases, mTOR and PIM2, as studies 
which inactivated either kinase rendered B cells unable to respond by either survival or 
growth (Woodland et al., 2008).  
 
BAFF also has a speculated role in regulating T cell immunity. In vitro studies show 
BAFF can deliver co-stimulation to T cells (Huard et al., 2001) and, in association with 
BAFF-R, induce proliferation of suboptimally stimulated T cells (Ng et al., 2004). 
Furthermore, blocking secretion of BAFF by dendritic cells can inhibit T-cell activation. 
(Huard et al., 2004).  
 
Collectively there is clear demonstration in animal models that signalling via BAFF has 
an essential role in survival of immature B cells and complete B-cell maturation; these 
observations are yet to be fully extrapolated to humans. 
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1.2.3 The role of BAFF and disease 
 
Given that central role of BAFF in controlling B-cell survival, it has been implicated in 
both autoimmunity and tolerance. In murine models of autoimmunity, transgenic-
BAFF mice have increased frequency of B cells, high levels of serum BAFF and develop 
SLE-type features (Mackay et al., 1999, Khare et al., 2000, Gross et al., 2000). The 
development of this lupus-like disease was T-cell-independent resulting in chronic 
activation and promotion of low-affinity self-reactive B cells (Groom et al., 2007). In 
addition, the progression of arthritis was supressed in mice deficient in BAFF (Gross et 
al., 2001). In humans, excessive BAFF production measured in sera is associated with 
disease activity in patients with SLE, RA and Sjörgen’s syndrome (Groom et al., 2002, 
Mackay et al., 2003, Sellam et al., 2011). 
 
During infection, elevated serum BAFF levels are described in the context of bacterial, 
viral and parasitic infections (Vincent et al., 2013). Moreover, levels of BAFF can 
correlate with disease progression in HIV & hepatitis C infection and acute malaria 
(Rodriguez et al., 2003, Sene et al., 2007, Nduati et al., 2011). 
 
During viral infection, increased BAFF is dependent on IFN and monocytes can release 
BAFF in response to IFN treatment (Nardelli et al., 2001). HIV-infected patients treated 
with IFN therapy in conjunction with anti-retroviral agents demonstrated both higher 
titres and broader specificity of anti-HIV antibodies and increased serum BAFF (Adalid-
Peralta et al., 2008). Similarly in bacterial infection, patients with active pulmonary 
tuberculosis had both elevated BAFF and IFN levels (Liu et al., 2012). It remains to be 
established if heightened BAFF expression is a direct effect of infection by BAFF-
producing cells or merely a bystander effect of inflammation. 
 
In cancer, BAFF may contribute to oncogenesis in both solid and haematological 
tumours (Vincent et al., 2013). Some examples of increased serum BAFF levels are 
seen in non-Hodgkin’s lymphoma (Briones et al., 2002) oral cavity cancers (Jablonska 
et al., 2011) and multiple  myeloma (Fragioudaki et al., 2012). Elevated serum BAFF 
was also noted in non-lymphoid epithelial cells of breast cancer, suggesting a wider 
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role of activity (Pelekanou et al., 2008). In contrast, epithelial cell-derived BAFF in 
prostate cancer has shown to be protective; limiting tumour survival (Di Carlo et al., 
2009). This suggests further understanding of BAFF in disease dynamics is required, in 
particular assessing BAFF-R phenotype, as this could have important implications 
toward the rationale of targeting BAFF as a therapeutic strategy. 
 
1.2.4 The presence of BAFF following transplantation 
 
B cells are recognised to contribute towards the process of acute and chronic allograft 
rejection, primarily through the production of alloantibody. The recent identification of 
BAFF in solid organ transplantation has been met with some interest. In murine 
models, BAFF-deficient mice demonstrated prolonged cardiac allograft survival, 
dependent on BAFF-R rather than BCMA or TACI (Ye et al., 2004). In addition, blocking 
BAFF with monoclonal antibodies increased survival in MHC-disparate islet allografts 
(Parsons et al., 2012). 
 
To date, human studies have predominantly assessed BAFF in patient sera and have 
associated heightened expression with negative outcome in both stem cell 
(Sarantopoulos et al., 2009) and renal transplantation (Xu et al., 2009a, Zarkhin et al., 
2009, Pahl et al., 2010). Firstly, in allogeneic hematopoietic stem cell transplantation 
(HSCT) elevated BAFF levels are associated with chronic graft versus host disease 
(GvHD). Focusing on renal transplant recipients, higher levels of surface BAFF on CD4 
and CD8 T cells has been identified with abnormal function five years post-transplant 
(Xu et al., 2009a). Similarly, rejecting patients had elevated serum BAFF which 
correlated with increased incidence of HLA class I donor-specific antibodies (DSA) and 
decreased clearance of creatinine (Zarkhin et al., 2009). Furthermore patients with 
ESRF have elevated serum BAFF levels. Here, expression of BAFF-R was also assessed 
and found to be significantly reduced on transitional B cells. (Pahl et al., 2010).  
 
Elevated BAFF levels are linked with antibody-mediated rejection (AMR), in particular 
following induction therapy with alemtuzumab, an anti-CD52 monoclonal antibody 
targeting T and B cells but more profoundly T cells. B cells can recover beyond baseline 
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levels within one year whereas T cells can take three years to achieve even half the 
baseline level (Bloom et al., 2006). Patients treated with alemtuzumab in the absence 
of calcineurin-inhibitors have increased frequency of AMR and DSA (Pascual et al., 
2008, Cai et al., 2004). Moreover, patients have heightened expression of BAFF (Bloom 
et al., 2009). Together, these studies suggest excessive production of BAFF may create 
a dysregulated environment for B cells, leading to the activation and expansion of 
alloreactive B cells.  
 
Recently, a cohort of patients with stable graft function at enrolment was assessed for 
the expression of BAFF-R transcripts and it was found that those who developed graft 
dysfunction had elevated levels. Furthermore, high level of serum BAFF could predict 
development of DSA, translating to a 38.3% risk compared to 10.7% in patients with 
low serum BAFF (Thibault-Espitia et al., 2012). A similar study measured serum BAFF 
levels in patients undergoing HLA-incompatible renal transplantation and associated 
elevated serum BAFF with increased risk of developing AMR (Banham et al., 2013b).  
Together these studies indicate the potential to measure serum levels of BAFF during 
the post-transplant period to provide an indication, perhaps earlier than a rise in 
serum creatinine, of graft dysfunction. 
 
A more detailed approach to identify BAFF and BAFF-R involvement in renal injury is 
direct localisation by immunohistochemistry within the kidney. This has previously 
been shown in graft loss biopsies from those with acute rejection and interstitial 
fibrosis/tubular atrophy where BAFF stained strongly in the perinephric tubular 
epithelial cell cytoplasm and cell membrane but was absent or weak in protocol biopsy 
sections
 
(Xu et al., 2009a). Furthermore there was correlation between intensity of 
expression for BAFF, C4d and IgG, although IgG was with weaker intensity (Xu et al., 
2009b). A study of chronically rejecting patients found BAFF was overexpressed in 
serum and by gene analysis and the source within the tissue was inflammatory cells 
infiltrating the graft (Thaunat et al., 2008). To date, these are the only two published 
data sets concerning renal transplantation; however intrarenal inflammation is a 
common feature of lupus nephritis and BAFF has been identified within renal tissue in 
this disease setting. Here both BAFF and BAFF-R accumulated in interstitial 
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inflammatory cells and BAFF-R was restricted to a small population of cells, consistent 
with B cells
 
(Neusser et al., 2011). Similarly, BAFF was abundantly expressed in the 
renal interstitium and associated with intrarenal B cells. Furthermore there was 
significant correlation between intrarenal B cells and the level of renal function (Sun et 
al., 2013). Together these studies demonstrate that, in rejecting allografts and lupus 
nephritis, BAFF can be localised within renal tissue to areas of infiltrating inflammatory 
cells and correlate with clinical parameters, implicating BAFF in the pathogenesis of 
disease and as a potential target for therapeutic intervention. 
 
1.2.5 BAFF as a therapeutic target in renal transplantation 
 
The importance of BAFF in B-cell biology suggests it as an interesting therapeutic 
target. Accordingly, an anti-BAFF human monoclonal antibody, belimumab, has been 
developed and approved for treatment in SLE by the USA Food and Drug 
Administration (FDA) (Vincent et al., 2013). However, due to cost-per-quality-adjusted 
life year, it has not been approved for use in the UK by The National Institute for 
Health and Care Excellence (NICE). In the USA, belimumab has been used in a Phase II 
trial studying desensitisation in renal transplant patients (ClinicalTrials.gov identifier: 
NCT01025193). However, the trial was terminated for failure to reach the primary 
outcome measures in effectively decreasing antibody levels and permitting 
transplantation. In the UK, a Phase II trial is currently approved but not yet recruiting 
to study the effect of belimumab in preventing rejection post-transplant 
(ClinicalTrials.gov identifier: NCT01536379). 
 
In renal transplantation, the optimal time to target B cells may be at the time of 
transplant, as ‘induction therapy’. Early targeting of the B-cell compartment is 
proposed to be beneficial, coinciding with the period of intense B-cell selection, as 
during this time three quarters of developing B cells alter their specificity through 
receptor editing or deletion (Cornall et al., 1995, Pelanda and Torres, 2006). In a 
murine model, humoral transplant tolerance was acquired following ablative therapy 
whereby B cells with specificity for self-antigen were supressed from migrating to the 
follicle and developing into mature B cells resulting in clonal deletion of alloreactive 
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specificities (Parsons et al., 2011). Therefore early shaping of the repertoire could 
prevent production and development of alloantibody in the months or years post-
transplant (Chhabra et al., 2013). However, employing rituximab, an anti-CD20 
therapy, at induction did not produce a favourable outcome and was implicated in an 
increased rate of acute rejection which included both cellular and humoral responses 
(Knechtle et al., 2009, Knechtle et al., 2003, Clatworthy et al., 2009). This may be 
attributed to the deletion of regulatory B cells; this is described in the next section. 
 
An alternative is to target BAFF in conjunction with anti-CD20 monoclonal antibody. In 
a murine model, blocking BAFF signalling increased the efficiency of anti-CD20 
monoclonal antibody by decreasing MZ and follicular B cells (Gong et al., 2005). 
Combining anti-BAFF antibody and B cell depletion was employed in NOD mice. This 
strategy showed delayed repopulation of autoreactive B cells and anti-islet 
autoantibody levels were reduced (Zekavat et al., 2008). 
 
This is yet to be applied to human studies. However, targeting BAFF in transplantation 
has a number of issues: first it is unlikely to be useful as an induction therapy due to 
the time taken to be effective; second, it is unlikely to be useful for sensitised patients 
as memory B-cell activation is independent of BAFF signalling. Therefore, the most 
likely scenario for the interruption of the BAFF pathway is in conjunction with B cell-
depleting therapy to deplete the recovering B-cell population of precursor B cells 
which contain alloreactive cells, thus preventing an alloresponse against the graft in 
the future.  
 
1.2.6 Summarising the role of BAFF in the immune system  
 
BAFF has a pivotal role in B-cell development and survival. Increasing evidence, in a 
range of pathologies, identifies an increased level of BAFF with disease activity. 
However it remains to be determined if there is a direct role in generating the 
manifestations of diseases or it is merely a marker of chronic inflammation. In the 
post-transplant setting, elevated BAFF levels are associated with rejecting allografts 
and its co-existence with alloantibody is suggestive of its making a contribution to 
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humoral rejection. Accordingly, it is a potential target for therapeutic intervention to 
enhance efficacy of B-cell immunotherapy by affecting the composition of the B cell 
compartment, impairing the ability to mount an alloresponse. 
 
 
1.3 Regulatory B cells 
 
The activities of B cells described place them as pathological mediators during an 
immune response; in contrast, a distinct population exists
 
to promote immune 
suppression. The notion that B cells could exert regulation was proposed over forty 
years ago by Morris and Moller (Morris and Moller, 1968) demonstrating murine B 
cells from immunised donors could produce antibodies which, upon antigenic 
stimulation, suppressed primary immune responses. At a similar time a specific T cell 
population was identified to negatively regulate, as opposed to augmenting an 
immune response, (Gershon and Kondo, 1970) prompting others to investigate if a 
population comparable to the negative feedback system seen in T cells exists in B cells. 
The first indication emerged through adoptive transfer studies where splenocytes 
depleted of B cells were unable to inhibit delayed-type hypersensitivity reactions (Katz 
et al., 1974). Evidence followed that suppression was independent of antibody. Here 
mice immunised with sheep erythrocytes induced the development of antigen-specific 
suppressive T cells (Shimamura et al., 1982). Interest in these cells did not remerge for 
some time, until a demonstration using the murine model of MS deficient of B cells, 
experimental autoimmune encephalomyelitis (EAE), was exacerbated and these mice 
failed to undergo spontaneous remission unlike their wild-type counterparts (Wolf et 
al., 1996). Similar observations followed in animal models of inflammatory bowel 
disease (Mizoguchi et al., 2002) and RA (Mauri et al., 2003).  
 
These studies provided evidence of B-cell-mediated immune suppression independent 
of antibody. This protection is now attributed to B cells producing the anti-
inflammatory cytokine, IL-10. The central role of this cytokine has been confirmed in 
animal models where manipulation directly impacted severity of disease (Mauri et al., 
2003, Yanaba et al., 2009, Mizoguchi et al., 2002, Fillatreau et al., 2002).  
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1.3.1 Regulatory B cell phenotypes in mouse and man 
 
Regulatory B cells do not have a unique set of cell surface markers or a defined 
transcription factor related to their activation and function in mouse or man. In murine 
models, a number of distinct subsets are described to exert protective capacity 
including: B10 cells, CD19
high
CD5
+
CD1d
high 
(Yanaba et al., 2008); transitional 2 marginal 
zone precursor (T2-MZP) cells, which are CD21
high
CD23
high
CD1d
high
 (Evans et al., 2007); 
CD1d
high
 B1b cells, which are CD5
-
B220
low
CD11b
+
IgM
+
CD1d
high
 (Mizoguchi et al., 2002); 
and CD1d
high
 Tim-1
+
 CD5
+ 
(Ding et al., 2011). Prominent among them are B10 cells and 
T2-MZP cells. B10 cells are a rare splenic population that produce, and are the 
predominant B-cell source of IL-10 following stimulation with LPS. In vivo adoptive 
transfer reduced inflammation during contact-hypersensitivity and EAE (Matsushita et 
al., 2010, Yanaba et al., 2008).  
 
CD21
high
CD23
high
CD1d
high
 T2-MZP cells identified in the collagen-induced arthritis (CIA) 
model produce IL-10 in response to CD40 stimulation. Similar to B10 cells, adoptive 
transfer could prevent development of arthritis in syngeneic recipient mice (Evans et 
al., 2007). This phenotype has also been identified in a murine model of lupus-like 
disease: these MRL/lpr mice expand in response to agonistic CD40 monoclonal 
antibody and produce IL-10 (Blair et al., 2009). Importantly their suppressive capacity 
was investigated and provides evidence that both in vitro and in vivo it is mediated by 
both IL-10 and cell-cell contact with CD4
+
 T cells (Mauri et al., 2003, Mizoguchi et al., 
2002).  
 
In human peripheral blood, only relatively recently was their existence demonstrated 
in helminth-infected MS patients as a distinct population of CD1d
+
 cells producing high 
levels of IL-10 (Correale et al., 2008). Since then others have sought to identify and 
correlate expression in disease settings. However, direct comparisons between studies 
are difficult due to the lack of a unique phenotype, and the additional challenge of 
their low frequency, further impacted by immunosuppression. In peripheral blood of 
normal healthy individuals, IL-10-producing B cells are found to represent <1% (Iwata 
et al., 2011) with approximately 60% expressing high levels of CD24 and CD38 
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(Kalampokis et al., 2013). An emerging pattern is found of  human IL-10-producing B 
cells being enriched within this immature transitional B-cell subset with growing 
evidence to support their suppressive role (Blair et al., Flores-Borja et al., 2013, Newell 
et al., 2010, Bouaziz et al., 2010). This includes the ability to inhibit production of Th1 
cytokines, IFN-γ and TNF-α (Blair et al., 2010) and maintain Tregs (Flores-Borja et al., 
2013).  
 
Of note are two further phenotypes exhibiting regulatory capacity. First, a population 
of IL-10-producing B cells to parallel murine B10 cells. In contrast to mice, C5
+
 cells are 
not the main source of IL-10-producing cells in humans. Although C5 is expressed at 
high levels in the foetal spleen (Antin et al., 1986), it is significantly reduced in cord 
blood with less than 2% secreting IL-10. In peripheral blood they have been identified 
within the CD24
high
CD27
+ 
subset (Iwata et al., 2011). However, functional studies 
revealed that suppressive capacity was not confined to this subset, as both 
CD24
high
CD27
+ 
and CD24
low
CD27
- 
populations inhibited production of IFN-γ by Th1 cells, 
independently of IL-10. In contrast, the IL-10-producing CD24
high
CD27
+
 subset inhibited 
TNF-α production by monocytes.  
 
Second is a B-cell subset expressing high levels of CD25 and secreting high levels of IL-
10 (Amu et al., 2007, Brisslert et al., 2006). This phenotype was depressed in patients 
with active ANCA-related vasculitis compared to those in remission (Eriksson et al., 
2010). A more detailed CD25
high
 Breg subset, CD25
high
CD27
high
CD86
high
 CD1d
high
IL-
10
high
TGF-β
high 
cells has recently been described in healthy controls to suppress CD4
+
 T 
cell proliferation and stimulate an increase in Tregs (Kessel et al., 2012).  
 
Together these studies show a population of IL-10-producing B cells exists in humans, 
but there remains no uniformity in the assignment of a unique phenotype to fully 
characterise or define functionality.  
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1.3.2 Activation of regulatory B cells 
 
Activation of B cells with regulatory function was first described following induction of 
EAE and CIA, where production of IL-10 was antigen-specific, dependent on both 
ligation of the BCR by antigen and CD40 by CD40L (Fillatreau et al., 2002, Mauri et al., 
2003). CD40L belongs to the TNF-family and is expressed on T cells, crosslinking CD40 
on B cells, inducing their maturation and development (Banchereau et al., 1994). A 
number of studies detail CD40 binding with its ligand as essential for activation of 
Bregs. For example, CD40-deficent mice suffer more severe EAE coupled with elevated 
Th1 and Th17 responses (Mizoguchi et al., 2000). In the murine model of lupus, 
administering anti-CD40 antibody could correct the deficit in number of Bregs and 
delay progression of disease (Blair et al., 2009). Similarly, anti-CD40 treatment 
prevented development of arthritis by promoting IL-10 production rather than a Th1 
cell response (Mauri et al., 2000). 
 
To activate IL-10 production by effector and memory B cells stimulation via the BCR 
and CD40 are sufficient, but in naïve B cells they depend on additional signalling 
through TLRs (Fillatreau et al., 2002).  TLR agonists are the strongest stimuli for 
inducing IL-10 secretion by B cells (Barr et al., 2007). Those most commonly employed 
are lipopolysaccharide (LPS) from Gram-positive bacteria or CpG-containing 
oligonucleotides that mimic bacterial DNA. The requirement for TLR signalling has 
been explored in animal models of disease. In mice, TLR2 and TLR4 were critical for 
development of Bregs and, in their absence, developed a chronic form of EAE similar to 
that observed in IL-10-deficient mice (Lampropoulou et al., 2008). These mice also 
exhibited heightened activation of autoreactive Th1 and Th17 cells (Park et al., 2005). 
Furthermore, the adoptive transfer of B cells activated with LPS protected non-obese 
diabetic mice from insulitis (Tian et al., 2001). 
 
In contrast, humans B cells express TLR9 and the agonist CpG, a ligand of TLR9 is a 
potent inducer of IL-10 (Bouaziz et al., 2010, Barr et al., 2007). In vitro studies show 
this can be enhanced when coupled with CD40L (Blair et al., 2010, Gantner et al., 
2003). Furthermore, the addition of agents which induce BCR signalling can augment 
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IL-10 secretion. This is based on disease progression in the absence of CD19, the 
receptor pivotal in BCR signalling as mice deficient of CD19 suffer severe EAE (Yanaba 
et al., 2008). In peripheral blood from healthy volunteers, inclusion of an antibody 
against the BCR enhanced production of IL-10 by B cells in conjunction with CpG which 
interestingly was reduced in the presence of CD40L (Bouaziz et al., 2010).  
 
The signals to drive activation of Bregs have not yet been established unequivocally 
and different models describe their ontogeny. Fillatreau and colleagues support a 
model for induction of IL-10 by B cells encompassing TLR signalling, BCR engagement 
and CD40 ligation. This multistep process begins with an initial TLR-dependent phase 
to commence IL-10 secretion and is followed by BCR recognition and CD40 interaction 
to sustain IL-10 production and maintain B-cell survival (Lampropoulou et al., 2010). 
Alternatively, Mizoguchi & Bhan propose Breg populations are generated from existing 
subsets via distinct activation pathways. Here ‘innate type’ Bregs develop from MZ B 
cells primed by inflammatory signals from TLR agonists, LPS or CpG. In contrast, 
‘acquired type’ Bregs are generated via CD40 engagement with or without BCR ligation 
(Mizoguchi and Bhan, 2006).  The exact signals inducing Breg maturation and 
activation remain to be determined; it is possible in the context of disease that a range 
of different stimuli may exist. 
 
1.3.3 Mechanisms of immune suppression by B cells 
 
Following the first demonstration by Janeway and colleagues that B-cell deficient mice 
are unable to control EAE (Wolf et al., 1996), it was proposed B cells fail to act as APCs 
which would normally activate T cells and induce Th2 cell differentiation. 
Consequently, the Th1 cell population is allowed to expand and migrate into the 
central nervous system allowing EAE to manifest (Adorini et al., 1997). This was 
accepted until evidence directed the cause of exacerbated disease to a deficiency in IL-
10-producing B cells (Fillatreau et al., 2002). Similar adoptive-transfer studies followed 
implementing IL-10 as the primary mediator of suppressive activity exerted by B cells 
through failure to ameliorate inflammation (Matsushita et al., 2008, Mizoguchi et al., 
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2002) Reinforcing this was the demonstration that transfer of IL-10-producing cells 
could actually improve the disease state in CIA (Mauri et al., 2003). 
  
These studies place IL-10 as the hallmark suppressive feature of Bregs and evidence 
suggests a similar reliance in humans. Analysis of B cells from patients with SLE and MS 
show reduced frequency of IL-10-producing cells compared to healthy controls (Duddy 
et al., 2007, Blair et al., 2010). Conversely, in tolerant renal transplant recipients these 
cells are elevated (Newell et al., 2010), suggesting their presence offers a level of 
immune protection. In conjunction with secretion of IL-10, the mechanisms of 
suppression by Bregs include suppression of T-cell responses, inhibiting antigen 
presentation and promoting expansion of Tregs (Figure 1.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Activation and effector mechanisms of regulatory B cells  
The release of IL-10 by regulatory B cells (Bregs) occurs following ligation of antigen 
with the B-cell receptor (BCR) and CD40 with CD40L on CD4+ T cells together with co-
stimulatory molecules, CD80/86 and CD28/CTLA4. Secretion of IL-10 is enhanced by 
Toll-like receptor 9 (TLR9) binding a ligand such as CpG. Activated Bregs inhibit 
activation of macrophages (Mφ) and differentiation of T helper (Th) Th17 cells & Th1 
cells, the latter resulting in reduced secretion of pro-inflammatory cytokines, TNF-α & 
IFN-γ while maintaining regulatory T cells (Tregs). Antigen processing and 
presentation by dendritic cells (DC) may also be an indirect consequence of IL-10 
production by B cells. 
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1.3.3.1  Suppression of T-cell responses  
 
The capacity of Bregs to suppress CD4
+
 T-cell responses are described in numerous 
murine models of autoimmunity (Fillatreau et al., 2008, Mauri and Ehrenstein, 2008, 
Bouaziz et al., 2008). This ability to dictate the differentiation of T cells has important 
implications on disease progression and IL-10-producing B cells are involved with 
supressing pathological T-cell responses during arthritis (Evans et al., 2007), MS 
(Fillatreau et al., 2002, Matsushita et al., 2010) & lupus (Blair et al., 2009). This is 
reliant on production of IL-10, suppressing polarisation of Th1 and inhibiting Th2 
responses, thus restoring the Th1/Th2 balance (Pestka et al., 2004). Recently Th17 cells 
were demonstrated to increase during the acute-stage of CIA, correlating with a 
reduced number of B10 cells (Yang et al., 2012). Moreover adoptive transfer of B10 
cells delayed the onset of arthritis and corresponded with a reduced frequency of Th17 
cells. Similar findings have also been reported using CD21
high
CD23
high
CD1d
high
 T2-MZP 
cells lacking IL-10: here CIA was exacerbated concurrently with a marked increase in 
both Th1 and Th17 cells (Carter et al., 2012). 
 
Studies using B cells stimulated with CpG and anti-Ig from healthy volunteers have also 
demonstrated suppression of CD4
+
 T cell proliferation (Bouaziz et al., 2010).    Similarly 
the CD19
+
CD24
high
CD38
high
 subset could inhibit the differentiation of Th1 cell 
production of pro-inflammatory cytokines (Blair et al., 2010), partially dependent on IL-
10. Furthermore this regulatory capacity relied on engagement of co-stimulatory 
molecules, CD80 and CD86, as addition of monoclonal antibodies against either could 
reverse suppression. 
 
1.3.3.2 Inhibition of antigen presentation  
 
As an indirect consequence, secretion of IL-10 by B cells affects the innate immune 
system inhibiting antigen-processing and presentation by dendritic cells (Moore et al., 
2001). This has been demonstrated in IL-10 producing CD1d
high
CD5
+
 cells during EAE 
(Matsushita et al., 2010). Furthermore dendritic cells from B-cell-deficient mice 
produced higher amounts of IL-12 resulting in an enhanced Th1 cell response (Moulin 
CHAPTER 1 
55 
et al., 2000). Conversely, IL-10 from B cells suppressed production of IL-6 and IL-12 by 
dendritic cells inhibiting the development of Th1 and Th17 cells (Lampropoulou et al., 
2008). 
 
Macrophages are also a target of IL-10 produced by B cells and can negatively impact 
the immune response by inhibiting their activation. In a murine tumour model this 
favoured the development of an ‘M2’ phenotype associated with promoting tumour 
angiogenesis and metastasis (Wong et al., 2010). 
 
1.3.3.3 Supporting the differentiation of regulatory T cells 
 
Increasing evidence suggests an important role of IL-10-producing B cells in generating 
and maintaining Tregs. An early study in a murine corneal transplant model showed 
generation of both suppressive CD4
+
 and CD8
+
 T cells following culture with purified 
antigen-specific B cells (Ashour and Niederkorn, 2006). During EAE, the expansion of 
Tregs depended on direct MHC-mediated contact (Sun et al., 2008a) and interactions 
with B7 co-stimulatory molecules (Mann et al., 2007). Subsequently IL-10 producing B 
cells were identified as inducing Treg development and protection against 
autoimmune inflammation (Gray et al., 2007). In a model of arthritis, IL-10-deficient B 
cells demonstrated not only to reduce expression of Tregs but also promote an 
increase of Th1 and Th17 cells (Carter et al., 2011). This dual regulatory role – 
inhibiting Th1 and Th17 cell differentiation, hence production of pro-inflammatory 
cytokines and promoting Tregs rather than effector T cells  is also reported of 
CD19
+
CD24
high
CD38
high
 cells isolated from healthy individuals (Flores-Borja et al., 2013). 
Moreover, when applied to patients with RA, failure to convert naïve T cells to 
functional Tregs or prevent Th17 cell development was observed. Similarly, 
CD25
high
CD27
high
CD86
high
CD1d
high
IL-10
high
TGF-β
high 
cells from healthy individuals could 
suppress CD4
+
 T-cell proliferation and stimulate an increase in Tregs (Kessel et al., 
2012).  However rather than IL-10, this was dependent on TGF-β. In humans the role of 
TGF-β is unclear: suppression of Th1 cell differentiation by CD19
+
CD24
high
CD38
high
 cells 
is partially dependent on IL-10 but not TGF-β (Blair et al., 2010). Certainly in mice, TGF-
β has an important role by enhancing the function of some Bregs subsets (Noh and 
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Lee, 2011, Tian et al., 2001) and inducing conversion of effector to Treg cells (Singh et 
al., 2008).  
 
The engagement of co-stimulatory molecules, CD80 and CD86, has proposed 
importance for generating Tregs. In EAE, CD86 on B cells can trigger activation of Tregs 
via IL-10 (Mann et al., 2007). In healthy individuals, CD86 is found over-expressed on 
Bregs in parallel with its ligand, CTLA-4, on Tregs during co-culture, suggesting CD86 is 
important in their activation (Kessel et al., 2012). Similarly, CD40-activated naïve B 
cells, following engagement of CD80 and CD86 promoted effective conversion from 
effector T cells to Tregs. In addition, these allospecific Tregs had potent suppressive 
capacity, more so than Tregs generated by immature dendritic cells (Tu et al., 2008, 
Zheng et al., 2010). 
 
These studies indicate B cells exert their regulatory function via secretion of IL-10 and, 
in a contact-dependent manner, perhaps acting as a catalyst for Treg differentiation 
which raises interest of their use in a therapeutic setting. It remains to be established if 
Bregs mediate suppression in situ with T cells or migrate to sites of inflammation. 
 
1.3.4 Regulatory B cells in disease 
 
Regulatory B cells were first described in murine models of autoimmune disease as 
discussed. Accordingly much effort has focused to identify equivalence in human 
conditions. An association was first described by reduced frequencies of IL-10-
producing B cells in relapsing MS compared to healthy controls (Duddy et al., 2007). 
Following this, MS patients with helminth infection had ameliorated symptoms in the 
presence of IL-10-producing B cells. Here IL-10 production was restored in response to 
antigenic challenge and CD40 stimulation inhibiting CD4
+
 T-cell proliferation and 
secretion of IFN-γ (Correale et al., 2008). Impairment in the function of Bregs is also 
reported in patients with lupus (Lemoine et al., 2011, Blair et al., 2010). IL-10-
producing cells were enriched in the CD19
+
CD24
high
CD38
high
 cells in SLE patients. 
However there is dysfunction in their regulatory properties by failure to respond to 
CD40 stimulation and inability to suppress production of Th1 cytokines as 
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demonstrated in healthy controls (Blair et al., 2010). The suppressive capacity of these 
cells was dependent on CD40:CD40L and CD80:CD86 interactions and on the 
production of IL-10.  
 
A pattern is emerging associating the transitional B-cell CD24
high
CD38
high
 subset and 
favourable outcome of disease. This is based on studies monitoring B-cell profiles in 
patients in long-term clinical remission from SLE, (Anolik et al., 2007, Palanichamy et 
al., 2009) and tolerant renal transplant recipients (Newell et al., 2010) who revealed a 
high ratio of transitional B cells compared to memory B cells. 
 
During infectious disease, IL-10-producing B cells are predominantly reported for their 
pathogenic rather than protective role. During infection by parasites such as 
Schistosoma mansoni, B cells are stimulated to express Fas ligand, leading to the 
apoptosis of CD4
+
 T cells, offering protection from a Th1 response (Lundy and Boros, 
2002). In bacterial infection, IL-10-producing B cells inhibit protective immunity against 
Salmonella by suppressing NK cells, neutrophils and pro-inflammatory T cells (Neves et 
al., 2010). In Listeria infection, IL-10-producing B cells were expanded, inhibiting 
macrophage activation and increasing the bacterial load, thus promoting T-cell 
expansion (Horikawa et al., 2013).  
 
In viral infection, HIV-infected individuals had increased frequency of 
CD19
+
CD24
high
CD38
high
CD10 cells that expanded in advancing disease and were 
unresponsive to activation through the BCR (Malaspina et al., 2006). In this setting IL-
10-producing cells indicate a role in maintaining viral load. Patients with chronic 
hepatitis B infection (HBV) had increased IL-10-producing B cells and IL-10 in serum 
which correlated with disease activity. In vitro studies showed predominantly 
CD19
+
CD24
high
CD38
high
 cells were able to supress HBV-specific CD8
+
 T-cell responses 
dependent on IL-10 (Das et al., 2012). This indicates a pathogenic role of IL-10 acting to 
suppress liver inflammation and the bystander effect of this is limiting HBV-specific 
CD8
+ 
T-cell response.  
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In cancer, fewer details exist but akin to infectious disease Bregs may disrupt immune 
suppression, consequently promoting tumour cell growth. The mechanisms include 
suppression of CD8
+
 T cells and conversion of Tregs (Fremd et al., 2013). In tumour 
immunology, the protective effect offered during autoimmune disease, converting 
naïve T cells to Tregs (Wei et al., 2005) may be reversed. In a murine model of breast 
cancer, Bregs producing TGF-β convert CD4
+ 
T cells to Tregs supporting metastasis by 
allowing escape from the immune system (Olkhanud et al., 2011). Unlike previous 
observations, a role for IL-10 was not reported here (Inoue et al., 2006).  
 
Together these data suggest Bregs can manipulate the immune response during 
infection by pathogens and promote tumour development by influencing both innate 
and adaptive immune responses. Given this, targeting Bregs may be of interest to 
release the suppressive restraints posed by these cells.  
 
1.3.5 Regulatory B cells in transplantation 
 
The suppressive capacity of B cells can be described in experimental graft-versus-host 
disease (GvHD) after allogeneic bone marrow transplantation by their ability to supress 
proliferation of CD4
+ 
T cells and inhibit the Th1 cell response (Rowe et al., 2006). 
Interestingly, the repopulating APCs preceding the pre-transplant irradiation regimen 
were predominantly IL-10-producing B cells. Moreover these cells may account for 
preventing GVHD by attenuating the alloresponse since B cells defective in IL-10 
production suffered more severe disease.  
 
In clinical renal transplantation, B cells are regarded primarily as detrimental to 
allograft survival by virtue of their capacity to present antigen to T cells and produce 
highly damaging donor-specific antibody. However, this negative stance is shifting as 
evidence emerges of certain B-cell subsets being beneficial and potentially promoting 
transplant tolerance (Newell et al., 2010, Pallier et al., 2010, Sagoo et al., 2010). This 
stems from studying recipients experiencing stable graft function in the absence of 
immunosuppression. By addressing B cells’ phenotypes in these patients, the 
frequency of IL-10-producing transitional and naïve B cells is increased (Newell et al., 
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2010). Furthermore when comparing patterns of gene expression; these studies 
showed 30 were increased by 2-fold in tolerant recipients and of those 30, 22 were B 
cell-specific with roles in activation and differentiation. Interestingly, three genes were 
identified solely in tolerant patients and all expressed by transitional B cells. A separate 
cohort of tolerant patients had increased B-cell numbers expressing CD1d and CD5. 
Here genes relating to the B-cell cycle and inhibitory molecules were over expressed, 
in particular BANK1 (B-cell scaffold protein with ankyrin repeats 1), an important 
protein involved in preventing hyperactive B-cell responses mediated by CD40 (Pallier 
et al., 2010). Interestingly, a similar inhibitory phenotype is observed in B cells of 
tolerant rats in a long-term cardiac allograft model (Le Texier et al., 2011). A further 
study found no significant increase in IL-10-producing B cells in tolerant recipients but 
a distinct gene expression profile identified with transitional B-cell biomarkers (Sagoo 
et al., 2010).  
 
The functional significance of Breg expression and transplant tolerance has not been 
established but there are suggestions that B-cell depletion at the time of transplant 
could be a contributing factor by favouring the repopulation of naïve and transitional B 
cells (Salinas et al., 2013), akin to B cell reconstitution observed following induction 
with Alemtuzumab (Heidt et al., 2012a, Knechtle et al., 2009, Cherukuri et al., 2012). A 
commonly used therapy to deplete B cells in transplantation is rituximab, a 
monoclonal antibody targeting CD20 expressed on the cell surface. This can 
successfully decrease DSA titre and effectively supress post-transplant T cell-mediated 
rejection in sensitised patients (Becker et al., 2006). 
 
In the post-transplantation setting, patients who received induction therapy with 
rituximab suffered a higher prevalence of acute T-cell-mediated rejection (Clatworthy 
et al., 2009). However, in a similar study, lower rates of rejection were reported (Tyden 
et al., 2009). The key difference between these studies was the timing of B cell 
depletion. The study reported by Clatworthy and colleagues administered two doses of 
rituximab at day zero and a second dose at day seven as opposed to a single dose at 
day zero, suggesting there may be a critical window of time during which is it possible 
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not to abolish a protective population of B cells and thus promote T-cell-mediated 
rejection. 
Early investigations in autoimmune disease provided evidence that B-cell depletion 
exacerbated disease features; in the transplant setting this may shift the balance of 
allograft stability to promote rejection rather than tolerance. Currently B-cell-depleting 
therapy cannot distinguish between protective and pathogenic B cells and it would be 
beneficial to develop strategies to enhance Bregs in vivo. Investigations in animal 
models identify mechanisms of suppressive capacity to induce tolerance. For example, 
adoptive transfer of B cells expressing Fas-ligand can promote acceptance of male-to-
female skin graft (Minagawa et al., 2004). In solid organ transplantation there are 
many more antigenic targets and the demonstration that monoclonal anti-TIM-1 
antibodies stimulate production of IL-10, preventing rejection of pancreatic allografts 
(Ding et al., 2011), raises encouraging prospects to investigate selective therapy 
augmenting the generation of Bregs and thus promote allograft survival. 
 
1.3.6 Summarising the role and functions of Bregs 
 
Understanding the role of Bregs in humans is in its infancy but evidence clearly 
demonstrates a population of B cells, distinct from T cells, capable of modulating 
effector responses in a contact-dependent and independent manner, predominantly 
driven through secretion of IL-10.  The current lack of a consensual identity hinders 
characterising their function or extracting conclusions from across the literature and 
the impetus remains to discover a unique identifier, perhaps a ‘master gene regulator’, 
analogous to Foxp3 in Tregs. The depletion of B cells in autoimmunity and pre-
transplantation has augmented disease and rejection, highlighting both the 
importance of these cells and the requirement for targeted therapeutic strategies to 
eradicate harmful effector B cells while promoting the beneficial regulatory subsets 
which induce immune suppression and tolerance. 
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1.4 The role of B cells in renal transplantation 
 
B cells have diverse functions in renal transplantation (Figure 1.4). Aside from the 
recent identification of regulatory B cells, in the clinical setting, B cells are 
predominantly considered pathogenic mediators of allograft rejection due to two key 
activities. First, their capacity to present antigen to T cells evoking effector responses 
and, second, their ability to produce donor-specific HLA antibody against the allograft. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The roles of B cells in transplantation 
B cells have multiple immunological functions. In addition to their primary role as 
antibody-producing cells they are efficient antigen-presenting cells (APCs) due to both 
specificity and high affinity of their B-cell receptor (BCR) for antigen which can drive 
activation of CD4+ T cells. They also have capacity to clonally expand becoming 
numerically dominant during an immune response. Indirect effector functions are 
predominantly exerted through cytokines, in co-operation with T-cell stimulation, 
pro-inflammatory cytokines; IL-12 and IFN-γ are secreted. Production of IL-16 can 
mediate dendritic cell maturation. The B-cell activating factor (BAFF) binding to its 
receptor (BAFF-R) promotes B-cell maturation and survival. Excessive levels of serum 
BAFF are reported during allograft rejection. In contrast to the pathological role of B 
cells, a small population are described to down-regulate the immune response. 
Regulatory B cells (Bregs) are proposed to mediate suppression of damaging T-cell 
responses via secretion of IL-10.  
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1.4.1 Antigenic targets in allograft rejection 
 
The major histocompatibility complex (MHC) in humans is the HLA system (this 
originally stood for ‘human leukocyte antigen’ but now is just ‘HLA’ since it is known 
that these molecules have a much wider distribution that just leucocytes). The HLA 
system has a critical role in regulating immunity. These molecules present peptides, 
derived from protein antigen, in a form that is recognised by T cells and in doing so 
initiate and propagate the immune response. 
 
HLA molecules are classified as HLA class I or class II. Classical HLA class I molecules are 
HLA-A, -B and –C and are expressed on all nucleated cells and platelets. Classical HLA 
class II molecules are HLA-DR, -DQ and -DP and are predominantly expressed on APCs, 
although during an inflammatory response their expression can be induced on other 
cell types (Jackson et al., 2009).  Clustered on the short arm of chromosome 6, the 
genes coding HLA molecules are the most polymorphic in the human genome with 
more than 8000 known alleles (www.ebi.ac.uk/imgt/hla/). Therefore finding an 
identical donor expressing the same HLA type for each patient is virtually impossible. 
As a result, transplantation proceeds in the presence of ‘non-self’ or mismatched HLA 
which is principally responsible for the immune response to alloantigen. 
 
In addition to these major classes of HLA, there are minor histocompatibility antigens, 
such as MHC class I polypeptide-related sequences A (MICA) and B (MICB). The clinical 
significance is not clear. However both have been implicated in allograft loss in 
recipients well matched for HLA (Stastny et al., 2009, Dragun et al., 2008). Other non-
HLA antigenic targets of the immune response in transplantation include vimentin 
(Carter et al., 2005), angiotensin II type I receptor (Dragun et al., 2005) and endothelial 
antigens (Sun et al., 2008b). Immune response to all of these has been implicated in 
poorer outcome. However, of recent years the primary focus in allograft rejection has 
been the effect of antibody against HLA, and specifically donor-specific HLA antibody 
(DSA). 
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1.4.2 The role of B cells in presenting alloantigen 
 
B cells can present antigen to T cells. As with other professional APCs, they bind and 
process antigen into peptides which are presented on the cell surface as HLA/peptide 
complex. The fate of the processed antigen being presented by HLA class I or class II is 
dependent upon its entry into the cell.  Endogenous protein antigens in the cytoplasm 
are processed and presented in the context of HLA class I to cytotoxic CD8
+
 T cells. 
Conversely, exogenously generated peptides are presented on HLA class II to CD4
+
 T 
cells.   
 
In response to allogeneic transplantation, APC mediate the immune response by a 
process of allorecognition where donor HLA expressed on the allograft disparate to the 
recipient are recognised by T cells. This occurs via the direct or indirect pathway 
(Lechler and Batchelor, 1982). The direct pathway describes the recognition of intact 
donor HLA on the surface of donor APCs by TCRs on recipient T cells. The indirect 
pathway involves donor HLA antigen being taken up by recipient APCs and processed 
into peptides which are presented in the context of HLA class II to recipient T cells. 
Following transplantation, the direct pathway is prominent as donor APCs migrate 
from the graft to secondary lymphoid organs and in doing so stimulate recipient T cells 
which migrate to the allograft and initiate an inflammatory response. This is a major 
factor in acute rejection (Benichou, 1999). The indirect pathway emerges when donor 
APC are exhausted and recipient APC maintain the immune response by processing 
antigen shed by the graft and presenting to recipient T cells.   
 
In the post-transplant setting, B cells have an important role in allograft rejection by 
presentation of allogeneic peptides to T cells via the indirect pathway. Both animal 
models and clinical studies suggest this pathway is dominant in chronic rejection 
(Noorchashm et al., 2006, Taylor et al., 2007). B cells are very effective APCs and 
represent the largest population in vivo (Lund and Randall, 2010).  This efficiency is 
attributable to the BCR; allowing B cells to extract antigen at very low quantity or 
tethered to the plasma membrane of target cells, such as those undergoing apoptosis 
(Tarlinton et al., 2008b, Ciechomska et al., 2011). In addition, their capacity to clonally 
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expand allows them to become the numerically dominant APC (Thaunat et al., 2010). 
Furthermore, the cognate interaction between T and B cells; previously described in ‘‘B 
cell development – Effector functions of B cells – Antigen presentation”, may serve to 
amplify and co-regulate the alloresponse. The direct extent is not known as it is 
difficult to ascertain since B cells have multiple functions therefore their absence 
would impact other aspects of immunity.  
 
CD4
+
 helper T cells are key regulators in allorecognition, helping and controlling CD8
+
 T 
cells but also providing essential help to activate B cells leading to antibody formation 
and plasma cells (details were outlined in “B-cell development - Mature B cells - The B-
cell response to antigen”). With respect to transplantation, alloantibodies directed 
against HLA molecules expressed on the transplanted graft are important mediators of 
allograft rejection. The binding of antibody to donor HLA antigens, predominantly 
expressed on vascular endothelium, triggers a series of events leading to the activation 
of the complement, clotting and kinin cascades, resulting in vascular thrombosis, 
ischaemia and ultimately necrosis (Afzali et al., 2007). 
 
1.4.3 Alloantibody production by B cells 
 
B-cell activation is a multistep process, initiated by binding of antigen and ultimately 
production of antibody-secreting plasma cells to clear the invading antigen. Following 
transplantation, B cells are well placed for activation by antigens derived from the 
allograft transported via the lymphatics to draining lymph nodes by dendritic cells. 
There is also evidence of a humoral response occurring locally within the graft.   
Cytokines secreted by B cells are important in the formation and maintenance of 
lymphoid tissue. Lymphoid neogenesis is detected in the rat model of chronic allograft 
rejection (Thaunat et al., 2005). Furthermore, the presence anti-MHC class I antibodies 
implicates the role of B cells in these structures.  
 
A heightened presence of B cells have also been found within the renal allograft 
biopsies of failing grafts, (Sarwal et al., 2003) and B-cell infiltrates associated with 
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adverse outcome (Muorah et al., 2009, Zarkhin et al., 2008). These studies place B cells 
as important mediators of allograft rejection. 
 
An important co-stimulator of B cells is BAFF, as previously described. Suffice it to say, 
elevated levels of BAFF are associated with declining renal graft function (Bloom et al., 
2009, Banham et al., 2013a, Thibault-Espitia et al., 2012). The direct involvement of 
BAFF in sustaining B-cell activation and driving alloantibody production is not known 
but its central role in both B-cell survival and function is suggestive of a contributory 
role in dysregulated immunity.  
 
The presence of pre-existing memory B cells, generated as a result of pregnancy, blood 
transfusion or previous transplantation, results in the production of high affinity 
antibody-secreting cells upon re-exposure to antigen. Interestingly, increased 
alloantibody production occurs in less than half of sensitised recipients indicating that 
alloantigen does not always evoke a memory B-cell response (Stegall et al., 2009). In 
the early post-transplantation setting, acute antibody-mediated rejection (AAMR) 
occurs when high levels of alloantibody are present and is likely due to a secondary 
immune response mediated by memory B cells. Evidence for this follows the 
identification of circulating HLA-specific B cells using tetramers which upon stimulation 
produce DSA (Zachary et al., 2007, Mulder et al., 2003). Similarly, memory cells from 
peripheral blood of sensitised patients were isolated and induced to secrete DSA (Han 
et al., 2009). The production of DSA by pre-existing memory B cells is a major obstacle 
in achieving long-term allograft survival. 
 
1.4.4 Role of B cells in transplant tolerance 
 
In contrast to the pathogenic function of B cells in allograft survival, there is evidence 
to suggest a role in tolerance. This is highlighted by the success of blood group or ABO-
incompatible paediatric heart transplantation (West et al., 2001, Henderson et al., 
2012). The reduced risk of hyperacute rejection was attributed to lack of ABO 
antibodies which do not occur until five to six months after birth, resulting in 
spontaneous tolerance to blood group antigens (Fan et al., 2004). This demonstrates a 
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case of acquired tolerance in humans and is proposed to result from clonal deletion. 
Since donor-reactive cells are dependent on alloantigen for their development, B-cell-
depleting therapy eliminates the probability of an alloantigen-specific germinal centre 
response (Parsons et al., 2009, Parsons et al., 2011). However, depleting B cells at the 
time of transplant may not be favourable as previously described in the context of 
regulatory B cells. An additional explanation is the nature of the antigen presented by 
B cells to T cells and their cognate interaction. This is proposed to promote T-cell 
immunity as endogenous or pinocytosed antigens presented by B cells can lead to T- 
cell tolerance (Chen and Jensen, 2008). In particular, antigen presented by naïve B cells 
stimulates naïve T cells towards Tregs (Reichardt et al., 2007, Chen and Jensen, 2007). 
Interestingly, the recent identification of a higher proportion of naïve and transitional 
B cells in stable transplant patients in the absence of immunosuppression suggests 
repopulation with immature and naïve B cells may facilitate B-cell transplant tolerance 
(Newell et al., 2010, Sagoo et al., 2010). Moreover, this may explain why the transfer 
of naïve B cells promotes murine skin allograft acceptance (Fuchs and Matzinger, 
1992). Collectively, evidence suggests certain populations of B cells could be exploited 
by therapeutic strategies to harness clinical transplant tolerance. 
 
1.4.5 HLA antibody-mediated allograft rejection 
 
Mismatched ‘non-self’ HLA molecules are targets for an immune response and 
antibodies against these can be raised following sensitising events. If a transplanted 
organ expresses HLA against any of these pre-existing HLA antibodies, there is an 
increased risk of both rejection and reduced allograft survival (Kerman et al., 1996, 
Susal and Opelz, 2002, Wahrmann et al., 2006). 
 
It is well established that the presence of pre-formed HLA antibodies is a 
contraindication to transplantation potentially resulting in hyperacute rejection (Patel 
and Terasaki, 1969). Hyperacute rejection rapidly follows transplantation, usually 
within 24 hours, as a direct result of DSA or blood-group antibody produced in 
response to antigen on allograft endothelial cells. This type of rejection has fortunately 
become a very rare occurrence, largely due to advances in pre-transplant antibody 
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detection and assessment of immunological compatibility between the donor and 
recipient. However, antibodies are still implicated in acute and chronic humoral 
rejection, and major barriers to successful transplantation. 
 
1.4.6 Defining and categorising antibody-mediated rejection 
 
Renal allograft rejection is classified by histopathological diagnosis of biopsy tissue.     
To standardise definition, the Banff classification scheme was introduced in 1993 
(Solez et al., 1993). Six categories were defined, but only one of those included an 
antibody-mediated component and this was hyperacute rejection. The 1997 revision of 
the Banff classification recognised the participation of antibody and hyperacute 
rejection was renamed antibody-mediated rejection (AMR) which included hyperacute 
rejection and accelerated acute rejection (Racusen et al., 1999). The 1997 update 
published in 2003 further placed a contributory role of HLA antibody with allograft 
rejection (Racusen et al., 2003). This was aided by the description of staining for C4d, 
an inactive cleaved component of the classical complement pathway. (Feucht et al., 
1993). Deposition of C4d on peritubular capillaries provided evidence of antibody 
involvement, given the relationship between antibody binding and complement 
activation in allografts, and became accepted as a marker of AMR (Racusen et al., 
2003). However, evidence showed AMR could be C4d-negative, indeed in up to two-
thirds of cases (Sis and Halloran, 2010). Equally, positive staining for C4d can occur in 
the absence of anti-donor activity. Accordingly, Banff criteria reflect the uncertainty 
surrounding the role of C4d as a marker of allograft rejection has led to the inclusion of 
‘C4d deposition without the morphological evidence of active rejection’ (Solez et al., 
2008). In addition, AMR was further defined as acute or chronic. 
 
1.4.6.1 Acute antibody-mediated rejection  
 
The criteria for diagnosing AAMR are morphological evidence of tissue injury, C4d 
positivity and detection of DSA (Sis et al., 2010). As noted above there is uncertainty of 
C4d expression and AAMR in the absence of C4d is classed as ‘suspicious of’ or 
‘consistent with’ AAMR (Racusen et al., 2004). Between 30-40% of sensitised patients 
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experience AAMR and it is a major cause of morbidity and early graft loss (Stegall et al., 
2010). Moreover, AAMR can contribute towards the development of chronic rejection 
and transplant glomerulopathy (TG) (El-Zoghby et al., 2009, Issa et al., 2008). 
Furthermore there is correlation between the incidence and levels of DSA post-
transplant as patients with low level DSA do not present with AAMR on biopsy, 
whereas those who develop high levels very often do (Burns et al., 2008).  
 
1.4.6.2 Chronic antibody-mediated rejection 
 
Diagnosing chronic antibody-mediated rejection (CAMR) is complicated by the number 
of non-immune factors involved such as age of the kidney, chronic ischaemia, drug 
toxicity, hypertension, diabetes and atherosclerosis (Kreis and Ponticelli, 2001, 
Fellstrom, 2001). 
 
According to Banff criteria, diagnosing CAMR include demonstration of C4d positivity, 
DSA and at least one feature of histological findings such as peritubular capillary 
basement membrane thickening, glomerular double contours or interstitial 
fibrosis/tubular atrophy, and/or intimal thickening of arteries (Colvin, 2009).  TG which 
results in glomerular capillary endothelium injury is diagnostic of CAMR and associated 
with reduced allograft survival, although CAMR can exist in its absence (Gloor et al., 
2007). In AAMR, the role of DSA in pathogenesis is well defined (Solez et al., 2008). 
However in chronic rejection this is not fully understood, as DSA can be absent in the 
presence of histological evidence of AMR and C4d positivity, but DSA may be an 
important developmental element. Evidence shows that recipients who develop CAMR 
have higher HLA antibody titres in the first year post-transplant (Kwun and Knechtle, 
2009).  
 
1.4.7 The impact of HLA antibody on allograft survival 
 
It has long been established that HLA antibody has a negative impact on allograft 
survival. In 1971, Terasaki and colleagues reported the presence of HLA antibodies 
prior to transplantation significantly decreased allograft survival (Terasaki et al., 1971). 
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Now clear evidence exists that pre-formed DSA pose a risk of immediate rejection, 
while post-transplant DSA significantly impairs allograft function and survival 
(Lefaucheur et al., 2010, Terasaki, 2003). With regard to HLA class, both HLA class I 
and/or class II correlate with a poorer prognosis of graft survival (Rifle et al., 2005, 
Susal et al., 2009). Furthermore, patients with DSA compared to non-DSA have 
significantly lower allograft survival (Lefaucheur et al., 2010).  Pre-existing DSA are 
particularly detrimental, as even in the absence of clinical AMR results in worse long-
term allograft survival (Lefaucheur et al., 2010, Haas et al., 2007). 
 
De novo DSA (dnDSA) have a particular association with late allograft loss (Cooper et 
al., 2011, Ginevri et al., 2012, Everly et al., 2013), with the presence of antibodies to 
both HLA class I and II being associated with increased risk of graft failure than the 
presence of antibodies to either class alone (Wiebe et al., 2012). Moreover, anti-HLA-
DQ antibodies are implicated with a significantly greater risk of rejection and reduced 
allograft survival than antibodies to other class II isotypes (Willicombe et al., 2012, 
DeVos et al., 2012).  
 
These data suggest immunogenic relevance in HLA antibody type and development of 
rejection. In general, HLA class I are associated with acute humoral rejection (Crespo et 
al., 2001), while HLA class II have a particularly important negative impact on long term 
graft survival (Langan et al., 2007, Campos et al., 2006), possibly due the expression of 
HLA class II on the endothelial cells of peritubular and glomerular capillaries 
(Muczynski et al., 2001, Gloor et al., 2007). These differences in immunogenicity are 
not an inherent property of the HLA molecule itself but reflect how the HLA epitopes, 
comprising triplets of amino acids, are presented to recipient HLA (Doxiadis et al., 
1996). During an alloresponse, the development of HLA antibody is directly related to 
the number of mismatched or non-self-triplets presented on the HLA molecule 
(Dankers et al., 2004, Kosmoliaptsis et al., 2008). Moreover, the physiochemical 
characteristics between mismatched HLA class I molecules influences the production 
of specific alloantibody post-transplant (Kosmoliaptsis et al., 2009).   
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Evidence demonstrates a strong association between HLA antibody and AMR, and 
subsequent allograft failure. The development of sensitive methods of detecting these 
antibodies has afforded more accurate definition and detailed analysis of their impact 
on transplant outcome. 
 
1.4.8 Clinical immunology: HLA antibody detection 
 
Immunological assessment of a recipient–donor pairing can help predict the potential 
risk of post-transplant AMR. The most clinically relevant HLA antibodies are DSA. 
However not all DSA cause deteriorating graft function or rejection. It is not clear why 
differences in pathogenicity exist, but the ability to activate complement could be an 
important factor (Wahrmann et al., 2006, Wahrmann et al., 2009). 
 
A number of methods are employed to allow detection of HLA antibody. Initially, this 
was achieved using cell-based assays, most commonly by complement-dependent 
cytotoxicity (CDC) assay. Prior to transplantation, a CDC assay can detect DSA in 
recipient serum, specifically against HLA molecules expressed on donor cells. Anti-
donor activity is visualised by the addition of a source of complement and a cell 
viability stain. A positive CDC assay is indicative of hyperacute rejection and considered 
an absolute contraindication to transplantation. However, a negative CDC assay cannot 
rule out presence of low titre DSA and a more sensitive flow cytometric test is also 
included. This is 10- to 250-fold more sensitive than the CDC assay and can be used to 
detect HLA antibody directed against HLA class I using T cells and HLA Class II using B 
cells (Mehra et al., 2013). Together the CDC and flow cytometric assays provide 
information of anti-donor activity.  
 
For specific identification and characterisation of HLA antibody, more sensitive solid 
phase assays (SPA) have been introduced. SPA utilise purified HLA derived from 
transfected cell lines or solubilisation from cell membranes. These purified HLA are 
coupled to a solid phase such as a plastic plate or latex beads to measure serum HLA 
antibody, revealing previous antigenic exposure and estimate the degree of circulating 
antibody. The clinical relevance of pre-transplant DSA detected by SPA at levels below 
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those detected by CDC is demonstrated by their association with reduced renal 
function (Lefaucheur et al., 2009). The most widely used SPA in transplantation 
laboratories are multiplex quantitation assays, namely Luminex technology. Here 
patient sera are exposed to a panel of purified HLA class I and class II molecules 
coupled to microbeads which determines relative antibody strength, specificity and 
identifies unacceptable antigens, if necessary to the single-antigen level. This 
information, combined with the CDC assay and flow cytometric cross-match gives the 
most informative evaluation of a recipient’s immune status. 
 
A strategy to increase the predictive value of SPA to include functional complement 
activation has been developed to better identify clinically relevant DSA. Using a 
modified form of the SPA used to detect HLA antibodies, the addition of a source of 
human complement and an antibody reactive against the complement fragment, C4d 
allows detection of DSA-induced complement activation (Smith et al., 2007, Bartel et 
al., 2008). In a clinical context, C4d fixing-DSA could predict allograft survival in cardiac 
allograft recipients (Smith et al., 2007), and in renal allograft recipients with low-levels 
of DSA in the context of negative CDC assay and flow cytometric cross-match, was 
predictive for AMR (Lawrence et al., 2013).  
 
Based on the same principle, an alternative SPA encompassing the detection of C1q, 
the first component in the complement cascade has been developed. The detection of 
C1q-fixing DSA are shown to be predictive of allograft rejection and graft loss (Yabu et 
al., 2011, Sutherland et al., 2012). This assay is reported to have higher sensitivity 
compared to detection of C4d by SPA (Tyan, 2012). However both are relatively new 
assays and data is currently limited. 
 
Defining immunological risk using improved SPA could better identify unacceptable 
donor-antigens and patients at risk of AMR to potentially improve outcome following 
renal transplantation. 
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1.4.9 Summarising the role of B cells in transplantation 
 
Multiple factors participate towards graft dysfunction and ultimate loss. The 
contribution of B cells and specifically the production of antibodies against the graft 
are a significant component in the process of allograft injury. 
 
The increased sensitivity of tests for detecting HLA antibodies has shifted the attention 
from simply identifying patients at risk of rejection to providing a relative level of risk. 
This has increased access to transplant by defining DSA and allowing monitoring in 
antibody-removal programmes. Moreover, has assisted clinically in the diagnosis of 
humoral rejection thus allowing appropriate therapy to target the B-cell compartment. 
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1.5 Aims and Objectives  
 
Aim 
 
To develop and implement methods of detailing the B-cell compartment in renal 
transplant recipients, and to assess if there were characteristics of these cells which 
could be harnessed to indicate renal allograft stability.   
 
Objectives 
 
1.  To determine if the risk of a renal transplant recipient developing antibody-
mediated rejection post-transplantation could be predicted pre-transplantation 
using in vitro analysis of allospecific B cells. 
 
2.  To identify and characterise donor HLA-specific B cells within the circulation, 
and determine whether HLA-DQ-specific B cells had any defining characteristics 
to account for the observed prevalence of de novo HLA-DQ antibodies post-
transplantation.   
 
3.  To determine if there was a relationship between differential expression of 
BAFF and level of allograft function; to promote its use as an effective 
biomarker post-transplantation. 
 
4.  To investigate phenotypic and functional properties of regulatory B cells, and 
determine if their presence or suppressive capability differed depending on 
level of graft function.  
 
  
 
 
 
 
Chapter 2 
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2.0 Materials and methods 
2.1 GM 1 Recruitment of study patients and blood sample collection 
 
Renal transplant recipients were recruited during attendance at routine clinic 
appointments at the Royal London Hospital, Barts and The London NHS Trust, London, 
UK.  
 
The study was ethically approved by a local ethics committee (Central London, REC1; 
Research Ethics Reference Number: 07/H0707/10; Appendix A) and written informed 
consent was obtained to participate. Venous blood samples were collected in ethylene 
diamine tetra-acetic acid (EDTA) vacutainers (Becton Dickinson (BD), UK) and 
processed within four hours for analysis of peripheral blood mononuclear cells (PBMC; 
40 ml). A clotted sample (6 ml) was also collected for serum retrieval. Blood tubes 
were centrifuged for 10 minutes at 2000 revolutions per minute (RPM), serum 
collected from the top layer and stored at -20 
o
C until further use. 
 
Staff working within Barts and The London NHS Trust or the Centre for Immunology & 
Infectious Disease, Queen Mary University of London served as blood donors for use as 
healthy controls as detailed in the ethics application (Appendix A). 
 
2.2 GM 2 Immunosuppressive regimes  
 
Immunosuppression protocols variably included anti-CD25 induction therapy with 
Basiliximab (Simulect; Novartis Pharmaceuticals) or Daclizumab (Zenapax; Roche) or, 
anti-thymocyte globulin (ATG). A number of patients were transplanted prior to the 
introduction of induction therapy. 
 
Maintenance immunosuppression included a calcineurin-inhibitor, anti-metabolite and 
rapidly tapering steroids. 
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2.3 GM 3 Defining level of allograft function in patient cohorts 
 
Patients were separated into three cohorts by level of allograft function based on eGFR 
(estimated glomerular filtration rate) measured over a 36-month period or 12 months 
if six or more samples had been collected. This could more accurately reflect current 
graft function; particularly if there was deterioration.                  
 
GFR (glomerular filtration rate) is used for diagnosis, staging and determining rate of 
deteriorating renal impairment by measuring serum creatinine. Creatinine is a waste 
product of muscle metabolism which enters the blood stream and is maintained at a 
steady level depending on kidney function. Elevated levels of creatinine can indicate 
renal function is impaired. The rate at which creatinine is cleared is proportional to the 
GFR. Previously, this required a urine sample taken over a 24-hour period. A more 
practical approach is to estimate GFR using serum extracted from whole blood and 
apply the Modification of Diet in Renal Disease (MDRD) equation (Levey et al., 1999). 
This formula (186 x (Creatinine/88.4)
-1.154
 x (Age)
-0.203
 x (0.742 if female) x (1.210 if 
black) = eGFR (ml/min/1.73m
2
) also accounts for patient age, sex and race providing a 
more accurate measure than would serum creatinine measurements alone. eGFR 
measurements are less accurate at near-normal levels of renal function (Levey et al., 
2014) (>60 ml/min). In this study, all patients had an eGFR of <60 ml/min. 
 
The criteria for patient group allocation was based on the presence or absence of a 
progressive process toward declining allograft function, and determined by linear 
regression analysis. This method was used by Dudley and colleagues in the “creeping 
creatinine study” to define patients with chronic deterioration in allograft function 
(Dudley et al., 2005). Based on this, eGFR measurements were plotted against time 
and a negative gradient with a significance value of P less than 0.05 and an R
2
 of more 
than 0.35 was considered to demonstrate rapidly deteriorating (RD) graft function. A 
negative gradient with an R
2 
of between 0.1 and 0.35 were defined to have slowly 
deteriorating (SD) graft function, and the stable (ST) group was defined as having no 
significant change in function. While it was recognised that using the gradient of the 
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slope would have been more informative of how eGFR changes as a function of time 
rather than how well a line fits the data, as demonstrated by the R
2
 value; the method 
detailed by Dudley and colleagues was used for a well-regarded clinical trial, and was 
therefore adopted here. 
 
2.4 GM 4 Peripheral blood mononuclear cells (PBMC) separation 
 
Peripheral whole blood (40 ml) was diluted 1:2 with sterile phosphate buffered saline 
(PBS; PAA laboratories, UK), layered over 15 ml of Ficoll-Hypaque solution (GA 
Healthcare, UK) in 50 ml Falcon tubes (BD) and centrifuged for 30 minutes at 2000 
RPM. Lymphocytes were collected from the interface, washed in RPMI-1640 
(Invitrogen, UK) and centrifuged at 1700 RPM for 10 minutes. If necessary, red blood 
cells were lysed (ACK buffer; Invitrogen) for five minutes at room temperature, then 
washed with RPMI for 5 minutes at 1400 RPM, this was the standard centrifuge speed 
and time unless otherwise stated. Supernatant was discarded and cell pellets 
resuspended in RPMI-1640 supplemented with 5% L-glutamine, 5% penicillin, 5% 
streptomycin (Sigma-Aldrich, UK) and 10% heat inactivated sterile-filtered (0.2 μm; 
VWR, UK) foetal calf serum (FCS; PAA laboratories); this medium was used throughout 
and shall be referred to as complete medium.  Cells were counted using a 
haemocytometer under a light microscope and viability evaluated by Trypan blue 
(0.4%, Invitrogen) exclusion.          
 
2.5 GM 5 CD19+ cell isolation by positive selection 
 
Immediately following PBMC isolation, CD19 cells were selected using magnetic-bead 
separation (Miltenyi Biotec) as per manufacturer’s instructions. Briefly 1 x 10
7 
PBMC 
were resuspended in 80 μl MACS buffer (PBS/0.5% FCS/0.05% EDTA) with 20 μl CD19 
microbeads in a 15 ml Falcon tube (BD) and incubated for 20 minutes at 4 °C. Cells 
were washed with 2 ml MACS buffer, resuspended in 500 μl MACS buffer and applied 
to a column (MS column; Miltenyi Biotec) attached to a magnetic plate. The labelled 
PBMC suspension was allowed to run completely through the column before being 
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washed three times with 500 μl MACS buffer. The column was removed from the 
magnet and the positively selected cells attached to the column were released by 
depressing the plunger. Cells were washed and resuspended in complete medium at a 
concentration of 1 x 10
6
/ml. 
 
2.6  GM 6 Cellular phenotyping by flow cytometry 
 
Cells were stained with fluorchrome-conjugated monoclonal antibodies analysed using 
a flow cytometer (LSRII analyser; BD Biosciences, UK). The optimal antibody 
concentration was determined by titration experiments. Unless otherwise stated, 0.5 
μg/million cells provided adequate staining. Cells were gated for lymphocytes on the 
basis of forward and side scatter profiles. The relevant
 
labelled isotype control 
antibodies were included in all experiments and used to set voltage and compensation 
parameters. All cells with a staining intensity higher than the upper limit
 
obtained 
using the isotype control (<0.5%) were considered positive. Data was analysed using 
Flowjo software (Treestar Inc.). 
 
2.6.1 GM 6.1 Extracellular staining for CD19+ cell subsets 
 
Cells were transferred to FACS tubes (BD), centrifuged and the cell pellet resuspended 
in 50 μl FACS buffer (PBS/2% FCS) and stained with a cocktail of mouse anti-human 
monoclonal antibodies or relevant isotype controls (Table 2.1). Cells were stained in 
the dark at room temperature for 20 minutes, washed in FACS buffer and analysed by 
flow cytometry. 
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Antibody 
Specificity 
 
 
Fluorochrome 
 
 
Clone 
 
Source species 
and isotype 
 
Company 
 
Reference 
 
CD19 
 
 
APC-Vio 770 
 
LT19 
 
Mouse IgG1, κ 
 
Miltenyi 
Biotec 
 
 
(Tedder et al., 
2002) 
 
CD27 
 
 
PerCP-Cy 5.5 
 
M-T271 
 
Mouse IgG1, κ 
 
Biolegend 
 
(Tangye and 
Tarlinton, 
2009) 
 
 
IgD 
 
 
FITC 
 
IA6-2 
 
Mouse IgG2a, κ 
 
BD Biosciences 
 
(Wei et al., 
2007) 
 
 
CD24 
 
 
PE-Cy7 
 
ML5 
 
Mouse IgG2a, κ 
 
BD Biosciences 
 
(Sims et al., 
2005) 
 
 
CD38 
 
 
V450 
 
HIT2 
 
Mouse IgG1, κ 
 
BD Biosciences 
 
(Sims et al., 
2005) 
 
 
BAFF 
receptor 
 
 
PE 
 
11C1 
 
Mouse IgG1, κ 
 
BD Biosciences 
 
(Mackay and 
Mackay, 2002) 
 
Table 2.1 Extracellular antibodies used to identify B-cell subsets by flow 
cytometry 
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2.7 GM 7 Polyclonal agonists applied during CD19+ cell culture 
 
Purified CD19
+
 cells were cultured with polyclonal agonists to induce proliferation and 
differentiation. Details of concentration and combination with additional supplements 
are detailed in Table 2.2. 
 
Table 2.2 Polyclonal agonists used to simulate B-cell proliferation and 
differentiation 
 
2.8 GM 8 HLA antibody detection in serum samples  
 
LABScreen single-antigen (LSA) microbeads (One Lambda, USA) were used to detect 
IgG antibodies to HLA class I and II antigens as prescribed by the manufacturer. In 
brief, 300 μl of wash buffer was added to the required wells of a 96-well filter plate 
and incubated at room temperature. After 10 minutes, the wash buffer was aspirated 
using a vacuum manifold. 20 μl of each serum was added per well with 2.5 μl of 
 
Stimulants 
 
 
Working 
Concentration 
 
 
Company 
 
Reference 
 
R848 (Resiquimod), TLR7/8 ligand 
Recombinant human IL-2 
 
 
 
2.5 µg/ml 
1000 U/ml 
 
 
Autogen Bioclear 
Peprotech 
 
(Tomai et al., 
2000) 
 
 
Type B CpG oligonucleotide 
CpG-B ODN 2006,  TLR9 ligand 
(CpG) 
 
 
10 µg/ml 
 
Invivogen 
 
(Bernasconi et 
al., 2002) 
 
CpG 
Recombinant human CD40 ligand 
(CD40L) 
 
 
10 μg/ml 
1 μg/ml 
 
Invivogen 
R&D Systems 
 
(Gantner et 
al., 2003) 
 
CpG 
CD40L 
Goat anti-human IgA+IgG+IgM 
(anti-Ig) 
 
 
10 μg/ml 
1 μg/ml 
20 μg/ml 
 
 
Invivogen 
R&D Systems 
Jackson 
ImmunoResearch 
Laboratories, Inc. 
 
 
(Bouaziz et al., 
2010) 
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microbeads and the plate was incubated in the dark for 30 minutes with shaking at 
room temperature. Following incubation, 275 μl wash buffer was added to each well 
and aspirated using the vacuum manifold. This step was repeated four times. Finally, 
100 μl of PE-conjugated anti-human IgG was added to each well and incubated for a 
further 30 minutes in the dark at room temperature while shaking. After incubation, 
the plate was washed as stated above and 80 μl PBS added to each well. The plate was 
read using a Luminex 100 IS analyser (One Lambda), and data exported to HLA fusion 
software (One Lambda) for analysis. To normalise data, the Baseline formula was used 
where the LSA microbead value is subtracted from the negative control microbead 
value for both the patient and negative control serum. These two values are then 
subtracted to give a normalised value. 
 
Baseline formula 
 
[(Raw Value of N) – (Raw Value of NC)] - [(Raw Value of N) – (Raw Value of NC)] 
 
                               Patient Sample                                             Negative control serum 
 
N = LSA test beads, NC = negative control bead 
 
To assign the strength of each anti-HLA reaction, results were expressed as mean 
fluorescence intensity (MFI); an MFI greater than 500 were defined as very weak 
positive, above 1000 MFI were weak positive and above 2000 MFI as positive. These 
tests were performed by the Clinical Transplantation Laboratory, Barts and The London 
NHS Trust, London, UK.  
 
2.9 GM 9 HLA-typing by PCR-SSP 
 
HLA Class I and Class II type was derived by DNA typing using the polymerase-chain 
reaction (PCR) with sequence-specific primers (SSP). Patients and donors were typed at 
the HLA-A, -B, -C, HLA-DRB1/B3/B4/B5 and HLA-DQB1 loci. These tests were 
performed by the Clinical Transplantation Laboratory, Barts and The London NHS 
Trust, London, UK.  
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2.10 GM 10   Statistical Analysis 
 
Experimental data was analysed using Prism software (GraphPad Software Inc., USA; 
Version 6.02). A p value of less than 0.05 (<0.05) was considered statistically 
significant. Data analysis is summarised by mean, median and standard deviation (sd). 
For categorical variables, differences were assessed by Chi squared test. The non-
parametric Kruskal-Wallis test with correction for multiple comparisons was used for 
analysis of differences between patient groups. If the p value was significant, where 
the difference lied was explored by investigating the largest median difference 
between groups and the Mann-Whitney test was performed. The Mann-Whitney test 
was also used to investigate differences between unpaired data within groups. 
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3.1 Introduction 
 
Achieving long-term allograft survival can be compromised by detrimental effects of 
memory B cells; this is increasingly relevant as the number of sensitised patients 
awaiting transplantation expands. The existence of a pre-existing humoral response to 
alloantigen is often identifiable by the presence of donor-specific HLA antibody (DSA) 
in serum, resulting in a positive crossmatch upon incubation with donor cells. 
However, alloreactive memory B cells generated as a result of pregnancy, blood 
transfusion or previous transplant can exist in the absence of detectable serum 
antibody. Upon transplantation, memory B cells become activated, resulting in a highly 
damaging secondary immune response. These cells can have a dual role in promoting 
allograft injury; primarily due to the effect of alloantibodies, leading to antibody-
mediated rejection (AMR) and reducing graft survival (Rifle et al., 2005, Campbell et 
al., 2007), but also acting as antigen-presenting cells (APCs), contributing to graft 
rejection by directly activating allospecific T cells. In the clinical setting, pre-
transplantation assessment does not include methods to address the potential for 
alloreactive memory B cells; their presence is unfortunately discovered in light of acute 
antibody-mediated rejection (AAMR).  
 
Within the live-donor transplantation programme, certain donor–recipient pairs are at 
heightened risk of developing AAMR. Of those are women sensitised during pregnancy 
as a result of maternal immunisation to paternal antigens inherited by the foetus. In 
general, pre-formed alloantibodies are detected during pre-transplantation 
assessment and, in the absence of any contraindication, transplantation generally 
proceeds to a favourable outcome. However, AAMR can occur and is reported 
following both offspring–mother and husband–wife transplantation (Rosenberg et al., 
2004, Bohmig et al., 2000, Matsuo et al., 2009). Given this, the policy of some 
transplant centres is not to transplant women with the donor whom they have been 
pregnant with (van Kampen et al., 2002). However with cadaveric donors in short-
supply and increased allograft survival offered by live-donation, for many recipients 
their husband or offspring is the best available option. Accordingly, a method to 
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determine the presence of memory B cells reactive against donor-antigens; indicative 
of AAMR, would benefit patients with undetectable serum HLA antibody. 
 
Detection and enumeration of antibody-secreting B cells was first described using an 
enzyme-linked immunosorbent spot assay (ELISPOT) (Czerkinsky et al., 1983). 
Following this, demonstration that memory B cells could be stimulated to produce 
antibody using polyclonal activators resulted in its application to monitor antigen-
specific memory B cells (Bernasconi et al., 2002). Frequently employed mitogens are 
CpG (TLR 9 agonist), pokeweed mitogen in combination with Staphylococcus aureus 
Cowen, CD40-ligand (CD40L), IL-2 & IL-10 and R848 (TLR7 and 8 agonist) together with 
IL-2 (Pinna et al., 2009, Crotty et al., 2004, Cao et al., 2010). The introduction of 
effective agents to successfully induce polyclonal activation of memory B cells has 
allowed application of ELISPOT in a number of disease settings, including memory B 
cells specific for viral antigen, for example to the anthrax vaccine (Crotty et al., 2004) 
and HIV antigens (Titanji et al., 2006). In addition, is utilised to detect antigen-specific 
B cells of the malaria-causing parasite, Plasmodium falciparum, (Dorfman et al., 2005) 
and blood-group antibodies following ABO-incompatible heart transplantation (Fan et 
al., 2004). Recently designed is an ELISPOT to detect and enumerate HLA-specific 
memory B cells. Synthetic HLA molecules are applied as the detection matrix and this 
assay has been employed in a small cohort of patients as a tool for monitoring post-
transplant alloreactivity (Heidt et al., 2012b).  
 
ELISPOT is a well-established method for detecting memory B cells. However until the 
publication by Heidt and colleagues, (Heidt et al., 2012b) its application has 
predominantly been restricted to the memory recall response to viral antigens. This 
study sought to develop and apply an IgG-detecting ELISPOT to measure and quantify 
the humoral response to alloantigen. By studying a cohort of women, as pre-emptive 
renal allograft recipients from either their husband or offspring, the study aimed to 
establish if this method can provide clinical information of allosensitistion not currently 
detected by conventional pre-transplant assessment and, thus, reduce the risk of 
AMMR. 
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3.2 Materials and methods  
 
Materials and methods detailed in Chapter 2, General Methods (GM) are indicated. 
 
GM1  Recruitment of study patients 
 
GM4  Peripheral blood mononuclear cells (PBMC) separation  
 
GM5  CD19+ cell isolation from PBMC  
 
GM6  Phenotyping CD19+ cells by flow cytometry 
 
GM7  Polyclonal agonists applied during CD19+ cell culture 
 
GM8  Detection of HLA antibody in serum by Luminex technology 
 
GM 9  HLA-typing by PCR-SSP 
 
GM10  Statistical analysis  
 
 
 
Responder-stimulator cell preparation 
 
Responder and stimulator cells (donor-type and third-party) were HLA-typed by PCR-
SSP (GM 9). 
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Stimulator cells – Third-party and donor-type 
 
PBMC were isolated from fresh peripheral whole blood as previously described (GM 4). 
PBMC (1 x 10
6
/ml) were resuspended in RPMI-1640 supplemented with 5% L-
glutamine, 5% penicillin, 5% streptomycin and 10% FCS (complete medium) and 
transferred to a 12-well tissue culture plate (Becton Dickinson; BD) before exposure to 
gamma irradiation at 30 Gy. Following this, cell viability was assessed by Trypan blue 
(0.4%; Invitrogen) exclusion. Cells were washed and resuspended in complete medium 
at 1 x 10
6
/ml. 
 
Responder cells 
 
CD19
+
 cells were isolated from PBMC as described in GM 4 & 5 and resuspended in 
complete medium prior to cell culture. Cells were phenotyped by flow cytometry to 
provide pre-culture B-cell subset frequency (GM 6, Table 2.1). 
 
Allogeneic and polyclonal cell culture conditions 
 
For polyclonal cell culture (GM 7), 100 µl 10
6
/ml CD19
+
 were cultured together with 
either R848 (2.5 μg/ml) and IL-2 (1000 U/ml) or a CpG-mixture (CpG-B 2006 (10 μg/ml); 
CD40L (1 μg/ml) and anti-IgG-IgM-IgA (anti-Ig; 20 μg/ml)) to give a final volume of 200 
µl in complete medium. 
 
For allogeneic cell culture, 100 µl 10
6
/ml CD19
+
 responder B cells and irradiated (30 Gy) 
10
5
/ml donor-type or third-party donor PBMC were resuspended in complete medium. 
 
200 µl of each cell culture were added in triplicate to a 96-well U-bottom plate (BD) 
and incubated at 37 
o
C in 5% CO2 for five days prior to transfer to the ELISPOT assay or 
retained in the plate for phenotype analysis by flow cytometry at day seven. 
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IgG-detecting ELISPOT assay 
 
At day five post-culture, 96-well filter plates (Millipore, MAHA N4510) were pre-wet 
with 70% ethanol (50 µl for 1 minute), washed five times with sterile water and coated 
with 100 µl goat anti-human IgG (1.25 µg/ml, Sigma-Aldrich) and incubated overnight 
at 4 
o
C. Following incubation, the plate was washed five times with PBS and blocked 
with 200 µl complete medium for two hours at room temperature. 
 
At day six post-culture, 200 µl of cell cultures were plated in duplicate into the pre-
coated wells and incubated for 24 hours at 37 
o
C, 5% CO2. For development, the plate 
was washed five times with PBS and 100 µl mouse anti-human IgG Fc biotin-
conjugated antibody (1 µg/ml; Sigma-Aldrich) in PBS/0.5% FCS added per well and 
incubated for two hours at room temperature in a humid chamber. The plate was 
washed and 100 µl of streptavidin–alkaline phosphate (1 µg/ml; Sigma-Aldrich) applied 
per well for 45 minutes at room temperature in the dark. After a further wash, 100 µl 
of the development reagent, BCIP/NBT (Mabtech) was added for 10 minutes at room 
temperature. This reaction was stopped by extensive washing under running water. 
The plate was allowed to dry overnight and analysed using an automated ELISPOT 
plate reader (AID). 
 
Post-culture phenotype analysis by flow cytometry 
 
Post-culture, responder CD19
+
 cells were assessed for expression of B-cell subsets by 
flow cytometry (GM 6, Table 2.1). Stimulator cells (donor-type and
 
third-party) were 
also assessed for expression of CD4 using a mouse anti-human eFlour 450-labeled 
monoclonal antibody (Clone SK3; eBioscience). To confirm the efficacy of irradiation, 
both irradiated and non-irradiated cells were examined. 
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3.3 Results  
 
This study aimed to determine if the alloresponse to donor-antigen could be measured 
by the frequency of antibody-secreting cells (ASC), utilising an IgG-detecting ELISPOT.   
Purified CD19
+
 cells (responder cells) cultured with donor-type PBMC (stimulator cells) 
were assessed for spot-forming units (SFU), each equating to a single IgG-secreting B 
cell.   
 
CD19
+
 cells represent a small percentage of lymphocytes even in healthy individuals 
(approximately 5-10%) and are reduced in patients with ESRF (Descamps-Latscha and 
Chatenoud, 1996, Pahl et al., 2010). Therefore to maximise cell number available for 
analysis in the pre-transplant study cohort, methods were initially optimised in healthy 
women, sensitised through pregnancy. Sensitisation was defined by serum analysis for 
HLA antibody against paternal antigen by Luminex technology. 
 
Optimising polyclonal activation of IgG-producing B cells detected by ELISPOT 
 
CD19
+
 cells purified from PBMC of sensitised women (n = 4) were polyclonally 
activated with TLR agonists previously described to induce expansion and 
differentiation of human memory B cells: R848  and  IL-2 (Pinna et al., 2009) and  CpG-
B 2006 together with CD40L and anti-human IgG-IgM-IgA (CpG-mixture) (Bouaziz et al., 
2010). The optimal concentration of each TLR agonist was assessed (Figure 3.1C). In 
both cases, the higher concentration of R848 (1000 U/ml) and CpG (10 µg/ml) 
promoted the greater expansion of ASC as detected by the ELISPOT assay (p = 0.43). In 
addition, the number of ASC was marginally higher at a seven-day interval compared to 
day-five or day 10 (p = 0.7; Figure 3.1D). Due to the limited number of CD19
+
 cells 
available, it was only possible to assess this during culture with the ‘CpG-mixture’. 
 
Comparing effectiveness of the TLR agonists, cell culture with the CpG-mixture induced 
greater expansion of ASC (96 ± 92 SFU vs. 58 ± 72 SFU by ELISPOT for CpG vs. R848 
respectively, Figure 3.1C). Phenotypic analysis demonstrated the majority of cells were 
non-switched memory B cells, particularly following culture with R848 and IL-2 (Figure 
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3.1E). The distinct pre-culture memory B-cell population was no longer present, 
however, overall a larger proportion of memory B cells existed following cell culture 
with the CpG mixture (31.26 ± 12.41% vs. 16.32 ± 9.25% for CpG vs. R848 respectively; 
Figure 3.1E). This, together with a greater proportion of ASC by ELISPOT, resulted in its 
use hereafter to polyclonally stimulate CD19
+
 cells and served as the positive control. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1   Optimising polyclonal expansion and differentiation of antibody-
secreting and memory B cells 
CD19+ cells from women sensitised by pregnancy (n = 4) as defined by serum analysis 
for HLA antibody were isolated from PBMC and cultured for 7 days with TLR agonist 
cocktails; R848 & IL-2 or ‘CpG mixture’. Post-culture, cells were assessed for IgG-
secretion by ELISPOT. Representative images of (A) unstimulated and (B) CpG-
activated B cells are shown. (C) The dot-plot represents mean number of spot-forming 
units (SFU) per duplicate well following culture at two concentrations with the TRL 
agonists. (D) At day 7 post-culture, the number of SFU detected following culture with 
the CpG mixture was marginally higher. ns is not-significant derived from Kruskal-
Wallis test. (E) Representative flow-cytometric plots show CD19+ cell co-expression of 
CD27 and IgD at day zero and day 7 with R848 & IL-2 or CpG mixture. Percentages 
denote proportion in each quadrant with phenotype typical of naïve, non-switched 
memory and memory B cells. 
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Measuring the alloresponse of recipient CD19+ cells to donor-antigen by an IgG 
detecting ELISPOT in sensitised healthy controls 
 
An IgG-detecting ELISPOT was applied to measure the alloresponse to donor-antigen 
using CD19
+
 cells isolated from the same cohort of women described, cultured with 
PBMC from their husband (donor-type stimulator cells). To control for specificity, cells 
were also stimulated with third-party PBMC, derived from a donor not expressing HLA 
matching the donor or which the recipient had pre-formed antibodies against. 
 
The frequency of IgG-secreting B cells following culture with a range of concentrations 
of donor-type or third-party cells was investigated (Figure 3.2). To prevent excessive 
proliferation of stimulator cells; donor-type and third-party PBMC were irradiated at 
30 Gy; a standard dose applied in numerous responder: stimulator assays (Game et al., 
2003, Tapirdamaz et al., 2010, Tanaka et al., 2012). The ELISPOT failed to discriminate 
between the responses to donor-type or third-party stimulation. Since the most 
evident separation was achieved at the lowest concentration of stimulator cells (1 x 
10
5
/ml donor-type PBMC: 1 x 10
6
/ml CD19
+
 cells) when compared with non-specific 
stimulation by third-party donor cells, this concentration was applied in the pre-
transplant study cohort. Due to the limited number of CD19
+
 cells, it was not possible 
to show the phenotype of these populations by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2  The IgG-detecting ELISPOT failed to discriminate between donor-
type or third-party stimulation  
Responder CD19+cells (n = 4; 1 x 106/ml) were assessed for spot-forming units (SFU) 
7 days after culture with irradiated (30 Gy) third-party or donor-type PBMC at a range 
of concentrations. 
The bar-chart shows the mean SFU for duplicate wells (error bars represent standard 
deviation) at each concentration of stimulator cells. ns is not-significant derived from 
Kruskal-Wallis test by comparing the median SFU following third-party to donor-type 
cell culture at each concentration (p = 0.07).  
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Measuring the alloresponse in the pre-transplantation study cohort 
 
To examine capability for measuring the humoral immune response before 
transplantation, a cohort of potential recipients (n = 12) were identified with defined 
pre-sensitisation to their donor or where a memory response was suspected as a result 
of pregnancy. In the majority of cases the donor was the father of a woman’s offspring 
(83%). Patients were separated by level of sensitisation as detected in serum by 
Luminex single-antigen (LSA) analysis and demographics are shown in Table 3.1. 
 
 
Table 3.1 Patient demographics for the pre-transplantation cohort 
 
FCM, flow-cytometric crossmatch; CDC, complement-dependent cytotoxicity; DSA, donor-
specific HLA antigen; NDSA, non-donor-specific HLA antigen; sd, standard deviation; 
UnSens, unsensitised. 
 
  
Unsensitised 
UnSens 
(n = 4) 
 
Sensitised 
NDSA 
(n = 3) 
 
Sensitised 
DSA 
(n = 5) 
Age,  median (range) 
Recipient 
Donor 
 
 
57 (52-63) 
36 (31-52) 
 
33 (28-46) 
36 (32-45) 
 
50 (30-60) 
46 (34-55) 
Relationship 
Husband: offspring, n 
 
2: 2 
 
3: 0 
 
5: 0 
 
 
Previous transplant, n (%) 
 
 
0 
 
1 (33) 
 
3 (60) 
HLA mismatches, n ± sd 
-A, mean ± sd 
-B, mean ± sd 
-C, mean ± sd 
 
-DR, mean ± sd 
-DQ, mean ± sd 
 
 
1 ± 0 
1.5 ± 0.6 
1.3 ± 0.5 
 
1 ± 0.8 
1 ± 0 
 
 
1.7 ± 0.6 
2 ± 0 
1.3 ± 0.6 
 
1.3 ± 1.2 
0.7 ± 0.6 
 
 
1.4 ± 0.6 
1.4 ± 0.6 
1.5 ± 0.6 
 
1.8 ± 0.5 
1.6 ± 0.6 
 
Pre-transplant assessment, 
Positive, n (%) 
T-cell FCM 
B-cell FCM 
CDC assay 
 
 
0 
0 
0 
 
 
0 
0 
0 
 
 
3 (60) 
4 (80) 
0 
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Measuring the frequency of antibody-secreting cells to donor-antigen by 
ELISPOT 
 
The IgG-detecting ELISPOT was applied to donor-recipient pairs, prior to 
transplantation. Clinically, identifying a memory B-cell response in recipients where 
sensitisation to a potential donor is not identified by serum analysis for HLA antibody 
would benefit these patients at risk of AAMR; therefore of particular interest was the 
unsensitised (UnSens) group. Figure 3.3 shows the number of ASC detected by ELISPOT 
when CD19
+
 cells from each of the three groups remained unstimulated (negative 
control) or co-cultured with the polyclonal agonist (positive control) or with donor-
type or third-party PBMC.  
 
The number of ASC observed following each culture condition was compared between 
groups, overall no significant difference was found (p = 0.06). Examining the B-cell 
response to donor-type cell stimulation showed while ASC expanded when compared 
to unstimulated cells in all three groups; this failed to reach a level of statistical 
significance, and although the number of ASC were greater in the DSA group, the 
difference between groups was minimal (48 ± 38, 32 ± 17 and 40 ± 17 IgG
+
 SFU/well for 
DSA, NDSA and UnSens groups respectively). Moreover, the response to third-party 
stimulation was of similar magnitude in each group, questioning the specificity of the 
donor-type response.  
 
Next each culture condition was compared to unstimulated cells within patient groups. 
Following polyclonal stimulation, when compared with unstimulated cultures, there 
was expansion of ASC in sensitised patients whether their antibodies were NDSA (20 ± 
15 vs. 165 ± 32 IgG
+
 SFU/well; unstimulated vs. polyclonal stimulation, p = 0.06) or 
significantly so, DSA (18 ± 17 vs. 144 ± 115 IgG
+
 SFU/well; unstimulated vs. polyclonal 
stimulation, p = 0.03), which was absent in the UnSens group (16 ± 11 vs. 20 ± 36 IgG
+
 
SFU/well; unstimulated vs. polyclonal stimulation, p = 0.82). 
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If the number of ASC detected by ELISPOT following allogeneic stimulation was 
compared to unstimulated cells within groups, the response to did not alter 
significantly with either third-party or donor-type cells. 
 
Overall these data demonstrate this ELISPOT cannot discriminate between the 
response to third-party and donor-type cell stimulation nor does it suggest patients 
with known sensitisation to their potential donor are more responsive to in vitro 
stimulation by donor cells, as measured by capacity to produce ASC. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Assessing alloreactivity between donor-recipient pairs prior to 
transplantation by IgG-detecting ELISPOT  
CD19+ cells were assessed for ASC by an IgG-detecting ELISPOT at day seven post-
culture following stimulation with a polyclonal agonist (positive control), third-party 
or donor-type allogeneic PBMC. Unstimulated cells served as the negative control.  
The dot-plot shows mean values of spot-forming units (SFU) of duplicate wells for 
each patient group: unsensitised (UnSens; n = 4), with donor-specific HLA antibodies 
(DSA; n = 5) or non-DSA (NDSA; n = 3) as defined by serum analysis for HLA 
antibodies by Luminex technology. There were no statistical significances between 
groups (p = 0.06) derived from the Kruskal-Wallis test. Comparing within groups, 
there was a significant difference in the number of ASC in patients with DSA 
following polyclonal stimulation compared to unstimulated cells (p = 0.03 by Mann-
Whitney test. 
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To characterise the cellular representation post-culture; the frequency of naïve and 
memory B cells were assessed. First, the pre-culture frequency of memory B cells were 
not significantly altered between groups (20.39% ± 7.5%, 14.19% ± 5.74 and 25.88% ± 
14.45, p = 0.46; UnSens, NDSA and DSA groups respectively). Post-culture, expression 
(percentage or absolute number) of both naïve (p = 0.76) and memory (p = 0.72) B cells 
also did not alter significantly between groups (Figure 3.4A and B). However, as the 
figures demonstrate, there are differences in the distribution of naïve and memory B 
cells following cell-culture conditions between the UnSens group and both the DSA and 
NDSA groups, but the small number of patients investigated results in a lack of 
statistical power. To confirm if these observed differences reflect pre-existing 
sensitisation would require a larger sample size. In particular, there may be statistical 
significance post-culture with donor-type cells, where memory B-cell frequency was 
seen to expand in sensitised patients when compared to the UnSens group (6.43% ± 
2.98%, 21.14% ± 4.12 and 25.38% ± 7.76; UnSens, NDSA and DSA groups respectively, 
Figure 3.4B). Moreover, patients with DSA appeared to be more responsive to memory 
B-cell activation following polyclonal stimulation when compared to the UnSens group 
(4.23% ± 2.12%, 21.43% ± 16.75 and 34.94% ± 25.26; UnSens, NDSA & DSA groups 
respectively).  
 
Similarly, while lacking statistical significance, naïve B-cell distribution post-culture was 
reduced in both sensitised groups compared to the UnSens group (47.02% ± 11.05%, 
18.79% ± 6.64 and 15.00% ± 8.79; UnSens compared to NDSA and DSA groups, Figure 
3.4A).  
 
Next distribution of both B-cell subsets within each patient group were compared by 
the frequency of unstimulated cells against culture conditions (polyclonal agonists or 
third-party and donor-type stimulator cells). Again no statistical differences were 
found. Particularly the UnSens group were relatively unaffected by cell-culture 
conditions, overall representing the lowest frequency of memory B cells (Figure 3.4B), 
and predominance of naïve B cells compared to sensitised patients (Figure 3.4A). For 
sensitised groups, the observed frequency of naive and memory B cells supported the 
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ELISPOT data; where B cells are responsive to the CpG mixture, and there was no 
notable difference between third-party and donor-type cell stimulation. 
 
Overall, the small number of patients studied limits the application of statistical tests 
and future studies would benefit from a larger cohort. However, the preliminary 
results obtained by the Ig-G detecting ELISPOT were not encouraging to pursue this 
study further. 
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Figure 3.4  Post-culture phenotyping of recipient CD19+ cells for expression 
of naïve and memory B cells 
CD19+ cells isolated from PBMC were cultured for 7 days with a polyclonal agonist; 
third-party or donor-type allogeneic cells, stained for CD19, CD27 & IgD and analysed 
by flow cytometry.  
The dot-plots show the frequency of naïve (CD19+CD27-IgD+; A) and memory 
(CD19+CD27+IgD-; B) B cells for each patient group defined as unsensitised (UnSens; n 
= 4) or with serum defined HLA antibody as donor-specific antigen (DSA; n = 5, or non-
DSA (NDSA; n = 3). Statistical analysis was performed using the Kruskal-Wallis test 
comparing the frequency of naïve and memory B cells between groups (p = 0.76 and p 
= 0.72 for naïve and memory B-cell frequency respectively). Comparing unstimulated 
cells with culture conditions within each group was performed by Mann-Whitney test. 
This did not show any statistical difference (all p > 0.05).  
 
 
 
 Memory B cells 
A 
B 
Naïve B cells 
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3.4 Discussion 
 
The ability to measure memory B-cell activity, as a potential route to producing 
alloantibody, would benefit certain patients entering the transplantation programme. 
In particular are those at heightened risk of AAMR; this generally describes a person 
having a second transplant sensitised by the first, and also includes women sensitised 
toward paternal antigen through pregnancy who are pre-emptive recipients of an 
allograft from that donor. Current methods employed during pre-transplant 
assessment assume compatibility between donor and recipient in the absence of DSA 
detectable in serum.  
 
This study attempted to measure the frequency of allospecific B cells in pre-transplant 
recipients by an IgG-detecting ELISPOT assay where allogeneic donor cells served to 
stimulate responder B cells, analogous to the transplant environment. To control for 
specificity, unstimulated CD19
+
 cells served as a negative control and demonstrated a 
low-level of IgG-secretion by B cells. As a positive control or a measure of total 
memory B-cell responsiveness, regardless of antigen specificity, CD19
+
 cells were 
activated with polyclonal activators, the TLR9 agonist; CpG or R848, a TLR 7 and 8 
agonist. Both induce BCR stimulation in the absence of T-cell help, (Poeck et al., 2004) 
and CpG in particular has been cited as a potent activator of memory B cells 
(Bernasconi et al., 2003, Hornung et al., 2002). In this study, CD19
+ 
cells from women 
sensitised through pregnancy, upon TLR ligation, demonstrated a greater response to 
polyclonal stimulation by CpG than R848, as detected by the IgG-detecting ELISPOT 
assay, and CpG was chosen for use in subsequent investigations with the pre-
transplantation cohort. 
 
Refining for specificity, reactivity toward allogeneic antigen was measured and minimal 
difference was found in the number of ASC between unsensitised and sensitised 
patients in response to donor-antigen. Moreover, the response to third-party antigen 
was comparable. Third-party donor cells were selected based on expression of HLA 
molecules distinct from the donor or pre-formed antibodies defined by serum analysis. 
Due to the limited number of HLA-typed third-party donors, it was not possible to 
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avoid all HLA antibody specificities in highly sensitised patients; while DSA were 
avoided, NDSA could not. However, given that unsensitised patients demonstrated 
comparable frequency of ASC in response to third-party antigen, this was probably not 
the contributory cause. An alternative possible explanation was the concentration of T 
cells in stimulator populations was too high, potentially activating B cells in the 
absence of BCR triggering. T cells activated by third-party antigen are capable of 
stimulating B cells via non-cognate interaction between CD40 on B cells and CD40L on 
T cells and cytokine production (Lanzavecchia et al., 1983). More recently it was 
demonstrated that while naïve B cells require BCR stimulation to proliferate in 
response to CpG, in the presence of T-cell help, memory B cells can respond with T-cell 
help alone to result in proliferation of memory B cells and differentiation to plasma 
cells (Bernasconi et al., 2002).  
 
Overall, in these experiments, while recognising this was a very small cohort, I have to 
conclude that the application of this ELISPOT could not distinguish between the third-
party and antigen-specific allogeneic response, limiting its value as a tool for 
interrogating any donor-specific response.  
 
In parallel to the ELISPOT, the phenotype of recipient cells post-culture was addressed 
to determine the distribution of naïve and memory B cells. On appearance, memory B 
cells were elevated in sensitised patients following polyclonal, third-party and donor-
type stimulation, and as demonstrated by ELISPOT and ASC number, memory B-cell 
frequency was comparable in response to either third-party or donor-type cells. 
However, potentially due to the small number of patients investigated together with 
the variance in B-cell subset frequency between patients no significant differences in 
both naïve and memory B cell distribution were found between groups. 
 
Supporting their activation status as cells which have not previously encountered 
antigen, unsensitised patients demonstrated a low frequency of memory B cells 
coupled with greater frequency of naïve B cells, unaltered in response to polyclonal or 
allogeneic stimulation. This was supported by the absence of detectable serum HLA 
antibody and suggests these patients may not be at risk of AAMR. As only a small 
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proportion of patients experience AAMR following transplantation, and given the 
cohort size of this study, it is quite probable to have not captured any patients who 
would actually suffer AAMR. Further study in a larger cohort and retrospective analysis 
post-transplant to establish if this method can identify those at higher risk is necessary. 
However the preliminary data generated by ELISPOT were not encouraging and did not 
warrant further effort. 
 
The key feature of ELISPOT is the inherent sensitivity: it is capable of detecting 
antibody secretion at the single-cell level. However, in addition to the issue of antigen-
specificity, there are numerous factors limiting its clinical application. First, access to 
donor and third-party cells, together with a source of irradiation may be impractical. In 
addition, ELISPOT gives information only of that population of responder cells, for 
additional phenotypic information it must be used in conjunction with flow cytometry 
requiring a relatively large number of B cells, while generally achievable pre-transplant, 
would probably not be feasible following transplant when B-cell numbers are affected 
by immunosuppression. Moreover, a limiting factor of this assay, and equally any 
functional assay accessing B cells from the periphery, is the unknown degree of 
representation in lymphoid organs as these cells may only represent a fraction of those 
with alloantibody-producing capability. Finally, a specific limitation of this IgG-
detecting ELISPOT is the lack of specificity for HLA. Recently, synthetic HLA molecules 
have been constructed and applied to the ELISPOT detection matrix to enumerate HLA-
specific memory B cells. (Heidt et al., 2012b). While technically feasible, use of HLA 
monomers is very expensive and together with high polymorphism of the HLA system 
would require patient-specific design, limiting general clinical application. 
 
Concluding remarks  
 
Examining the presence of DSA in serum provides an individual’s antibody repertoire, 
but is not informative about the patient’s latent memory B cells. This study described a 
method for detecting allospecific B cells in the periphery.  In this small cohort, 
observations were not encouraging to suggest this method be applied in the pre-
transplant setting as an indication of alloreactivity. An alternative approach might be 
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to directly identify circulating HLA-specific B cells by flow-cytometry to predict the B-
cell response to donor antigen. This could potentially be a valuable tool in both the 
pre- and post-transplant setting. Such an approach is described in the next chapter. 
 
  
 
 
 
 
Chapter 4 
 
Identifying donor HLA-specific B cells in 
the periphery 
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4.1 Introduction 
 
The presence of HLA antibody is an identifying feature of alloreactivity and is 
associated with both early and late graft loss (Everly et al., 2009, Worthington et al., 
2003, Zhang et al., 2005). Retrospective analysis of patients with failed grafts shows a 
higher prevalence of HLA antibody (Mizutani et al., 2005, Lee et al., 2009). Moreover, 
their absence is predictive of superior graft survival (Lefaucheur et al., 2010, van 
Timmeren et al., 2009). Accordingly, much effort is centred on characterising HLA 
antibodies and the advent of solid-phase assays coupled with Luminex technology has 
increased the sensitivity of our ability to detect them.  
  
In the pre-transplant setting, finer definition of HLA antibodies permits a wider 
selection of permissible donors for sensitised patients and provides a useful tool 
during desensitisation protocols to assess the efficacy of treatment. During the post-
transplant period, early detection and diagnosis of antibody-mediated rejection (AMR) 
could prevent development of chronic rejection and transplant glomerulopathy (TG) 
(El-Zoghby et al., 2009, Issa et al., 2008). In either setting, a patient’s profile of HLA 
antibody specificity is defined by analysing serum. These specificities reflect the 
presence of B cells actively secreting antibody; yet little is known of the cells 
themselves as to their prevalence, relationship with secreted levels of alloantibody or 
phenotypic characteristics.  
 
Donor HLA-specific B cells (DS-B cells) are very rare in the circulation; however 
identification is feasible and has been demonstrated through the use of HLA tetramers. 
Tetramers are conventionally used to detect HLA-specific T cells by acting as surrogate 
APC binding with high avidity to a T-cell receptor specific for the given HLA molecule 
(Altman et al., 1996, Burrows et al., 2000). These complexes consist of four-identical 
HLA-molecules embedded with biotin-labelled peptide bound to a fluorescently 
labelled streptavidin molecule, allowing detection and enumeration by flow-cytometry 
(Altman, 2004). This approach has been transferred to enable identification of antigen-
specific B cells by exploiting the nature of the B-cell receptor (BCR) to bind native, 
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unprocessed antigen. This was first applied in mice to detect B cells specific for a 
nominal antigen (R4A peptide) (Newman et al., 2003). In humans, DS-B cells were 
detected in women sensitised to HLA-A2 via pregnancy, demonstrating tetrameric 
HLA-A2 was capable of recognising HLA-A2-specific BCR (Mulder et al., 2003). This 
method was later applied to renal transplant recipients (Zachary et al., 2007). Here, a 
higher frequency of B cells bound to HLA-A*0201, HLA-A*2402 & HLA-B*0702 in 
sensitised compared to non-sensitised patients. Moreover, cell-culture with polyclonal 
agonists induced secretion of HLA antibody sharing specificity with the HLA antigen of 
the tetramer. Collectively, these studies showed DS-B cells can be detected in the 
periphery by utilising the capability of a BCR to bind synthetic HLA molecules; 
importantly, this proved sufficiently sensitive in immunosuppressed patients. In 
addition to peripheral identification of DS-B cells, HLA-specific pentamers (a 
development on the use of tetramers) have been successfully applied in situ to 
examine a murine model of the alloresponse (Panoskaltsis-Mortari et al., 2008). Using 
H2-pentamers, allospecific CD19
+ 
cells were identified within spleen sections by 
immunohistochemistry. 
 
The study by Zachary and colleagues demonstrated differential expression of DS-B cells 
post-transplant as an index of sensitisation. The ability to achieve this through 
analysing peripheral blood is an attractive concept to explore further. Of particular 
interest is the development of de novo donor-specific HLA-antibodies (dnDSA) formed 
against the allograft in patients who had no evidence of sensitisation prior to 
transplant.  dnDSA are increasingly recognised as contributing toward antibody-
mediated injury and reduced allograft survival (Terasaki et al., 2007, Willicombe et al., 
2011, Yabu et al., 2011, Wiebe et al., 2012). Indeed, dnDSA are attributed with a 10-
fold increase in the risk of allograft failure, resulting in 40% lower graft survival at 10 
years (Wiebe et al., 2012). Specifically, HLA-class II antibodies are more prominent 
than class I (Everly et al., 2013, Gloor et al., 2007). Recently DQ antibodies are reported 
as the most prevalent dnDSA and associated with inferior outcome (Everly et al., 2013, 
DeVos et al., 2012, Willicombe et al., 2012, Freitas et al., 2013). This could indicate 
discordance between matching at the HLA-DR and HLA-DQ loci. Currently, HLA-DQ is 
not included in HLA-matching algorithms used for organ allocation programmes due to 
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the supposed strong linkage disequilibrium between HLA-DR and HLA-DQ (Navarrete 
et al., 1985). However, the frequency of HLA-DQ incompatibility in HLA-DR-matched 
transplant recipients is not known; mismatching for HLA-DQ may me a major risk 
factor for DSA development. These data suggest characterising the B cells responsible 
for their secretion could promote understanding for this apparent enhanced 
immunogenicity.  
 
In addition to characterising DS-B cells in patients with dnDSA, there are further clinical 
applications. First, detection of HLA antibody in serum can be transient and identifying 
peripheral DS-B cells could benefit patients with historic unacceptable-defined HLA 
antibodies (UDA) who are awaiting transplantation or where historic serum is not 
available and the presence of donor-specific memory B cells are suspected. This poses 
a particular risk for recipients previously sensitised through pregnancy, affecting 
women receiving allografts from their offspring or the father of their children. Second, 
detecting DS-B cells could minimise the impact of dnDSA arising in the immediate post-
transplant period. This suggests DSA are potentially missed during analysis of serum 
which could be attributed to a high MFI cut-off or lack of historic sera, resulting in a 
misleading negative-crossmatch.   
 
While the detrimental effect on allograft survival of DSA directed against HLA-A, -B and 
-DR proteins is well established; with an emerging view of similar involvement by HLA-
DQ, little is known of the B cells responsible for their production. This study aimed to 
detect, characterise and quantify DS-B cells in transplanted patients with varying 
degrees of sensitisation to their allograft, as determined by serum analysis. Detailing 
their magnitude may allow for monitoring the effectiveness of treatment, and 
describing phenotypic characteristics may provide insight for development of targeted 
therapy to aid their removal. 
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4.2 Materials and methods  
 
Materials and methods detailed in Chapter 2, General Methods (GM) are indicated. 
 
GM1  Recruitment of study patients 
 
GM2  Immunosuppressive regimen  
 
GM3  Defining level of allograft function in patient cohorts  
 
GM4  Peripheral blood mononuclear cells (PBMC) separation  
 
GM5  CD19+ cell isolation from PBMC  
 
GM6  Phenotyping CD19+ cells by flow cytometry  
 
GM8  Detection of HLA antibody in serum by Luminex technology 
 
GM10  Statistical analysis  
 
 
Detection of DS-B cells using HLA-coated microbeads by flow-cytometry 
 
LABScreen single-antigen (LSA) microbeads (One Lambda) in conjunction with Luminex 
technology are conventionally used to detect HLA antibody in serum samples. 
Measuring 5.6 μm, these polystyrene beads are coated with HLA-antigen of a single 
specificity derived from a transfected human cell line. In this study, these properties 
were exploited to detect B cells with a BCR specific for the same HLA molecule as was 
coupled to the microbead surface. The microbeads contain a fluorochrome allowing 
detection by flow cytometry. Using the 635 nm red-diode laser, this excites the 
fluorochrome-labelled microbeads to emit light at 658-712 nm and the flow cytometer 
can be programmed to analyse cells in this channel. Additional B-cell markers can be 
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examined simultaneously by selecting fluorochromes excited by different lasers and 
emitting light in different channels. 
 
CD19
+
 cells were isolated from PBMC (GM 4 & 5) and stained with the extracellular 
antibody B-cell panel or isotype controls (GM 6, Table 2.1). 3 x 10
5
 CD19
+
 cells were 
resuspended in 50 μl FACS buffer (PBS/2% FCS) and 5 μl LABScreen single-antigen 
microbeads (One Lambda) bearing HLA-A*0201, HLA-A*0203 or HLA-DQB1*0301 and 
incubated in the dark for 45 minutes with mixing every 15 minutes. Without washing, 
CD19
+
 cells were analysed immediately by flow cytometry. A minimum of 250,000 
events were collected and data were exported to Flowjo (Tree star Inc.) for analysis. 
Double-positive CD19
+
HLA
+
 cells were selected above a background threshold of 0.05% 
based on cells stained with only the CD19 antibody. 
 
Statistical analysis of rare events by flow cytometry 
 
For analysing a population of cells representing <1% of the total, Poisson distribution 
statistics were applied. This describes the probablity of a random event occuring in a 
fixed volume. Based on the lowest frequency of positive events expected for 
CD19
+
HLA
+ 
cells  (0.01% or 30 events), a minimum of 2.5 x 10
5
 total events were 
aquired (Hedley and Keeney, 2013). This was achieved from a starting population of 3 x 
10
5
 CD19
+
 cells and equates to a 20% Poisson coefficent of variation (CV) of the 
counting error. This is defined as 100/√posibve events counted. In this case,  the actual 
CV is 18.25% (100/√30). 
 
Ethical approval for the observation study of de novo donor specific antibody 
development in a single renal transplant centre 
 
HLA antibody data and renal allograft outcome details were taken from information 
collated and stored by the Clinical Transplantation Laboratory, Barts and the London 
NHS Trust.  This research study audited current practice to assess de novo HLA 
antibody production and graft outcome. Since the data analysed was anonymised and 
from established procedures it did not require specific ethical approval. 
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4.3 Results 
 
Establishing the principle of identifying DS-B cells in the periphery 
 
To establish the feasibility of identifying DS-B cells in peripheral whole blood using a 
flow-cytometric based method, two groups of transplanted patients were selected 
based on sensitisation to HLA-A*0201, as this antigen is expressed at high frequency 
within the donor population. Both groups had received an allograft mismatched for 
this antigen and during the post-transplant period tested positive or negative for anti-
HLA-A*0201 (HLA-A2) in serum samples by Luminex single-antigen (LSA) analysis. The 
anti-HLA-A2 group (n = 5) had an MFI of >1000 (range; 1230-8675 MFI) and the 
unsensitised (anti-HLA
-
) group (n = 5) all had an MFI <150. The ability of CD19
+
 cells 
isolated from these patients to bind microbeads coated with recombinant HLA-A*0201 
was assessed by flow cytometry (Figure 4.1). A small population of CD19
+
anti-HLA-
A*0201 cells is evident in the ‘test’ (Figure 4.1B) but not the negative control (Figure 
4.1A).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD19 
Anti-HLA-A*0201 
Figure 4.1 Post-transplantation detection of CD19+ anti-HLA-A*0201 cells by 
flow cytometry 
CD19+ cells (3 x 105) from HLA-A2 mismatched patients (n = 5) were isolated from 
PBMC and binding to microbeads coated with HLA-A*0201 assessed by flow 
cytometry. 
Representative flow-cytometric plots show the negative control, CD19 cells stained for 
CD19 only (A) used to determine the percentage of anti-HLA-A*0201 positive CD19+ 
cells (B). 
 
0.04% 0.11% 
A B 
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In an effort to increase the detection frequency of CD19
+ 
anti-HLA-A*0201 cells, CD19
+
 
cells were cultured with a polyclonal agonist against TLR7 (R848) and IL-2, known to 
induce B-cell expansion (Pinna et al., 2009). However, this resulted in high-level non-
specific staining which could not be eliminated by stringent gating of lymphocytes 
(data not shown); therefore using cultured CD19
+ 
cells was rejected. In addition, the 
efficacy of pentamers of HLA-A*0201 was investigated in a small number of sensitised 
patients (n = 4). Compared to HLA-coated microbeads, this method suffered from 
considerable non-specific staining (data not shown). As a consequence, and due to 
their high-cost, they were not utilised further and all subsequent investigations 
employed HLA-coated microbeads with freshly isolated CD19
+
 cells.  
 
The volume of microbeads (suspended at a constant concentration) used per test was 
assessed in relation to the detected frequency of CD19
+ 
anti-HLA-A*0201 specific cells 
in sensitised patients (n = 3) and 5 μl proved to have an adequate concentration to 
produce saturation at a standardised concentration of CD19
+
 cells (Figure 4.2). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2  Optimising HLA-A*0201 
microbead concentration used per test  
CD19+ cells (2 x 105) from HLA-A2 
mismatched patients (n = 3) were isolated 
from PBMC and binding to 2.5 μl, 5 μl or 10 
μl of microbeads was assessed by flow 
cytometry for frequency of CD19+ anti-HLA-
A*0201 specific cells.  
The dot-plot shows the mean percentage of 
CD19+ anti-HLA-A*0201 specific cells and 
increasing volumes of microbeads at 
constant concentration. 5 μl was an adequate 
volume per test as determined by comparing 
the frequency of CD19+ anti-HLA-A*0201 
specific cells to other volumes by the 
Kruskal-Wallis test (p = 0.04), and was used 
throughout. 
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Selecting a negative control 
 
Selecting a negative control was problematic due to the difficulty identifying an 
irrelevant HLA-specificity with a clear absence of potential memory B cells. Initially, 
HLA-A*4301 microbeads were used as antibodies against this antigen are relatively 
rare, but this did not give uniform negativity in all patients. Next, CD19
+
 cells from 
unsensitised male volunteers were investigated as employed by Zachary and 
colleagues (Zachary et al., 2007). However, using CD19
+
 cells from each patient labelled 
only with CD19 antibody allowed for more stringent selection of antigen-specific B 
cells. While not an ideal negative control, this gave the best consistency, and was used 
across the study cohort.              
 
Investigating level of specificity of donor-specific B cells toward HLA-coated 
microbeads 
 
Most often antibody-specificity is defined at the level of the broad HLA-A2 serotype. 
The serotype encompasses the genotypes of many HLA-A2 alleles, usually against 
epitopes expressed by HLA-A*0201,*0202,*0203,*0206 and *0207. To address the 
level of allelic specificity CD19
+
 cells isolated from sensitised patients had toward HLA-
coated microbeads, HLA-A*0203 microbeads were applied in conjunction with HLA-
A*0201 microbeads to those with serum antibody specificity against only HLA-A*0203. 
However, after extensive review, I could find only two patients who met these criteria, 
and the results were inconclusive. Therefore this study was unable to determine the 
application of this approach to the allelic level of antibody specificity. 
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Elevated frequency of peripheral CD19+ anti-HLA-A*0201 cells in sensitised 
patients 
 
Transplanted patients with donor-specific anti-HLA-A*0201 antibody defined by serum 
analysis demonstrated a higher frequency of CD19
+
 cells capable of binding HLA-
A*0201 microbeads compared to unsensitised patients (0.12 ± 0.05% and 0.04 ± 
0.01%, anti-HLA-A2
+
 and anti-HLA
-
 respectively; p=0.008, Figure 4.3A). Assessing if a 
correlation exists between heightened level of serum antibody and frequency of cells 
bearing that specificity showed a positive trend, however the relationship was not 
significant (R
2
=0.52; p=0.17, Figure 4.3B). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These data confirmed the principle and methodology of the assay – that is was capable 
of detecting B-cell reactivity to donor-specific antigen presented on microbeads – and 
it was therefore applied to further patient groups. 
 
Figure 4.3 Increased frequency of CD19+ anti-HLA-A*0201 cells in patients 
with anti-HLA-A*0201 DSA detected in serum  
CD19+ cells from patients mismatched for HLA-A2; without HLA antibodies (anti-HLA-
; n = 5) or with donor-specific HLA antibody (DSA; n = 5) were isolated from PBMC 
and assessed for ability to bind microbeads coated with HLA-A*0201 by flow 
cytometry. 
 A. The dot-plot shows frequency of CD19+ cells bound to HLA-A*0201 microbeads was 
significantly higher in sensitised patients (p=0.008 by the Mann-Whitney test 
comparing anti-HLA- group against DSA group). 
 B. The dot-plot shows there is not a statistically significant relationship between 
CD19+ anti-HLA-A*0201 cell frequency and the level of circulating anti-HLA-A*0201 
shown as mean fluorescence intensity (MFI) in serum. P value derived from linear 
regression analysis. 
 
B A B 
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Characterising DS-B cells in patients transplanted with allografts expressing 
HLA-A*0201 and HLA-DQB1*0301 
Study group demographics 
 
The frequency of DS-B cells was examined to determine if this parameter represented 
a useful index of sensitisation to HLA expressed by the allograft. Two antigens, HLA-A2 
(HLA-A*0201) and HLA-DQ7 (HLA-DQB1*0301) were selected: HLA-A2, a HLA Class I 
antigen with high frequency within the donor population, and HLA-DQ7, a common 
HLA Class II antigen found in our transplanted patients.  
 
Patients transplanted with an HLA-A2-expressing allograft were separated into three 
groups based on sensitisation prior to transplantation (Table 4.1). Unsensitised (US) 
patients were all negative prior to transplantation by CDC crossmatch, T and B-cell 
flow-crossmatch and for DSA by Luminex single-antigen (LSA) analysis. The US group 
was separated by post-transplant sensitisation into two groups, those that did not 
have any detected HLA antibodies (anti-HLA
-
), and those whom developed de novo 
DSA (dnDSA). The third group, pre-sensitised (PS) patients had varying levels of 
sensitisation: all tested positive for HLA-A*0201 in serum by LSA analysis (MFI: range 
1000-10035, median 1050); 43% tested positive by T and B cell flow-crossmatch and 
had historically defined HLA-A2 by CDC assay. All patients were negative by CDC assay 
at the time of transplantation. None of the patients transplanted with an HLA-
DQB1*0301-expressing allograft were sensitised to this antigen prior to 
transplantation. The demographics of these patients are shown in Table 4.2. 
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Patients transplanted with a graft expressing HLA-A*0201  
 
 
Pre-transplant 
 
Unsensitised 
(US) 
 
 
Sensitised 
(PS) 
 
Post-transplant 
 
Anti-HLA
-
 
 
De novo DSA 
(dnDSA) 
 
 
DSA 
Total number of patients, n (%) 
 
5 (29.4) 5 (29.4) 7 (41.2) 
Recipient 
Gender (F,M) 
Age, median (range) (years) 
Time post-transplant, median (range) 
(months) 
 
 
2,3 
44 (40-70) 
60 (12-120) 
 
2,3 
33 (28-58) 
12 (12-60) 
 
2,5 
52 (43-54) 
 24 (12-180) 
Type of allograft, n (%) 
Live donation 
DBD 
DCD 
 
 
2 (40) 
1 (20) 
2 (40) 
 
2 (40) 
3 (60) 
0 
 
1 (14) 
5 (72) 
1 (14) 
HLA mismatches, n + sd  
A,  mean ± sd 
B, mean ± sd 
DR, mean ± sd 
 
 
1.6 ± 0.6 
1.6 ± 0.6 
0.8 ± 0.5 
 
1.6 ± 0.6 
1.4 ± 0.6 
1 ± 0.7 
 
1.7 ± 0.5 
1.3 ± 0.5 
0.7 ± 0.8 
Cause of ESRF, n (%) 
IgA nephropathy 
Diabetes 
FSGS 
GN 
PKD 
Other/Unknown aetiology 
 
 
0 
1 (20) 
1 (20) 
1 (20) 
0 
2 (40) 
 
1 (20) 
0 
0 
0 
0 
4 (80) 
 
0 
1 (14) 
0 
1 (14) 
1 (14) 
4 (58) 
 
Table 4.1 Demographics for patients transplanted with a graft expressing HLA-
A*0201  
 
Abbreviations: DBD, donation after brainstem death; DCD, donation after circulatory 
death; DSA, donor-specific HLA antibody; ESRF, end-stage renal failure; FSGS, focal and 
segmental glomerulosclerosis; GN, glomerulonephritis; PKD, polycystic kidney disease; sd, 
standard deviation.   
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Patients transplanted with a graft expressing HLA-DQB1*0301  
  
Anti-HLA
-
 
 
De novo DSA 
(dnDSA) 
Total number of patients, n (%) 
 
7 (50) 7 (50) 
Recipient 
Gender (F,M) 
Age, median (range) (years) 
Time post-transplant, median (range) 
(months) 
 
 
2,5 
59 (40-70) 
60 (12-120) 
 
4,3 
39 (27-61) 
24 (12-60) 
Type of allograft, n (%) 
Live donation 
DBD 
DCD 
 
 
2 (40) 
1 (20) 
2 (40) 
 
2 (40) 
3 (60) 
0 
HLA mismatches, n + sd 
A,  mean ± sd 
B, mean ± sd 
DR, mean ± sd 
 
 
1.1 ± 0.6 
1.6 ± 0.5 
0.7 ± 0.5 
 
1.8 ± 0.4 
1.0 ± 0.7 
1.0 ± 1 
Cause of ESRF, n (%) 
IgA nephropathy 
Diabetes 
GN 
Hypertension 
PKD 
Other/Unknown aetiology 
 
 
1 (14) 
2 (28) 
0 
2 (28) 
1 (14) 
1 (14) 
 
0 
0 
2 (28) 
2 (28) 
0 
3 (42) 
 
Table 4.2 Demographics for patients transplanted with a graft expressing HLA-
DQB1*0301  
 
Abbreviations: DBD, donation after brainstem death; DCD, donation after circulatory 
death; DSA, donor-specific HLA antibody; ESRF, end-stage renal failure; FSGS, focal and 
segmental glomerulosclerosis; GN, glomerulonephritis; PKD, polycystic kidney disease; sd, 
standard deviation.   
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 A 
Analysing peripheral blood from HLA-A*0201 transplanted patients 
 
Total lymphocyte and CD19+ cell populations 
 
To identify any difference between groups, PBMC and CD19
+
 cell constitution were 
assessed. The total PBMC count was determined following lymphocyte isolation by 
density gradient centrifugation of peripheral whole blood within four hours of 
venesection (Figure 4.4). The difference between the absolute number of PBMC was 
minimal (702 ± 229 cells/μl; 765 ± 156 cells/μl and 568 ± 198 cells/μl, for anti-HLA
-
, 
dnDSA & DSA groups respectively; p = 0.33 comparing anti-HLA
-
 against other groups). 
 
Following PMBC isolation, CD19
+
 cells were positively selected by magnetic bead 
separation. There were no significant differences between groups in frequency, (3.15 ± 
2.4%; 2.13 ± 1.15% and 2.01 ± 1.09% for anti-HLA
-
, dnDSA and DSA groups, 
respectively; p<0.99, Figure 4.4B) or absolute numbers (21 ± 17 cells/μl; 16 ± 11 
cells/μl; 11 ± 7% for anti-HLA
-
, dnDSA & DSA groups, respectively; p = 0.72, Figure 
4.4C). 
 
 
 
       
 
 
 
 
     
 
 
 
 
 
 
Figure 4.4 Comparable total lymphocyte 
and CD19+ cell counts in HLA-A2 
transplanted study groups 
Dot-plots show the PBMC counts (A) for each 
group based on lymphocyte isolation by density 
centrifugation of fresh peripheral whole blood 
(40 ml) with both frequency (B) & number (C) of 
positively selected CD19+ cells. p values (all p > 
0.05; ns is not significant) derived from 
comparing anti-HLA- group (n = 5), de novo 
donor-specific HLA antibody (dnDSA; n = 5) and 
DSA (n = 7) groups by Kruskal-Wallis test.  
US, unsensitised; PS, pre-sensitised.  
C  B 
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Detecting CD19+ anti-HLA-A*0201 cells by flow cytometry 
 
The frequency of donor-specific anti-HLA-A*0201 B cells (DS-A2 B cells) were assessed 
post-transplant. Patients identified with preformed alloantibody prior to transplant 
demonstrated the highest frequency of CD19
+
 cells capable of binding HLA-A*0201 
microbeads compared to those with either dnDSA or unsensitised (0.23 ± 0.2%; p = 
0.005, 0.09 ± 0.03%; p = 0.02 and 0.04 ± 0.03%; DSA, dnDSA and anti-HLA
-
 groups 
respectively).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Elevated frequency of DS-A2 B cells in HLA-A*0201 transplanted 
patients with dnDSA and DSA 
CD19+ cells isolated from PBMC were assessed for binding microbeads coated with 
HLA-A*0201 by flow cytometry. 
Dot-plot shows percentage of CD19+ anti-HLA-A*0201 cells for the three groups. Pre-
sensitised (PS) patients with donor-specific antibody (DSA; n = 7) had the highest 
frequency compared to those without detectable HLA antibody (anti-HLA-; n = 5) 
patients and those with de novo DSA (dnDSA; n = 5). A significant difference existed 
between patients without HLA antibody (anti-HLA-) and both dnDSA and DSA groups. p 
values derived from comparing HLA- group with other groups by Mann-Whitney test. 
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To probe the relationship between DS-A2 B cells and elevated levels of serum 
alloantibody, linear regression analysis was performed and a significant, if small 
correlation observed (R
2
= 0.27, p = 0.04; Figure 4.6A). To investigate if elevated 
frequency of DS-A2 B cells correlated with level of graft function, the same analysis 
was applied to rate of deterioration, extracted from measuring GFR over a period of up 
to 36 months. No significant association was found (R
2 
= 0.07, p = 0.29). When groups 
were separated based on graft function (as defined in GM 3), there was comparable 
frequency with stable function (40%, 40%, and 43% for anti-HLA-, dnDSA and DSA 
groups, respectively, Figure 4.6B). Rapidly deteriorating graft function was only 
observed in patients with dnDSA (20%; p = 0.36), or DSA (43%; p = 0.2). 
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.6 Correlation between the frequency of DS-A2 B cells and serum 
HLA-A*0201 antibody level 
 A. Linear-regression analysis assessing the frequency of CD19+ anti-HLA-A*0201 
cells compared to the level of serum anti-HLA-A*0201 expressed as mean 
fluorescence intensity (MFI) as determined by Luminex technology for all patients (n 
= 17) showed a significant correlation. 
 B. Assessing the level of graft function in patient groups. The frequency of patients 
with stable (ST), slowly deteriorating (SD) and rapidly deteriorating (RD) are shown 
as a percentage (%) of the total for each group. Only patients with donor specific HLA 
antibody (DSA; n = 7) or de novo DSA (dnDSA; n = 5) had RD graft function. 
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Detailing the phenotype of DS-A2 B cells 
 
The phenotype of DS-A2 B cells were analysed to distinguish frequency of memory 
(CD19
+
CD27
+
IgD
-
), naïve (CD19
+
CD27
-
IgD
+
) and transitional B cells 
(CD19
+
CD38
high
CD24
high
). The last group is proposed to have regulatory capacity (Blair 
et al., 2010, Flores-Borja et al., 2013). Moreover, elevated expression of both naïve and 
transitional B cells is associated with tolerance in renal transplant recipients (Newell et 
al., 2010). Figure 4.7 compared the distribution of these phenotypes between groups 
for the total B-cell population and DS-B cells. 
 
Overall no significant differences were found in the distribution of B-cell subsets for 
total CD19
+
 cells and DS-A2 B cells between groups (naïve B cells; p = 0.33, memory B 
cells; p = 0.67 and transitional B cells; p = 0.67). As the figures illustrate, there was 
often wide variance in the frequency of the B-cell subsets measured between 
individual patients. On appearance, PS patients with DSA had a higher frequency of 
naïve B cells for both total and DS-A2 B cells (52.13 ± 16.13% and 43.07 ± 18.94%; total 
and DS-A2 B cells) compared to those with dnDSA (25.35 ± 18.87% and 27.08 ± 
19.83%) or US patients (32.42 ± 18.49% and 24.43 ± 19.48%; Figure 4.7A), and 
increasing the sample size number may confirm a significant difference. 
 
Comparing the frequency of memory B cells within each group, the most notable 
difference was between total CD19
+
 cells and CD19
+
 DS-A2 cells in the anti-HLA
-
 group 
(26.89 ± 10.61% vs. 11.78 ± 6.79%;  p = 0.09, Figure 4.7B). 
 
Similar to memory B-cell frequency, the dnDSA group had an elevated frequency of DS-
A2 transitional B cells, although neither was to a level of statistical significance. 
However, when the frequency of total CD19
+
 cells and CD19
+
 DS-A2 transitional cells 
were compared within each group, in each case transitional B cells were enriched in 
the DS-A2 B-cell subset (5.27% vs. 28.86%; p = 0.02, 6.07% vs. 25.46%; p = 0.02 and 
4.02% vs. 15.19%; p = 0.04, for anti-HLA
-
, dnDSA and DSA groups respectively, Figure 
4.7C).  
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The frequency of B cells expressing BAFF-R was also measured and the difference 
between groups was minimal, for both total and DS-A2 B cells (p = 0.33; Figure 4.7D). 
Similarly, serum BAFF levels were not statistically different (1032.1 ± 460.9 pg/ml; 
797.8 ± 242.7 pg/ml and 804.5 ± 345.6 pg/ml; p = 0.33 for DSA, dnDSA and anti-HLA
-
 
groups respectively, Figure 4.7E). 
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Figure 4.7 Comparing the frequency of naïve, memory and transitional B 
cells and expression of BAFF in patient groups for total and DS-A2 B cells 
The dot-plots show frequency of naïve (A), memory (B), transitional (C) B cells for 
total CD19+ cells and CD19+ anti-HLA-A*0201 cell populations in each patient group.  
 A. Unselected naïve B cells were present at a higher frequency in patients with donor-
specific HLA antibody (DSA; n =7), when compared to the de novo DSA (dnDSA; n =5) 
and without HLA antibody (anti-HLA-) groups. The difference was not significant (p = 
0.33 by Kruskal-Wallis test).   
 B. Comparing total memory B-cell frequency and DS-A2 memory B cells between 
groups did not show a significant difference (p = 0.67 by Kruskal-Wallis test). DS-A2 
memory B cells were reduced compared to total CD19+ cells in the anti-HLA- group, 
this did not reach a level of statistical significance (p = 0.09 by Mann-Whitney test). 
C. The frequency of total CD19+ cells compared to DS-A2 transitional B cells were not 
significantly different between groups (p=0.67 by Kruskal-Wallis test). All groups 
showed transitional B cells were enriched in the DS-A2 B-cell subset compared to total 
CD19+ cells (anti-HLA- group; p=0.02, dnDSA group; p = 0.02 and the DSA group; p = 
0.04 by Mann-Whitney test). D. CD19+BAFF-R+ cells and serum BAFF levels (E) did not 
alter significantly between groups. 
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Summarising the presence of DS-A2 B cells in the study cohort 
 
The percentage of DS-A2 B cells was significantly elevated in patients with preformed 
DSA and dnDSA compared to unsensitised patients. Furthermore, there was significant 
correlation between serum level of alloantibody and frequency of DS-A2 B cells. More 
detailed phenotypic analysis revealed patients with DSA had a higher frequency of 
naive B cells and a reduced memory B cell population compared to other groups, albeit 
not to a statistically significant level. When DS-A2 B-cell phenotypes were examined 
compared to the total B cell population, the most notable difference was the 
heightened presence of DS-A2 transitional B cells; this was apparent for all groups. 
 
Next, the same analysis was applied to patients transplanted with an HLA-DQB1*0301 
expressing allograft and these findings compared to the prevalence and phenotypic 
characteristics observed for DS-A2 B cells. 
 
Analysing peripheral blood from HLA-DQB1*0301 transplanted patients 
 
Total lymphocyte and CD19+ cell populations 
 
The difference in the absolute number of PBMC between the two groups (there are no 
pre-sensitised patients in this cohort) was minimal (768 ± 210 and 636 ± 335 cells/μl, 
for anti-HLA
-
 and dnDSA groups, respectively; p = 0.78, Figure 4.8A). Both the 
frequency of CD19
+
 cells, (1.98 ± 1.38 and 2.54 ± 0.89% for anti-HLA
-
 and dnDSA
 
groups, respectively; p = 0.26, Figure 4.8B) and number of CD19
+
 cells were not 
significantly altered between groups (15 ± 13 and 19 ± 6 cells/μl for anti-HLA
-
 and 
dnDSA
 
groups, respectively; p = 0.05, Figure 4.8C).  
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Detecting CD19+ anti-HLA-DQB1*0301 cells by flow cytometry  
 
The frequency of donor-specific anti-HLA-DQB1*0301 B cells (DS-DQ7 B cells) post-
transplant were significantly higher in patients with dnDSA (0.21 ± 0.17% and 0.07 ± 
0.03%; dnDSA and anti-HLA
-
 groups, respectively, p = 0.03; Figure 4.9A). Linear 
regression analysis demonstrated a small, but significant correlation between the 
frequency of DS-DQ7 B cells and level of serum alloantibody (R 
2
= 0.37, p = 0.03; Figure 
4.9B). Comparing for level of graft function, a greater proportion of patients without 
HLA antibody was stable (57% vs. 14%, p = 0.09 for anti-HLA
-
 vs. dnDSA groups; Figure 
4.9C). Moreover, an increased number of patients with dnDSA had rapidly 
deteriorating function (29% vs. 43%, p = 0.19 for anti-HLA
-
 vs. dnDSA groups). 
 
 
 
Figure 4.8    Comparable total 
lymphocyte and CD19+ cell counts in the 
HLA-DQ7 transplanted study groups 
Dot-plots show mean PBMC count (A) for 
each group based on lymphocyte isolation 
by density centrifugation of fresh 
peripheral whole blood (40 ml) with both 
frequency (B) & number (C) of positively 
selected CD19+ cells. p values  all >0.05 
derived from comparing anti-HLA- (n = 7) 
with de novo DSA (dnDSA; n = 7) group by 
Mann-Whitney test. ns is not significant 
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Detailing the phenotype of DS-DQ7 B cells 
 
The frequency of both total and donor-specific naïve and memory B cells did not differ 
significantly on the basis of presence or absence of serum alloantibody (Figure 4.10A 
and B). Similar to observations in HLA-A2 transplanted patients, DS transitional B cells 
were elevated compared to total CD19
+
 cells; however, this was not statistically 
significant, possibly in part because of a large standard deviation (Figure 4.10C). Also, 
expression of BAFF-R did not differ between groups (Figure 4.10D). Serum BAFF was 
elevated in patients with dnDSA, although due to wide variation was not statically 
significant (1001.9 ± 272.6 and 1831.1 ± 1843.7 pg/ml; anti-HLA
-
 and dnDSA groups 
respectively; p = 0.45, Figure 4.10E). 
Figure 4.9  Elevated frequency of DS-DQ7 B cells in patients with serum HLA-
DQ7 alloantibody 
CD19+ cells from patients mismatched with a HLA-DQB1*0301 expressing allograft (n 
= 7) were isolated from PBMC and assessed for binding to microbeads coated with 
HLA-DQB1*0301 by flow cytometry compared to those without HLA antibodies (anti-
HLA-; n = 7).   
A. Dot-plot showing the frequency of CD19+ cells bound to HLA-DQB1*0301 
microbeads was significantly higher in patients with de novo DSA (dnDSA; p = 0.03 by 
Mann-Whitney test). B. Linear regression analysis showed a significant correlation 
between CD19+ anti-HLA-DQB1*0301 cell frequency and level of serum anti-HLA-
DQB1*0301 (MFI) as determined by Luminex technology. C. The frequency (%) of 
patients with stable (ST), slowly deteriorating (SD) and rapidly deteriorating (RD) 
graft function. A higher proportion of patients without post-transplant HLA antibody 
had stable function. 
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Comparing phenotypic expression of DS-DQ7 and DS-A2 B cells in patients 
with dnDSA 
 
De novo anti-HLA-DQ antibodies are reported as the most prominent HLA-type and 
may impact allograft survival as much as antibodies against HLA-A, -B and –DR (DeVos 
et al., 2012, Everly et al., 2013). Here, DS-DQ7 B cells in patients with dnDSA were 
present at greater frequency than patients with dn-HLA A2 (0.2 ± 0.17% and 0.09 ± 
0.03%, DS-DQ7 and DS-A2 B cells respectively, p = 0.02 Figure 4.11A). The phenotype 
of these cells was compared and, interestingly, while there was minimal difference in 
percentages of naïve and memory B cells (Figure 4.11B and C), transitional B cells were 
Figure 4.10 Comparing the frequency of naïve, memory and transitional B 
cells and expression of BAFF in patient groups for total and DS-DQ7 B cells  
The dot-plots show frequency (%) of naïve (A), memory (B), transitional (C) B cells 
and BAFF-R (D) by total CD19+ cells and DS-DQ7 B cells, and serum BAFF levels (E). No 
statistically significant differences existed between those without HLA antibodies 
(anti-HLA-; n = 7) and de novo donor-specific antibodies (dnDSA; n = 7) when 
comparing frequencies by Mann-Whitney test. 
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significantly reduced in those with dn-DQ7 DSA (7.1 ± 3.6% and 2.9 ± 2.9%; p = 0.03 
Figure 4.11D). In addition, the level of serum BAFF was elevated in this group, although 
again, not significantly so (1843.7 vs. 812.9 pg/ml; dn-HLA DQ7 and dn-HLA A2 groups 
respectively; p = 0.26) (data not shown). 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Relating level of graft function with type of dnDSA (Figure 4.12), a greater proportion 
of patients with dn-A2 DSA (40%) had stable function compared to dn-DQ7 DSA (14%). 
Furthermore, rapidly deteriorating graft function associated with dn-DQ7 DSA (43% vs. 
20%, p=0.27; dn-DQ7 and dn-A2 DSA respectively). To date, biopsy-proven AMR has 
occurred in 29% (n = 2/7) of these patients compared to 40% (n = 2/5) with dn-A2 DSA. 
Allograft loss has not been experienced by individuals in either group.  
 
 
Figure 4.11  Increased frequency of donor-specific transitional B cells in 
patients with de novo serum HLA-A2 compared to and dnHLA-DQ7 antibodies 
The dot-plots show elevated frequency of DS-DQ7 (n = 7) compared to DS-A2 B cells 
(n = 5) in patients with de novo donor-specific antibodies (dnDSA; A) with phenotypic 
representation for naïve (B), memory (C) and transitional B cells (D). The frequency 
of DS-A2 transitional B cells was significantly higher in patients with dnDSA (p = 
0.03). P values derived comparing the two groups by Mann-Whitney test. 
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This study cohort was too small to make any general assumptions relating the 
incidence of de novo DQ antibodies on allograft survival; therefore an observation 
investigation was conducted with a wider context of patients transplanted in a single 
centre over a four-year period. 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.12  Deteriorating graft function associated with presence of serum de 
novo HLA-DQ7 antibodies 
The bar chart shows the percentage of patients with dn-A2 & dn-DQ7 DSA with stable 
(ST), slowly deteriorating (SD) and rapidly deteriorating (RD) graft function as 
determined by regression analysis of GFR over time. A greater proportion of patients 
with dn-DQ7 DSA had deteriorating graft function (43% vs. 20%). 
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Investigating the incidence of de novo DQ antibodies post-transplant within a 
single renal transplantation centre 
 
The incidence of de novo DQ antibody was compared to anti-HLA-A, -B, -C & -DR in 434 
patients who received a renal transplant from either a living or deceased donor 
(excluding HLA antibody-incompatible, blood-group-incompatible or simultaneous 
kidney-pancreas transplant) between 4
th
 November 2007 and 9
th
 October 2012 at the 
Royal London Hospital, London, UK. Patients included only those assessed for HLA 
antibody by LSA analysis prior to transplantation to maximise detection at low 
expression levels. The remaining patients were assessed for dnDSA and results are 
summarised in Figure 4.13. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
434 renal transplant recipients 
November 2007-October 2012 
 
104 patients 
excluded where 
LSA not performed 
 
dnDSA (1 or more) 
37 (11.2%) 
HLA Class I & II 
9 (24.3%) 
HLA Class II 
16 (43.2%) 
HLA Class I 
12 (32.4%) 
330 recipients included  
All received LSA pre-transplant 
DR alone 
6 (37.5%) 
No DSA  
293 (88.8%) 
 
Figure 4.13  Flow-chart representing disposition of the study cohort with 
de novo DSA 
 
DQ alone 
8 (50%) 
DP alone 
1 (6.3%) 
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Of the 330 patients included, 37 (11.2%) developed dnDSA and, of those, 13 had DQ 
antibodies (35.1%). There was similar frequency of HLA-A (n = 14, 37.8%) and HLA-DR 
(n = 14, 37.8%) and a lesser percentage of antibodies to HLA-B (n = 10, 27%), HLA-C (n 
= 4, 10.8%) and HLA-DP antibodies (n = 1, 2.7%). dnDQ antibodies were detected at a 
slightly higher frequency in isolation (21.6%) compared to dn-DR (16.2%) and dn-A 
antibodies (16.2%). 
 
Examining the development of dnDSA in relation to HLA-incompatibility expressed by 
the allograft (Figure 4.14A), patients transplanted with a mismatch at the HLA-DQ 
locus had the highest prevalence of dnDSA (55.6% compared to 44.4%, 30.6%, 13.3% 
and 35.3% for HLA-A, -B, -C and -DR dnDSA, respectively). This was significantly so 
when compared to patients mismatched with an allograft expressing HLA-C (p=0.02). 
The most common of the DQ antibodies detected were DQ7, and all patients 
mismatched for this HLA type developed dnDSA (Figure 4.14B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Analysing HLA mismatching and corresponding dnDSA production  
A. The bar-chart relates percentage of patients (n = 37) transplanted with HLA-A, -B, -
C, -DR & -DQ mismatched allograft with the frequency of developing dnDSA. There was 
a significant difference in those transplanted with an allograft mismatched at HLA-DQ 
compared to HLA-C (p = 0.02 by Chi squared test). 
 B. Post-transplant, patients mismatched for DQ7 all developed dnDSA (n = 9).  
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Time of appearance and strength of dnDSA 
The exact time of development of antibodies was not known; an indication was given 
by the first time dnDSA were recorded following LSA analysis. This was at a median 
time of 2.6 months (range, 0.03-59.4) and a mean of 8.7 ± 14 months. Further 
examination showed HLA-class I antibodies had the shorter time to detection (median, 
2.3 months (range, 0.03-15.2) and mean 4.4 ± 5.4 months) compared to HLA-class II 
antibodies (median, 3.6 months (range, 0.3-59.4) and mean 15.2 ± 19.1 months). 
Assessing dnDQ antibody; these antibodies appeared at a significantly later time than 
HLA-class I antibodies (median, 8.7 months (range, 0.3-42.6) and mean 15.8 ± 16.9 
months; p = 0.04).  
 
The level of dnDSA was assessed for all HLA loci. Comparing those directed against 
HLA-class I and -class II, MFI values were very similar (mean, 5932 (482-12826) & 5492 
(454-13662). Investigating for individual HLA antibody, the highest mean MFI was 
observed for HLA-B antibodies and HLA-DQ antibodies (Figure 4.15A). The lowest levels 
of dnDSA were HLA-C and HLA-DP and were also the least frequent.  
 
Assessing level of graft function, as determined by regression analysis of eGFR over the 
last 12 months, we saw that half of the patients had stable function, and a small 
fraction had deteriorating function (Figure 4.15B). Graft failure had occurred in 30% of 
patients; of those, AMR was confirmed by biopsy in 27% (Figure 4.15B). Of those, the 
rapidly deteriorating group represented the highest frequency of biopsy-proven AMR 
(16% vs. 57%, p = 0.07 for ST vs. RD groups, respectively). Addressing the detrimental 
impact of dnDQ antibodies and allograft function, none of the categories examined 
(level of graft function, rate of failure and biopsy proven AMR) were significantly over-
represented compared to other dnDSA (p > 0.05; Figure 4.15C). 
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Figure 4.15  Investigating the level and frequency of dnDSA and associated 
level of graft function  
 A. Dot-plot shows the frequency of patients with serum HLA-A, -B, -C, -DR, -DQ & -DP de 
novo donor-specific HLA antibodies (dnDSA) against relative strength (mean 
fluorescent intensity; MFI) as determined by Luminex technology. The mean MFI value 
is shown. Comparing MFI values between those with dnDSA-DQ antibodies and other 
HLA types of dnDSA did not indicate any significant differences (p = 0.23 by Kruskal-
Wallis test). 
 B. Bar-graph shows the frequency of patients (%) with level of graft function. Those 
with rapidly deteriorating (RD) graft function had a higher incidence of biopsy proven 
AMR (4 of 7 patients) than the stable (ST) group (3 of 19 patients; p = 0.07 by Chi 
squared test). 
 C. Comparing HLA-A, -B, -C, -DR, -DQ & -DP dnDSA with graft function & failure, and 
biopsy proven AMR did not show an over presentation of categories in those with dn-
DQ antibodies (p>0.05 by Chi squared test). 
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4.4 Discussion 
 
Allograft rejection is multifaceted. However, a prevailing view is held of a causative 
role for DSA (Terasaki and Cai, 2008, Einecke et al., 2009). In a primate model, 
following progression of chronic antibody-mediated rejection (CAMR), four stages are 
identified: the presence of DSA, leading to deposition of C4d, development of 
transplant glomerulopathy (TG), followed by raised creatinine and ultimate loss of 
graft function (Smith et al., 2008). In transplanted renal patients, allograft failure 
occurs more frequently in those with HLA antibody (Terasaki et al., 2007, Lefaucheur et 
al., 2010). In particular, the presence of DSA is predictive of inferior graft outcome 
(Worthington et al., 2003, Mao et al., 2007, Lachmann et al., 2009). Thus, the 
detrimental effect of DSA on allograft function and survival is well established. More 
detailed examination during the post-transplant period has disclosed that 
pathogenicity of DSA is not equal. Recently, a number of studies observe a prevalence 
of dnDQ DSA and an association with allograft dysfunction (Hidalgo et al., 2009, 
Willicombe et al., 2012, DeVos et al., 2012). Given evidence supporting a negative 
impact of DSA on allograft loss, identification in serum is relied upon as a prognostic 
marker of dysfunction. However, this may not capture the complete profile of 
alloreactivity and details of the cells responsible for producing antibody are largely 
unknown.  
 
The method described to identify DS-B cells directly from peripheral blood provides a 
novel approach to monitor their presence and prevalence and could be easily adapted 
to clinical practice. Moreover it offers a lower cost alternative to the application of 
HLA-specific tetramers as described by Zachary and colleagues (Zachary et al., 2007). In 
this study at least, the high degree of non-specific staining experienced with HLA-
A*0201 pentamers was reduced using HLA-coated microbeads.                               
 
The theoretical basis of identifying HLA-specific B cells by flow-cytometry relies upon 
the capability of a BCR, unlike a TCR, to recognise soluble, unprocessed antigen, in this 
instance coated to the surface of microbeads. The ability to utilise microbeads in this 
way may be possible because of their size, together with the high density of BCR 
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expressed per B-cell (approximately 10
5
/cell; (Unanue et al., 1971)). With a diameter of 
5.6 μm, they are slightly smaller than a B-cell (average diameter of 7 μm) and 
potentially capable of cross-linking and engaging with a number of BCRs expressing 
antigen-specificity toward the HLA presented on the bead. This interaction was 
sufficiently stable for detection by flow-cytometry. Through coupling fluorescently 
labelled antibodies targeted at B cells and utilising the inherent fluorescent property of 
the HLA-coated microbeads, it was possible to identify a small population of DS-B cells. 
To increase the stringency of this method, future studies would benefit from the 
inclusion of an additional fluorochrome such as 4’, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI) to allow for selection of only viable cells. 
 
The ability to detect DS-B cells in peripheral blood is considerably preferable to 
isolating cells from bone-marrow aspirates, as described by Perry and colleagues (Perry 
et al., 2008). While they reported aspirate removal as being well-tolerated without 
post-operative complications, this method is logistically far more involved and 
expensive compared to the relative ease of taking blood during routine clinic 
appointments. They cite adopting this method following unsuccessful detection of DS-
B cells in peripheral blood; however a low volume was analysed (20 ml). Moreover, 
their method of isolating antibody-secreting B cells relied on intracellular expression of 
immunoglobulin κ and λ chains. Intracellular staining requires a process of 
permeablisation and fixation, resulting in cell loss, potentially reducing the very small 
population of interest. In this study, a minimum of 40 ml was drawn, generating 
approximately one-million CD19
+
cells or 2.3%; from this a median of 0.11% or 330 
CD19
+ 
anti-HLA
+
 cells were detected per million CD19
+
 cells (range, 0.01-0.63% or 28-
1750). This is a higher frequency than cited for women sensitised via preganancy using 
teteramer recognition of HLA-A2-specific B cells (179/10
6 
CD19
+
 cells) (Mulder et al., 
2003). However given the permanent antigenic stimulation offered by the allograft, a 
higher frequency should probably be expected. 
 
This study decribed the identification of cells at low-frequency and the validity of these 
data is governed by Poisson statistics. Accuracy increases with cell-number aquired by 
the flow-cytometer. Using a method previously decribed to determine cell-number 
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requirements and level of precision (Hedley and Keeney, 2013), the Poisson coefficient 
of variation (CV) of the counting error was calculated at 18.25%. To increase the 
stringency or lower the CV would require more cells or events. Obviously the volume 
of blood requested from patients is limited. However, during this study, cells were 
required to optimise and test parameters; should this method be applied in clinical 
practice, the CV could be improved by increasing the number of cells acquired with 
minimal allocation for controls.  
 
This study established that a higher frequency of peripheral DS-A2 B cells was present 
in sensitised (0.16%) compared to non-sensitised patients (0.04%), and to a level 
comparable with that previously described in women sensitised to HLA-A2 via 
pregnancy (0.11%) (Mulder et al., 2003). Both of these values are considerably lower 
than those reported by Zachary et al., (4.1%) which may be explained by differences in 
B-cell selection methods (Zachary et al., 2007). In this, and that of Mulder and 
colleagues, positive CD19
+
 cell selection was employed rather than T cell-depletion, 
the latter having potential to allow inclusion of cells expressing lower levels of CD19. 
 
With reference to the frequency of DS-DQ7 B cells, I am not aware of any publications 
on this to date. The rationale for examining the binding of this antigen to B cells was 
based on the reported elevated frequency of dnDQ antibodies following 
transplantation and their impact on reducing allograft survival (Willicombe et al., 2012, 
Everly et al., 2013, DeVos et al., 2012). Accordingly, it was of interest to identify 
differences in prevalence or phenotypic characteristics compared to DS-B cells from 
patients with dn-A2 DSA. Firstly, DS-B cells were present at significantly higher levels in 
patients with serum dnDSA against HLA-DQ7 and HLA-A2 compared to unsensitised 
patients. Moreover, there was significant correlation between the increased presence 
of DS-B cells and level of serum antibody (as determined by MFI). Comparing the 
presence of DS-B cells, DS-DQ7 B cells were at a significantly higher overall frequency 
than DS-A2 B cells.  
 
Further examination of memory and naïve B cell distribution by DS-B cells compared to 
the total B-cell population did not reveal an associated phenotype or a distinction in 
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those patients with dn-DQ7 DSA. However DS-A2 memory B cells were reduced in 
patients without HLA antibody and could relate with the absence of DSA development. 
Obviously these data represented a very small cohort and wider investigations may 
reveal differences. This could include assessing HLA-specificity on plasmablasts. In 
mice, over-expression of autoantibody is associated with prolonged survival of 
extrafollicular plasmablasts (William et al., 2005). Extrafollicular plasmablasts are 
formed from activated B cells. These are short-lived and responsible for production of 
early antibody with specificities encoded by the primary repertoire (Jacob and Kelsoe, 
1992). It is possible these cells are responsible for early de novo alloantibody 
production. Recently described was a subset of phenotype, CD20
+
CD27
+
CD43
+
CD70
-
CD69
-
. This has been proposed as the human equivalent of murine B1 cells and 
demonstrated the capacity to differentiate into pre-plasmablasts and plasma cells in 
vitro (Covens et al., 2013). In addition, circulating plasmablasts spontaneously 
producing anti-citrullinated protein antibody (ACPA) have been identified in patients 
with rheumatoid arthritis. Moreover the ACPA-specific B cells were not confined to 
CD20
+
 memory B cells (Kerkman et al., 2013). These studies support more detailed 
phenotypic analysis of DS-B cells at the level of B cell differentiation into antibody-
secreting cells and could aid towards developing strategies beyond those currently 
targeted by CD20 depletion. 
 
DS-B cells were examined for phenotypic expression of transitional B cells. Exhibiting 
high levels of CD24 & CD38, they are ascribed with regulatory capacity via their ability 
to suppress Th1 cytokines and promote development of regulatory T cells (Flores-Borja 
et al., 2013, Blair et al., 2010). Moreover, a reduced presence was observed during 
ESRF (Kim et al., 2012) and following renal transplantation correlated with poor graft 
function (Cherukuri et al., 2012). Chapter 6 of this thesis is dedicated to considering 
their role. Suffice it to say at this stage that transitional B cells were enriched in DS-B 
cells compared to total B-cell populations for all patient groups. In addition, DS-
transitional B cells from patients with dn-A2 DSA were present at a significantly higher 
frequency compared to those with dn-DQ7 DSA. This coupled with superior graft 
function in patients with dn-A2 DSA is an interesting observation, compatible with a 
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potentially protective role of these cells in limiting a pro-inflammatory response and 
damage to the allograft.  
 
In terms of graft function and serum alloantibody, patients with stable graft function 
were equally represented in the HLA-A2 transplanted group (US, dnDSA and DSA). 
Conversely, a lower frequency of patients with dn-DQ7 DSA had stable renal function 
(14%) compared to those without DSA (57%). This, together with the correlation 
between DS-DQ7 B cells and level of serum alloantibody, suggests an association with 
allograft dysfunction. In both cohorts, patients were tested at a single time-point and 
the natural history of emerging DS-B cells prior to detection of DSA in serum is not 
known.  Equally their prevalence during progression from normal to acute allograft 
dysfunction was not determined. Establishing if these cells appear prior to 
presentation of changing clinical features, such as rising creatinine or proteinuria, 
requires further investigation. 
 
In summary, DS-B cells can be identified in peripheral blood, their frequency was 
elevated in patients with dnDSA and a positive association existed between their 
frequency and level of serum alloantibody. Moreover, deteriorating graft function 
prevailed in patients with dn-DQ7 DSA. To place these findings in a wider context, an 
observational study was performed on an entire cohort transplanted over a four-year 
period to determine the prevalence of dnDQ DSA and their impact on allograft 
survival. dnDSA occurred at a rate of 11%; this is slightly lower than recent reports of 
approximately 18%, albeit for larger cohorts (DeVos et al., 2012, Willicombe et al., 
2012). The appearance of dnDSA at a median of three-months is consistent with 
others, where the majority are detected within six-months post-transplantation 
(Cooper et al., 2011, Gill et al., 2010, Piazza et al., 2001). Collectively, these data 
indicate monitoring DS-B cells or serum dnDSA should be concentrated in the early 
months post-transplant. Several risk factors can influence the development of dnDSA, 
including non-compliance (Sellares et al., 2012), immunosuppression minimisation, or 
use of less potent immunosuppression (Ginevri et al., 2012) and for these patients 
identification could allow potential intervention prior to irreversible chronic damage. 
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The levels of dnDQ DSA were comparable to those of HLA-B DSA, and together were 
the only antibodies detected at greater than 5000 MFI. Compared to HLA-A, B, C or DR 
antibodies, DQ antibodies were not over represented and, at 35%, was below the 
lower range reported by others (52-91%) (DeVos et al., 2012, Everly et al., 2013, 
Willicombe et al., 2012). This variation may be reflective of differing MFI cut-off values. 
Moreover, retrospective analysis of samples excluded from this study due to absence 
of pre-transplant LSA analysis could increase the dnDSA cohort. 
 
Two points of particular interest transpire from this analysis: first, dnDQ DSA were the 
most prevalent detected alone. Second, the incidence of DQ antibodies; of the 37 
patients who developed dnDSA, 66% were mismatched at HLA-DQ and, of those, 56% 
developed dnDQ-DSA, representing the highest proportion. Further analysis showed 
DQ7 antibodies were the most common DQ allele to provoke an immune response, in 
line with a recent study (DeVos et al., 2012). Indeed every patient mismatched with an 
allograft expressing HLA-DQ7 subsequently developed dn-DQ7 antibodies, an 
observation not seen with other HLA alleles, indicating that immunogenicity may not 
be equal between alleles. To address this, the level of graft function and incidence of 
failure, together with frequency of biopsy-proven AMR was examined. In this cohort, 
dnDQ DSA was not found to be particularly pathogenic by these categories assessed. 
However, at present, the mean time post-transplantation is 3.6 years. If equal 
assessment is performed in five or ten years, it may be shown to have a contributing 
role in chronic allograft damage. 
 
Concluding remarks 
 
This study described the application of flow-cytometry-based methods for detecting 
and enumerating DS-B cells in peripheral blood of patients identified with serum DSA. 
Applied in conjunction with cell-surface markers used to define B-cell subsets, it was 
possible to further detail phenotypic characteristics. Moreover, positive correlation 
between DS-B cell frequency and level of serum alloantibody indicated a level of both 
sensitivity and specificity of the method.  
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Presently, post-transplant assessment of an ongoing alloresponse is limited to 
analysing serum, usually together with biopsy. The ability to detect DS-B cells could 
enrich the clinical information available, and may also hold potential following HLA-
incompatible transplantation for monitoring the effectiveness of agents targeting B 
cells. Recent evidence implementing dnDSA and, in particular, DQ antibodies with graft 
damage suggests an application to aid identification and assess magnitude of an 
emerging alloresponse, potentially prior to manifestation detectable in serum, 
allowing more timely therapeutic intervention and limiting irreversible graft damage. 
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Analysing expression of BAFF as a 
biomarker of allograft function 
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5.1 Introduction  
 
B cells are increasingly recognised as important mediators of transplant survival, 
promoting antibody-mediated rejection (AMR) but also potentially supporting allograft 
longevity. However their activity post-transplant is currently not addressed until a 
patient presents with symptoms suggestive of allograft dysfunction. If appropriate, B-
cell-mediated pathology is examined by serum analysis for HLA antibodies and ideally 
allograft biopsy; together they can identify and diagnose AMR. Pursuing these clinical 
investigations initially relies upon measuring changes in levels of creatinine and 
proteinuria to gauge renal function. Yet at this time injury to the allograft may have 
already occurred and alternative modes to immunologically monitor functional 
changes have not been widely explored. An attractive candidate is the B-cell activating 
factor, BAFF, a cytokine critical for B-cell survival and maturation, as demonstrated in 
BAFF-deficient mice where B cells fail to reach maturity (Mackay et al., 2003). Equally, 
over-expression resulted in increased B-cell survival, development of pathogenic 
autoantibodies and manifestation of a lupus-like disease (Groom et al., 2007).  
 
Given the central role of BAFF in B-cell survival, serum levels are reported in 
autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid 
arthritis and Sjörgen’s syndrome (Pers et al., 2005, Gottenberg et al., 2009, Hegazy et 
al., 2010). In each disease modality, BAFF is identified in excess and proposed to 
contribute toward development and survival of autoantibodies. Moreover, studies of 
SLE have correlated elevated serum BAFF (sBAFF) with disease activity (Petri et al., 
2008, Carter et al., 2013) and in multiple myeloma, reduced sBAFF correlated with 
clinical responsiveness and favourable prognosis (Fragioudaki et al., 2012). In the 
context of transplantation, elevated sBAFF could predict the development of graft 
versus host disease (GvHD) (Sarantopoulos et al., 2007, Sarantopoulos et al., 2009). 
Collectively these studies demonstrate BAFF as a biomarker of disease activity and this 
may equally apply to monitoring allograft function. Recent reports link increased sBAFF 
levels with ability to predict the development of DSA, (Thibault-Espitia et al., 2012) and 
increased risk of experiencing AMR when undergoing HLA-incompatible renal 
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transplantation (Banham et al., 2013b). However, these studies have not addressed 
involvement of BAFF in the post-transplantation period as an indication of 
deteriorating function resulting from immunological activity or association with renal 
injury by direct localisation within the kidney. Indeed published data of intrarenal 
expression of BAFF is limited: to date only two studies have identified BAFF in allograft 
biopsies; first, following loss as a result of acute antibody-mediated rejection (AAMR) 
(Xu et al., 2009a) and second, in two patients with chronic antibody-mediated 
rejection (CAMR) (Thaunat et al., 2008). Neither explored differential expression 
depending on the level of renal graft function or examined the presence of BAFF-R. 
The localisation of BAFF and BAFF-R within renal tissue to areas of infiltrating 
inflammatory cells in conjunction with presence of DSA and elevated levels of sBAFF 
could provide evidence for measuring sBAFF as an effective marker of AMR, offering a 
low risk and relatively inexpensive alternative to the invasive biopsy procedure. 
Moreover this could obviate issues with sample quality and retrieval. It is reported that 
0.02% of the kidney is presented by the biopsy section and it is known that the 
sampled core may not always be entirely representative (Rush, 2006). 
 
Understanding the biology that governs the function of B cells may allow for advances 
in immunological monitoring to detect changes prior to irreversible damage to the 
allograft and influence the fate of transplant survival. Defining BAFF expression in an 
evolving B-cell compartment could potentially identify dysfunction and enable timely 
intervention to treat AMR or monitor the response to treatment. In the small study by 
Thaunat and colleagues, they demonstrated that, despite B-cell depletion with 
rituximab, alloantibody production persisted in patients with graft loss as a result of 
CAMR (Thaunat et al., 2008). Tertiary lymphoid organs were evident in the explanted 
grafts and proposed to support the humoral response. In addition to detecting 
intrarenal BAFF by immunohistochemistry, expression at the gene and protein level 
was elevated. This raises the possibility of utilising sBAFF measurements as an 
indicator of B-cell depletion effectiveness and also following alterations or reductions 
in maintenance immunosuppression. 
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To summarise, excessive BAFF may be indicative of dysregulation in the B-cell 
compartment, suggesting a role in disease pathogenesis. The development of a non-
invasive test to monitor allograft function could allow early intervention to prevent 
rejection and ensuing injury to improve long-term transplant outcome. This study 
explores if there is correlation between BAFF localisation within the allograft, together 
with elevated sBAFF and the presence of DSA, as this could provide evidence of 
humoral rejection, perhaps limiting the requirement for biopsy.  
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5.2 Materials and methods  
 
Materials and methods detailed in Chapter 2, General Methods (GM) are indicated. 
 
GM1  Recruitment of study patients 
 
GM2  Immunosuppressive regime  
 
GM3  Defining level of allograft function in patient cohorts  
 
GM4  Peripheral blood mononuclear cells (PBMC) separation  
 
GM5  CD19+ cell isolation from PBMC  
 
GM6  Phenotyping CD19+ cells by flow cytometry 
 
GM8  Detection of HLA antibody in serum by Luminex technology 
 
GM10  Statistical analysis  
 
 
Detection of BAFF by ELISA 
 
Human BAFF detecting ELISA (R&D Systems) was used to measure serum levels as per 
manufacturer’s instructions. In brief, serum samples were thawed and diluted 1:2 in 
calibrator diluent before applying to a microplate pre-coated with mouse monoclonal 
antibody against human BAFF (as provided in the kit; therefore at unknown 
concentration) and incubated with shaking for three hours at room temperature. The 
plate was washed four times with wash buffer and residual liquid removed after each 
wash with blotting. A polyclonal antibody against BAFF conjugated to horseradish 
peroxidase provided in the kit was applied to each well and incubated with shaking for 
an hour at room temperature. Following this, the plate was washed again four times 
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and developed for 30 minutes using equal volumes of neat tetramethylbenzidine 
(TMB) and neat hydrogen peroxide. This reaction was stopped by addition of sulphuric 
acid (2N) and the plate analysed using an automated microplate reader (Labtech) set 
at an absorbance wavelength of 450 nm with wavelength correction at 540 nm. Data 
were exported to Excel and, using the concentration of serially diluted positive controls 
against absorbance, generated a linear regression curve used to estimate the 
concentration of BAFF in serum samples. 
 
Renal biopsies and Immunohistochemistry 
 
Immunohistochemistry was carried out on 3 µm sections of renal biopsies. The 
sections were cut on a rotary microtome (ThermoFisher Scientific), floated on a warm 
water bath, to remove creases and dried in a 60 °C oven over night before staining. 
 
Immunohistochemistry was performed to detect expression of CD19 BAFF and BAFF-R. 
Mouse anti-human monoclonal antibodies were used against CD19 (clone LE-CD19; 
Dako) and BAFF (clone T7-241; LifeSpan BioSciences). A polyclonal rabbit anti-human 
antibody was used to detect BAFF-R (C-terminus, LifeSpan BioSciences). Staining was 
performed using the Dako Envision FLEX detection system with an Autostainer (Dako 
Link 48). Initial optimisation was carried out on tonsil tissue and antibodies were 
tested at two pH (pH 9.0 and 6.0), at a range of concentrations and also with and 
without the pre-treatment linker system (Dako). The slides were examined by a 
consultant histopathologist and the optimised conditions gave the strongest and most 
accurate staining with the least background. 
 
In brief, the cut paraffin-embedded tissue were mounted onto slides before being de-
waxed, rehydrated and treated with FLEX peroxidase-blocking reagent (Dako) to block 
endogenous peroxidase. To reduce non-specific background staining, neat horse serum 
and an avidin-biotin blocking kit (Invitrogen) were also used. Deparaffinised tissue 
sections were treated with heat-induced epitope retrieval using Target retrieval 
solution (Dako) at high pH (pH 9.0, CD19) or low pH (pH 6.0, BAFF & BAFF-R) and the 
PT linker system (Dako); this was a series of water baths. The antigen retrieval process 
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allowed access of the primary antibody to the antigen which can become masked 
during the tissue fixation process. The slides were cooled to 65 
o
C transferred to wash 
buffer at room temperature and then moved to the Autostainer. Slides were stained 
with optimised concentrations of CD19 (1:50), BAFF (1:200) or BAFF-R (1:200) 
antibodies for 30 minutes. FLEX/HRP detection reagent and FLEX DAB+ chromagen 
reagent (Dako) were used to visualise the target antigen. Here the secondary antibody 
labelled with horseradish peroxidase (HRP) converts 3, 3’ diaminobenzidine (DAB) to 
brown; this was the visualising chromagen. Counter-staining of nuclei used FLEX 
Hematoxylin (Dako). Following staining, slides were mounted and examined by a 
consultant histopathologist. Slides were graded by percentage expression in the core. 
Tonsil tissue was used for negative and positive controls. 
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5.3 Results 
 
To assess differential expression of sBAFF and BAFF-R as a factor of allograft function, 
three cohorts were selected (details of patient group allocation were outlined in 
Chapter 2, GM 3) and defined as stable (ST; n = 31), slowly deteriorating (SD; n = 29) 
and rapidly deteriorating (RD; n = 33). Patient demographics are shown in Table 5.1.  
 
 
Allograft function 
 
Stable 
(ST) 
 
Slowly 
deteriorating 
(SD) 
 
Rapidly 
deteriorating 
(RD) 
Total number of patients, n (%) 31 (33.3) 29 (31.2) 33 (35.5) 
Recipient 
Gender (F,M) 
Age, mean (range) (years) 
Time post-transplantation, mean (range) 
(years) 
 
 
11,20 
45 (22-68) 
6 (1-21) 
 
9,20 
48 (26-70) 
9 (1-25) 
 
14,19 
46 (22-67) 
8 (1-23) 
Type of allograft, n (%) 
Live donation 
DBD 
DCD 
 
 
19 (61) 
11 (36) 
1 (3) 
 
11 (38) 
14 (48) 
4 (14) 
 
 8 (24) 
22 (67) 
3 (9) 
HLA mismatches, n ± sd  
A,  mean ± sd 
B, mean ± sd 
DR, mean ± sd 
 
 
1.1 ± 0.6 
1.0 ± 0.6 
0.9 ± 0.6 
 
1.3 ± 0.7 
1.3 ± 0.6 
0.9 ± 0.7 
 
1.4 ± 0.5 
1.2 ± 0.4 
0.7 ± 0.7 
HLA antibody - post-transplantation 
Negative 
NDSA 
DSA 
 
 
19 (61) 
5 (16) 
7 (23) 
 
11 (38) 
4 (14) 
14 (48) 
 
10 (30) 
5 (15) 
18 (55) 
Cause of ESRF 
IgA nephropathy 
FSGS 
GN 
Hypertension 
PKD 
Diabetes  
Other/Unknown 
 
 
3 (10) 
2 (6) 
7 (23) 
2 (6) 
1 (3) 
 2 (6) 
14 (45) 
 
2 (7) 
3 (10) 
4 (14) 
0 
2 (7) 
0 
18 (62) 
 
2 (6) 
1 (3) 
4 (12) 
4 (12) 
3 (9) 
0 
19 (58) 
Table 5.1 Patient demographics for the study cohort 
Abbreviations: DBD, donation after brainstem death; DCD, donation after circulatory 
death; DSA, donor-specific HLA antibody; ESRF, end-stage renal failure; FSGS, focal and 
segmental glomerulosclerosis; GN, glomerulonephritis; PKD, polycystic kidney disease; sd, 
standard deviation.   
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Investigating serum BAFF levels in patients with different allograft function 
 
Elevated serum BAFF levels correlate with reduced graft function 
 
Serum BAFF levels were measured at a single time-point post-transplantation. Patients 
with ST graft function had significantly lower levels compared to those with SD or RD 
graft function (662.3 ± 326.9 pg/ml, 877.9 ± 388.8 pg/ml;  p = 0.03 & 1096.1 ± 999.2 
pg/ml; p = 0.009 for ST, SD & RD groups respectively; Figure 5.1A). When separated by 
low (n = 60; 64.5%) or high (n = 33; 35.5%) sBAFF level relative to the mean value 
(878.8 pg/ml), there was a significant, if small correlation between the level (for both 
low (p = 0.03) and high (p = 0.04) and rate of allograft deterioration, extracted from 
regression analysis (Figure 5.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  Elevated serum BAFF in patients with deteriorating allograft 
function 
 A. Dot-plot representing serum BAFF (sBAFF) levels measured by ELISA for patients 
with stable (ST; n = 31), slowly deteriorating (SD; n = 29) and rapidly deteriorating 
(RD; n = 33) graft function. sBAFF was significantly elevated in both SD & RD groups 
compared to the ST group (p values by Mann-Whitney test). 
B. Linear regression analysis showed significant correlation with level of sBAFF (low 
and high) and rate of deteriorating graft function (gradient of eGFR over time) in 
patients with either low or high sBAFF (< or > mean 878.8 pg/ml). 
 
 
A 
B 
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Correlating level of serum BAFF with donor-specific HLA antibody 
 
Expression of sBAFF was examined in relation to patients’ HLA antibody status (Figure 
5.2A). Overall, DSA was more prevalent in patients with high levels of sBAFF (sBAFF
high
) 
compared to low sBAFF (sBAFF
low
). Equally, sBAFF
low
 was associated with the absence 
of DSA (sBAFF
high
 - 60.6% vs. 28.3% and sBAFF
low 
- 24.2% vs. 58.4% for DSA vs. HLA 
negative groups, respectively; p = 0.0009).  
 
Examining sBAFF level and DSA together with allograft function, there was no 
statistically significant difference between the prevalence of DSA, high levels of sBAFF
 
and poor-graft function. Equally, patients without HLA antibody did not have 
statistically significant lower levels of sBAFF. 
 
A relationship between elevated sBAFF and the presence of DSA was investigated 
further to support the hypothesis that excess sBAFF may maintain a dysregulated B-
cell compartment and the production of alloantibody. There was a weak positive trend 
toward rate of declining graft-function and sBAFF level in patients with DSA (R
2
=0.11, p 
= 0.19, Figure 5.2B), which was absent in patients with NDSA (R
2 
= 0, p = 0.99). 
Furthermore, of those where a biopsy was performed, AMR was entirely restricted to 
patients with DSA and sBAFF
high
 (33.3%).  
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Low sBAFF (n = 60) 
 
High sBAFF (n = 33) 
 
Figure 5.2 Level of serum BAFF and presence of donor-specific HLA antibody 
 A. Bar-chart representing the frequency of patients with low (n = 60) or high levels of 
sBAFF (n = 33; < or > mean value 878.8 pg/ml) and presence of donor-specific HLA 
antibody (DSA), non-DSA (NDSA) or negative for HLA antibody. Relating this to graft 
function, the majority of stable (ST), slowly deteriorating (SD) groups with low sBAFF 
did not have HLA antibody. In contrast, SD and rapidly deteriorating (RD) groups with 
high sBAFF had a higher prevalence of DSA. 
B. Linear-regression analysis assessing the level of sBAFF in relation to rate of graft 
deterioration (extracted from the gradient of eGFR over time) showed the absence of 
a statistically significance difference. 
 
 
   A 
   B 
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Measuring serum BAFF as a marker of early renal dysfunction 
 
To evaluate BAFF levels during developing renal dysfunction and its potential 
application as a biomarker, sBAFF levels were analysed where stored serum was 
available for the duration of a patient’s transplant (n = 3; Figure 5.3). For patients 1 & 
3, a rise in serum creatinine (sCr) appeared in conjunction with increasing sBAFF. For 
patient 2, sBAFF increased prior to sCr. Overall, measurements of sBAFF were more 
prone to fluctuation over time than sCr, reflected by lower R
2
 and p values. With 
limited samples available it was not possible to determine if sBAFF was detected prior 
to a rise in sCr. Both sCr and sBAFF reached their peak value at the point of allograft 
failure. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Monitoring serum creatinine together with BAFF levels over the 
duration of allograft survival for three patients was inconclusive  
Assessing level of sBAFF in relation to serum creatinine (sCr) from time of transplant 
through to allograft failure (n = 3). Linear-regression analysis was performed for both 
sBAFF and sCr over time; R2 and p values are stated for each patient. 
Patient 1 
sBAFF sCr 
 
R2 = 0.27  R2 = 0.5 
p = 0.1  p = 0.01 
 
 
Patient 2 
sBAFF sCr 
 
R2 = 0.65  R2 = 0.84 
p = 0.009 p = 0.0004 
 
 
Patient 3 
sBAFF sCr 
 
R2 = 0.53  R2 = 0.77 
p = 0.027 p = 0.001 
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Summarising serum BAFF levels in renal transplant recipients 
 
Serum BAFF levels were elevated in patients with slowly and rapidly deteriorating graft 
function. When separated based on serum level, there was significant correlation 
between declining renal function and high sBAFF. The potential contribution towards 
deregulating homeostasis within the B-cell compartment is highlighted by the 
prevalence of DSA in these patients. 
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Phenotyping CD19+ cells for expression of BAFF receptor 
 
BAFF-R is primarily expressed by B cells and is the principal receptor for BAFF (Bossen 
and Schneider, 2006). To investigate if elevated sBAFF is due to lack of available 
receptor, BAFF-R was measured on the cell surface of CD19
+
 cells isolated from PBMC 
in the three groups. The initial constitution of lymphocytes (512 ± 210, 628 ± 273 and 
645 ± 262 cells/μl for ST, SD and RD, respectively; p = 0.29) and CD19
+
 cells (19 ± 15, 17 
± 14 and 20 ± 14 cells/μl for ST, SD and RD, respectively; p = 0.68) was not significantly 
different between groups (Figure 5.4A). However, the frequency of BAFF-R was 
reduced in patients with RD graft function (84.3 ± 16.6, 75.6 ± 18.3 and 67.5 ± 17.5 % 
for ST, SD and RD respectively, p = 0.002; Figure 5.4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Expression of BAFF-R on CD19+ cells is reduced in patients with 
deteriorating allograft function 
CD19+ cells isolated from PBMC were stained with anti-human monoclonal antibodies 
against CD19 and BAFF-R and analysed by flow cytometry. 
A. Initial evaluation of lymphocyte and CD19+ cell number showed minimal difference 
between patient groups; stable (ST; n = 31), slowly deteriorating (SD; n = 28) and 
rapidly deteriorating (RD; n = 24) graft function. There was no significant (ns) 
difference between groups by Kruskal-Wallis test. 
B. Expression of BAFF-R was significantly reduced on CD19+ cells from patients with 
RD graft function (p = 0.002) and not SD graft function (p= 0.15). P values derived by 
comparing ST to other groups by Mann-Whitney test. 
 
A 
B 
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The frequency of CD19
+
 cells and expression of BAFF-R were examined to determine if 
increased sBAFF was related to a reduced numbers of B cells. Patients with sBAFF
high
 
had a significantly lower number and percentage of CD19
+
 cells (sBAFF
high
 cohort: n = 
31; 2.43 ± 1.68%, 13 ± 7 cells/μl compared to sBAFF
low
 cohort: n = 53; 3.65 ± 2.12%, 22 
± 16 cells/μl, p = 0.01 for both percentage and number; Figure 5.5A). Next, reduced 
expression of BAFF-R on CD19
+
 cells was investigated to determine if there was a 
correlation with increased sBAFF. Patients were separated based on low or high 
percentage of CD19
+
BAFF-R
+
 cells; defined by the mean value (75.3%; n = 30). Serum 
BAFF levels in the CD19
+
BAFF-R
low
 group were not significantly higher (CD19
+
BAFF-R
low
 
group, mean 1014 pg/ml (median 847, range 369-5947 pg/ml) vs. CD19
+
BAFF-R
high
 
group, mean 816 pg/ml (median 749, range 231-2799 pg/ml); p = 0.17). Moreover, 
examination by linear-regression analysis did not reveal a significant correlation (R
2
 = 
0.09, p = 0.12; Figure 5.5B).  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure 5.5 CD19+ cells were reduced in patients with elevated sBAFF but 
there was no significant correlation with low expression of BAFF-R  
A. Patients with elevated sBAFF (> mean value of 879 pg/ml; n = 31) had reduced 
numbers of CD19+ cells compared to those with low sBAFF (n = 53; p = 0.01). P value 
derived by Mann-Whitney test.  
B. Reduced frequency of BAFF-R on CD19+ cells (< mean value of 75.3% shown in 
boxed area; n = 30) were assessed in conjunction with sBAFF levels.  Analysis by 
linear regression did not support a statistically significant relationship. 
A 
B 
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More detailed phenotypic analysis of B-cell subsets and elevated sBAFF demonstrated 
a significantly lower distribution of naïve B cells (CD19
+
CD27
-
IgD
+
) when compared to 
the sBAFF
low
 cohort (30.9 ± 15.4% vs. 43.6 ± 18.2%, p=0.002, Figure 5.6). Memory B 
cells (CD19
+
CD27
+
IgD
-
) were not significantly differently expressed between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Phenotypic distribution of naïve and memory B cells altered with 
expression level of sBAFF 
CD19+ cells stained with anti-human monoclonal antibodies against CD19, CD27 and 
IgD were assessed by flow cytometry. Naïve B cells (CD19+CD27-IgD+) were elevated 
in patients with low levels of sBAFF (sBAFFlow; n = 53) compared to patients with high 
levels of sBAFF (sBAFFhigh; n = 31). There was no statistical difference in the 
frequency of memory B cells (CD19+CD27+IgD-) between groups. P values derived by 
Mann-Whitney test. 
sBAFF
high
 
sBAFF
low
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Investigating if elevated serum BAFF is a bystander effect of raised serum 
creatinine  
 
The correlation between elevated sBAFF and impaired renal function was investigated 
by analysing expression in different disease settings. Patients were selected on the 
basis of the presence or absence of a condition believed to be linked aetiologically to 
B-cell involvement: they were diagnosed with polycystic kidney disease (PKD; n = 21), 
SLE (without lupus nephritis, LN; n = 21) and with LN (n = 21). PKD is a cystic genetic 
disorder often resulting in chronic kidney disease (CKD). Without a direct 
immunological component, patients with already impaired renal function were to 
serve as the negative control group. Conversely, B cells contribute to the pathogenesis 
of SLE by the production of autoantibodies and acting as APC to present self-antigens 
to autoreactive T cells (Lipsky, 2001, Renaudineau et al., 2004). Patients with SLE were 
divided into two cohorts based on renal involvement (+/- LN) and served as positive-
control groups. For the purpose of this comparative study, clinical manifestation of 
renal impairment for PKD and LN groups were based on sCr measurements. 
 
Serum BAFF was significantly elevated in patients with SLE, irrespective of the 
presence or absence of nephritis (mean values, 377.4 ± 117.2, 812.1 ± 385.5 & 758.7 ± 
344.2 pg/ml for PKD, SLE & LN groups, respectively; p<0.0001; Figure 5.7A). Indeed, 
renal function was worse in the PKD cohort, compared to the LN cohort, but sBAFF 
levels were still higher in the latter group (Figure 5.7A). The severity of PKD is classified 
in stages by level of renal function. Patients in this cohort were not separated by 
disease stage as reflected by the wide range of sCr measurements (mean, 
231.4 μmol/L (range, 117-475); Figure 5.7B). Equally, the LN group had variable sCr due 
to an individual’s disease state or effectiveness/compliance with treatment (mean, 
122 μmol/L (range, 85-493); Figure 5.7B). However, when separated by renal function, 
the same correlation as seen with transplanted patients existed between elevated 
sBAFF and poor renal function (Figure 5.7C). This may represent correlation with either 
or both of degree of aggressiveness of immune response and renal dysfunction. 
Overall, both LN and PKD groups have renal impairment. However, unlike LN, PKD lacks 
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immune-related aetiology and the low sBAFF expression in these patients suggests 
elevated sBAFF is not merely a bystander effect of raised sCr, although it may make a 
contribution. 
 
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Elevated expression of sBAFF was not a bystander effect of 
raised serum creatinine 
Three cohorts of patients were assessed for expression of sBAFF based on B-cell 
involvement in disease aetiology.  
A. Dot-plot representing sBAFF levels measured by ELISA. Serum levels were 
significantly lower in patients with polycystic kidney disease (PKD; n = 21) 
compared to SLE (n = 21) and lupus nephritis (LN; n = 21). There was minimal 
difference in sBAFF levels for SLE patients with or without LN.  
B. Dot-plot shows both PKD and LN patients had renal impairment based on raised 
serum creatinine (sCr) compared to the normal range (60-100 μmol/l), however 
only LN patients had elevated sBAFF levels (A). 
C. Separating LN patients by renal function based on measuring eGFR over time, 
showed those with rapidly deteriorating (RD; n =9) renal function had elevated 
sBAFF compared to stable (ST; n =8) and slowly deteriorating (SD; n = 4) patients, 
analogous to what was seen in transplanted patients.  
P values derived by Mann-Whitney test. 
 
A 
C B 
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Immunohistochemistry of renal allograft biopsies 
 
Cohorts of patients with and without AAMR were assessed for presence of B-cell 
infiltrates and associated expression of BAFF-R and soluble BAFF by 
immunohistochemistry using the same renal allograft tissue sections used previously 
to diagnose AAMR. Antibodies reactive to CD19, BAFF-R and BAFF were applied and 
initially optimised in tonsil tissue (Figure 5.8). A reliable staining pattern was 
established and, using an isotype-matched immunoglobulin, demonstrated a clear 
negative control for all antibodies. Transferring these methods to renal tissue (in which 
it can be difficult to clearly define antigen) required the use of multiple blocking 
methods, as detailed in the materials and methods, and the optimised method 
employed hydrogen peroxide, horse serum and an avidin-biotin block.  
 
Intrarenal expression of CD19, BAFF-R and BAFF was examined in tissue sections from 
patients with (n = 16; Figure 5.9A) and without AAMR (n = 11; Figure 5.9B). Staining 
intensity was graded as a percentage of the core sections (Table 5.2). The density of 
CD19
+
 cell infiltrates were variable among AAMR patients, associating with small 
populations of sub-capsular interstitial lymphoid aggregates and ranging from <1-10%. 
BAFF-R expression showed a similar distribution to CD19
+ 
cells, consistent with 
inflammatory cell accumulation. There was occasional expression on podocytes, 
mesangial cells and apoptotic bodies. In general, expression was lower than CD19. The 
distribution of BAFF was more diffuse, ranging from <1–20%. BAFF was noted to stain 
strongly with CD19
+
 cell infiltrate and was also associated with podocytes, fibroblasts 
and mesangial cells with some tubular staining. Patients without rejection had a lower 
percentage of CD19 infiltrates (<1-2%), similarly BAFF-R (<1-3%) and soluble BAFF (<1-
5%) which did not reach the level seen in some patients with AAMR. Overall those with 
AAMR appeared to show a higher staining intensity for CD19 (2.58 ± 2.61% vs. 1.67 ± 
0.52%; p = 0.57), BAFF-R (2.3 ± 2.75% vs. 1.31 ± 0.8%; p = 0.99) and BAFF (4.36 ± 5.79% 
vs. 2.44 ± 1.4%; p = 0.69) compared to those without rejection (Figure 5.10A). 
However, there was wide variation in these data within groups and no statistical 
difference was demonstrated (Table 5.2).  
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Figure 5.8 Optimising methods in tonsil tissue stained with CD19, BAFF-R 
and BAFF  
Immunohistochemistry was performed with monoclonal antibodies directed 
against CD19 and BAFF-R, and a polyclonal antibody against soluble BAFF in tonsil 
tissue to optimise staining prior to application in renal biopsy material.                   
The negative control is shown on the left of each set of images, followed by the 
stained sections at x 10 and x 40 magnification.  
A. Positive-staining for CD19 was associated with dense regions of inflammatory 
infiltrates 
B. Staining for BAFF-R showed a similar pattern to CD19, although less diffuse. 
C. Soluble BAFF was not as prominent as the receptor; at higher magnification 
(x40) staining was not only confined to the cell membrane. 
 
CD19 
BAFF-R 
BAFF 
X10 X40 
X10 X40 
X10 X40 
A 
B 
C 
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Figure 5.9  Localisation of lymphocyte aggregates within renal allograft 
tissue stained with CD19, BAFF-R and BAFF  
Immunohistochemistry was performed with monoclonal antibodies directed against 
CD19 and BAFF-R and a polyclonal antibody against soluble BAFF in renal allograft 
tissue. Representative figures show a patient with AAMR (A) and a patient without 
evidence of rejection (B). 
A. Application of a CD19 antibody showed positive staining in association with 
inflammatory infiltrates within the core. BAFF-R showed a similar pattern to CD19 
with more diffuse distribution of BAFF. 
B. A patient without rejection had no positively for CD19, BAFF-R or BAFF by 
immunohistochemistry. 
 
 
 
BAFF 
CD19 
A 
B 
 CD19 
BAFF 
BAFF-R 
BAFF-R 
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CD19 (%) 
 
BAFF-R 
(%) 
 
BAFF (%) 
 
sBAFF 
(pg/ml) 
 
DSA 
(%) 
 
AAMR (n=16), mean 
Range 
 
2.58 
<1-10 
 
 
2.3 
<1-10 
 
 
4.36 
<1-20 
 
 
758.71 
142-
2677 
 
100 
AAMR with BAFF
low 
(n=10 of 16) 
BAFF
low 
= ≤2% intrarenal BAFF 
 
 
1.35 
 
0.9 
 
1.2 
 
 
652.03 
 
AAMR with BAFF
high  
(n=6  of 16)
 
BAFF
high 
= >2% intrarenal BAFF 
 
P value compares AAMR with 
BAFF
low 
and BAFF
high
 
 
3.25 
 
 
p =0.41 
 
2.83 
 
 
p=0.26 
 
8.33 
 
 
p=0.0001 
 
936.5 
 
 
p=0.77 
 
Without AAMR (n = 11), mean 
Range 
 
 
P value compares AAMR with 
patients without AAMR 
 
1.67 
<1-2 
 
 
p=0.57 
 
1.31 
<1-3 
 
 
p=0.9 
 
2.44 
<1-5 
 
 
p=0.68 
 
622 
142-
1027 
 
p=0.9 
 
 
27 
 
Table 5.2 Summarising intrarenal expression of CD19, BAFF-R and BAFF in 
patients with or without AAMR  
Renal biopsy sections were stained with antibodies against CD19, BAFF-R and BAFF and 
examined by immunohistochemistry. The table shows mean values for staining intensity 
(%) for each antibody assessed. Serum BAFF (sBAFF) values are shown, together with 
presence of donor-specific HLA antibodies (DSA). 
P values derived by Mann-Whitney test comparing AAMR group against those without 
AAMR and those with AAMR and low intrarenal BAFF (BAFFlow; ≤2%) against AAMR with 
high intrarenal BAFF (BAFFhigh; >2%). 
 
 
The AAMR group was investigated further by separation based on expression of 
BAFF; determined as greater or less than 2% staining intensity (Table 5.2). The 
staining intensity of CD19, BAFF-R and BAFF was compared in those classified as 
‘BAFF
high
’
 
or ‘BAFF
low
’. In each case, the percentage of staining was higher in the 
BAFF
high 
group (CD19: 3.25% vs. 1.35%, p=0.41; BAFF-R:  2.83% vs. 0.9%, p = 0.26 and 
BAFF: 8.33% vs. 1.2%, p = 0.0001 for BAFF
high 
vs. BAFF
low 
respectively). This was 
significantly so for intrarenal BAFF. 
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The relationship between serum and intrarenal BAFF was next examined. First, 
comparing groups, those with AAMR did not have especially higher levels of sBAFF 
(758.7 ± 656.1 pg/ml vs. 605.1 ± 275.3 pg/ml; p = 0.47). Comparing levels of 
intrarenal BAFF, patients with AAMR had elevated levels (3.9 ± 5.55% vs. 2.05 ± 1.4%; 
p = 0.29). As these data show, there was wide variation in expression of both serum 
and intrarenal BAFF.  
 
By linear-regression analysis, there was a positive, albeit not quite statistically 
significant trend between intrarenal, sBAFF levels and AAMR (R
2 
= 0.22, p = 0.067; 
Figure 5.10B). When separated by expression of high intrarenal BAFF (>2%), the level 
of sBAFF increased but again not significantly (937.5 pg/ml vs. 622 pg/ml; p= 0 .42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Increased intensity of staining for intrarenal CD19, BAFF-R and 
BAFF in patients with AAMR 
A. Intensity of staining for CD19, BAFF-R and BAFF was graded as a percentage of 
the core biopsy. In each case, AAMR patients (n = 16) had higher expression levels 
than those without rejection (n = 11). ns is not significant by Mann-Whitney test. 
B. Linear-regression analysis of serum BAFF (sBAFF) levels (pg/ml) and intrarenal 
BAFF expression (%) in patients with AAMR showed a positive trend, however a 
statistically significant correlation did not exist. 
 
A 
B 
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Clinical outcome and intrarenal expression of BAFF 
 
Patients with AAMR exhibited variable intrarenal expression of CD19, BAFF-R and 
BAFF. In particular, BAFF expression ranged from 1-20%. Investigating the clinical 
outcome of those expressing more than 2% (median value) of the core section (n = 6), 
two patients had dnDSA compared to none of those with low intrarenal BAFF. Graft 
function was variable and one patient died with a functioning graft. Of those with low 
intrarenal BAFF, two patients suffered graft loss as a result of CAMR. As expected, all 
patients with AAMR had DSA, of those without AAMR, 27% had DSA and evidence of 
CAMR.  
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5.4 Discussion 
 
BAFF is an important effector molecule of the B-cell compartment, responsible for 
regulating cell maturation and survival. Given this, it has been widely investigated in 
autoimmune disease where aberrant expression is proposed to enhance B-cell activity, 
increase auto-antibody production and exacerbate pathology (Vincent et al., 2012, 
Scholz et al., 2013). Similar investigations have been applied to transplant recipients 
and elevated BAFF levels reported during allograft rejection, (Xu et al., 2009b, Banham 
et al., 2013a) and the development of DSA (Thibault-Espitia et al., 2012). These studies 
begin to provide a rationale for measuring expression levels of BAFF to give 
information of graft function and potentially allow for more timely treatment of 
rejection, minimising irreversible graft damage and promoting allograft longevity.  
 
This study measured sBAFF during the post-transplant period and associated elevated 
levels with deteriorating (slow and rapid) graft function, together with a prevalence of 
DSA and AMR. Moreover, a significant correlation existed between the level of sBAFF 
and degree of functional allograft deterioration. The comparable B-cell numbers 
between groups suggests BAFF production is independent of B-cell frequency and 
supported by Bloom and colleagues who report increased levels in alemtuzumab-
treated patients were not altered by frequency of CD20
+ 
cells (Bloom et al., 2009). 
These data are in contrast to the close relationship reported by others where B-cell 
numbers decrease in response to BAFF neutralisation (Batten et al., 2000, Gross et al., 
2000). However, these murine studies do not reflect the altered B-cell compartment in 
immunosuppressed transplant recipients. Moreover, DSA was more prevalent in those 
with high sBAFF where patients are most likely received intravenous immunoglobulin 
treatment; further altering B-cell numbers. 
 
Binding of BAFF to BAFF-R has a critical role in B-cell homeostasis by preventing 
apoptosis (Schneider, 2005). Patients with rapidly deteriorating graft function showed 
BAFF-R was down-regulated and this may account for an excess of unbound BAFF. 
While elevated BAFF was associated with low expression of BAFF-R in some patients, 
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this was not a uniform observation. Elevated BAFF may promote survival of 
alloantibody-producing B cells. In autoimmunity, the generation of B cells in a micro-
environment rich in BAFF leads to increased autoreactive B cells by failing to respond 
to cell-death-promoting factors (Lesley et al., 2004). Similarly, in mice, over-expression 
of BAFF made B cells less susceptible to anti-CD20-mediated depletion (Gong et al., 
2005). It is possible that elevated BAFF levels promote alloreactive B-cell development 
and decrease susceptibility to elimination and may explain predominance of DSA in 
those with high sBAFF and absence in those with reduced BAFF levels. 
 
The role of BAFF in supporting the survival of B-cell subsets was investigated by 
phenotypic analysis of naïve, memory and transitional B cells. In conjunction with 
signalling through the BCR, BAFF is demonstrated to mediate survival of transitional B 
cells (Batten et al., 2000, Goodnow et al., 2005). The expression of BAFF-R on IL-
10
+
CD24
high
CD38
high
 cells were investigated (described in Chapter 6). In brief, this small 
cohort demonstrated very high expression of BAFF-R on transitional B cells in those 
with stable and slowly deteriorating graft function and to a lesser degree in those with 
rapidly deteriorating graft function. Assuming BAFF is bound with BAFF-R on these 
transitional B cells, this interaction may favour their survival as observed in a murine 
model of autoimmunity where over-expression of BAFF alters the process of B-cell 
maturation, promoting survival of transitional B cells (Mackay et al., 1999).  
 
Memory B cell frequency increased in patients with elevated BAFF. In mice, BAFF has 
been demonstrated to be essential for formation of splenic germinal centres (Yan et 
al., 2000) and in human CD27
+
 memory B cells, BAFF enhances their survival and 
promotes generation of plasma cells in vitro (Avery et al., 2003). This supporting role in 
survival could explain why memory B cells increase in patients with elevated BAFF. 
Increased BAFF could potentially break immune tolerance during B-cell maturation, 
providing a critical role in promoting the humoral immune response. 
 
Measurement of sBAFF as a reliable marker of B-cell mediated allograft dysfunction is 
reliant on both accuracy and specificity and a number of parameters were assessed to 
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address this. Firstly, in transplanted patients factors can affect allograft function such 
as infection, drug nephrotoxicity and malignancy, potentially altering expression of 
BAFF. Here, those with elevated sBAFF or low BAFF-R did not have any clinically 
remarkable events at the time of sample procurement as measured by C-reactive 
protein (CRP) to contribute toward raised sBAFF. However excluding interfering factors 
in sBAFF measurements requires further investigation. Secondly, the possible 
bystander effect consequential of raised sCr was examined using patient samples with 
PKD; a disease modality absent of B-cell involvement in aetiology in parallel to SLE; a 
disease where elevated sBAFF is established (Cheema et al., 2001, Morimoto et al., 
2007). Raised sBAFF was not seen in PKD patients compared to those with SLE both 
with and without nephritis. It may have been expected that sBAFF be more 
pronounced in conjunction with nephritis. However, a similar study investigating sBAFF 
levels in SLE patients with/without nephritis did not find a significant association 
(Eilertsen et al., 2011). Examining renal function in LN patients supported the 
correlation found in the transplanted cohort of elevated sBAFF and worsening allograft 
function. Future studies would benefit measuring the impact renal function has on 
sBAFF levels using eGFR data in patients with a non-immunological disease, in this case 
the PKD population. Finally, this study attempted to address if sBAFF increased prior to 
the elevation of sCr, which would offer its application as an early marker of 
deteriorating function. Unfortunately too few samples were available over the 
duration of allograft survival to draw any conclusions and this requires further 
investigation.  
 
To address the reliability of BAFF as a marker of B-cell activity in renal injury, 
histological analysis of biopsy material was performed. In this cohort, a number of 
patients with AAMR had significant infiltrate of CD19
+
 cell aggregates. Expression of 
BAFF-R and BAFF accumulated at these areas, suggesting the predominant source of 
BAFF to be inflammatory cells infiltrating the graft. Comparing intensity of staining for 
CD19, BAFF-R and BAFF to those without AAMR, although greater did not reveal any 
statistically significant difference, which is in part due to extremes of staining intensity. 
When the AAMR cohort were separated based on higher expression of intra-renal 
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BAFF, an interesting observation was the presence of dnDSA noted in a third of these 
patients; absent in those with low intrarenal BAFF. Although in terms of clinical 
outcome there was nothing remarkable in this, dnDSA are attributed with increased 
risk of allograft failure, (Wiebe et al., 2012) and heighten B-cell activity may contribute 
toward this. This study described a very small number of patients and long-term 
follow-up of those with prominent CD19
+
 cell infiltrate, associated with BAFF-R and 
BAFF in a larger cohort is required. Of final note, a correlation was found between 
increasing intensity of intrarenal BAFF and sBAFF. This did not quite reach a level of 
statistical significance but the principle of association is important as it provides 
evidence that elevated sBAFF levels are transferable to patients with active humoral 
rejection identified in the allograft. This is further supported by the correlation of DSA 
and elevated sBAFF. Collectively these data provided evidence of BAFF during AAMR 
and in the presence of alloantibody supporting the notion of a non-invasive alternative 
to performing biopsy, carrying no risk to the patient or the inherent issue of variability 
of sample size, and quality or lack of injured tissue. Clinically the application of a BAFF-
detecting ELISA would be easy as it is already a well-established method and 
measuring sBAFF levels could indicate potential for developing AMR. This may be 
particularly beneficial in CAMR, most frequently diagnosed when a graft is failing such 
that when biopsy is performed damage to the allograft is already apparent and 
intervention with treatment may be too late to reverse lesions. Equally useful could be 
monitoring sensitised patients to assess effectiveness of antibody-removal treatment. 
 
Concluding remarks 
 
B cells are implicated in the pathogenesis of transplant rejection through production of 
alloantibody. Elevated BAFF may support this by promoting survival of B cells, 
potentially allowing alloreactive cells to manifest, leading to B-cell-mediated pathology 
and graft dysfunction. The activity of B cells post-transplant is not measured. Here 
elevated sBAFF, low expression of BAFF-R and DSA correlated with deteriorating graft 
function. Performing immunohistochemistry provided direct evidence of BAFF 
associated with infiltrating B cells within allografts of patients with AAMR. Together, 
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these data demonstrated BAFF as a potential biomarker of dysregulation within the B-
cell compartment and of humoral mediated allograft rejection. 
 
  
 
 
 
 
Chapter 6 
 
Characterising and investigating 
functional capabilities of regulatory  
B cells in renal transplant recipients 
 
 
 
CHAPTER 6 
 
168 
6.1 Introduction 
 
The presence and role of B cells with suppressive capacity have not been widely 
explored following transplantation. Research primarily focuses on their position in 
autoimmunity where they are believed to regulate disease progression, since 
depletion, in some cases, leads to exacerbation of symptoms. This regulatory function 
is partially mediated through secretion of IL-10 and a number of methods are 
described to activate production by peripheral B cells. In general, this is achieved via 
TLR stimulation with CpG and CD40 ligation, both with (Bouaziz et al., 2010) or without 
BCR engagement (Iwata et al., 2011). Following activation, intracellular expression of 
IL-10 can be identified at the single cell level by flow cytometry following a short 
stimulation with phorbol myristate acetate (PMA), ionomycin and monensin. PMA 
activates a protein kinase pathway, triggering calcium release and a cascade of cellular 
responses to mediate cytokine production (Truneh et al., 1985). Used in conjunction 
with PMA is ionomycin, an ionophore produced by Streptomyces conglobatus to 
transport ions across the lipid bilayer. In this context, it is utilised to stimulate 
production of intracellular cytokines. During the last stages of stimulation monensin is 
added to prevent cytokines exiting the cell by inhibiting their transport across the 
endoplasmic reticulum and preventing export to the Golgi complex resulting in 
enhanced detection. Employing these methods has allowed IL-10-producing B cells to 
be identified at relatively low frequency. In peripheral blood of healthy controls the 
reported range is between 1 and 7% (Bouaziz et al., 2010, Iwata et al., 2011, Blair et al., 
2010, Das et al., 2012).  
 
An obstacle in studying regulatory B cells (Bregs) is the lack of a unique surface 
phenotype, and a consensual view is yet to be achieved. A number are ascribed to 
human B cells with regulatory function which include CD19
+
CD24
high
CD38
high
 (Blair et 
al.), CD19
+
CD24
high
CD27
+ 
(Iwata et al., 2011) and CD19
high
CD1d
high
CD5
+ 
‘B10’ (Yanaba et 
al., 2008). There does appear to be agreement that IL-10-producing cells are enriched 
in the CD24
high
CD38
high
 B-cell compartment (Blair et al., 2010, Flores-Borja et al., 2013, 
Bouaziz et al., 2010). This was initially described as a suppressive B-cell phenotype 
lacking in patients with SLE, (Blair et al., 2010) and has since been included in a B-cell 
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signature of tolerance in renal transplant recipients, those with stable graft function in 
the absence of immunosuppression (Newell et al., 2010). Here tolerance was linked 
with increased frequency of CD24
high
CD38
high 
transitional B cells expressing IL-10, and 
also naïve B cells. In a separate study, tolerant allograft recipients displayed a distinct 
phenotype with increased expression of inhibitory molecules and expanded activated 
and memory B cells (Pallier et al., 2010). These data suggest regulatory B cells reside in 
committed subsets and importantly their frequency is positively associated with good 
graft function.  
  
IL-10-producing B cells can be characterised by expression of cell-surface markers 
creating a detailed, if not unique phenotype of these cells. This can aid identification 
and allow potential numerical deficits in disease settings to be revealed. The functional 
role of these cells
 
to control effector immune response, in addition to secretion of IL-
10, is dependent on direct contact with CD4
+
 T cells (Mauri et al., 2003, Blair et al., 
2010, Mizoguchi et al., 2002, Kessel et al., 2012). The anti-inflammatory effects exerted 
on the suppression of CD4
+ 
T-cell differentiation, specifically T helper 1 (Th1) cells 
responsible for producing pro-inflammatory cytokines can be measured in vitro. 
Activated CD4
+
 T cells can be defined as Th1 or Th2 cells based on their pattern of 
cytokine expression (Mosmann et al., 1986). Th1 cells predominately secrete pro-
inflammatory cytokines, IFN-γ, TNF-α and lymphotoxin, but also IL-2 involved in cell-
mediated immunity. Th2 cell cytokines include IL-4, IL-5 and IL-13 associated with the 
humoral response, and IL-10 with anti-inflammatory effects (Zhu et al., 2010).  In vivo 
CD4
+
 T cells are activated from naïve T cells following binding by specific antigen. This 
requires two signals: first engagement of the T cell receptor (TCR) with an antigen 
presented in association with the MHC receptor complex; the second follows ligation 
of co-stimulatory receptors – CD28 on T cells and CD86 on antigen-presenting cells 
(June et al., 1994) – resulting in cytokine production, cytokine receptor expression and 
proliferation of activated T cells. In vitro, naïve T cells can be non-specifically activated 
in the absence of antigen by a number of agents. This is usually achieved by direct 
cross-linking of the TCR on a large proportion of responder cells with anti-CD3 
antibodies bound to a tissue culture plate. Although this method does not require the 
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presence of accessory molecules, the response may be suboptimal, (Jenkins et al., 
1990) and combining with CD28 can enhance T-cell activation and proliferation 
(Lenschow et al., 1996). This method has been used to evaluate regulatory activity of 
CD19
+
CD24
high
CD38
high 
cells (Blair et al., 2010). Co-culture of these cells with naïve T 
cells reduced the frequency of pro-inflammatory cytokines, TNF-α and IFN-γ produced 
by Th1 cells. This analysis was then applied to patients with SLE who lacked the 
suppressive capacity seen in healthy controls.  It is possible that this type of 
suppression is impaired in those with poor graft function post-transplantation. 
 
In response to contact with T cells, B cells produce cytokines. Secretion can also occur 
constitutively, in response to antigen presentation or TLR stimulation, all of which can 
indirectly modulate T-cell behaviour (Lund, 2008, Lund et al., 2005). The commitment 
of naïve T cells to become 1) effector Th1 and Th2 cells, 2) protective regulatory T cells 
(Tregs), or 3) cytopathic Th17 cells is influenced by the cytokine environment (Strom 
and Koulmanda, 2009). Th1 cell cytokines, TNF-α, IL-1β and IL-6 can promote 
differentiation to the damaging Th17 phenotype (Acosta-Rodriguez et al., 2007) 
preventing commitment to Tregs. (Bettelli et al., 2006). 
CD19
+
CD25
high
CD27
high
CD86
high
CD1d
high
CD10
high
TGF-β
high
 cells, defined as Bregs can 
enhance expression of Foxp3 and CTLA-4 on Tregs and supress proliferation of CD4
+
 T 
cells which interestingly was dependent not on IL-10 but on TGF-β. (Kessel et al., 
2012). This suggests although IL-10 is regarded as pivotal in regulatory cells inhibiting 
pro-inflammatory responses, their cytokine production may extend beyond this. 
Indeed a range of other cytokines produced by B cells demonstrates immune 
regulation. For example, IL-12 can promote Th1 differentiation, IL-4 induces Th2 
maturation, and IL-6 and TGF-β are important in Th17 cell development. (Hamze et al., 
2013). Furthermore IL-6, TNF-α and IL-10 can indirectly modulate T-cell responses 
through interactions with macrophages (Wong et al., 2010). Evidence of suppressed 
Th1 cell cytokines by CD19
+
CD24
high
CD38
high
 cells (Blair et al., 2010) may have 
implications following transplantation due to their association with allograft rejection. 
Prominent are IL-6, implicated in cardiac allograft rejection, (Diaz et al., 2009) and TNF-
α and IL-1β in chronic renal allograft rejection (De Serres et al., 2011). An additional 
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cytokine important in regulating B-cell survival and maturation is BAFF (B-cell 
activating factor). Studies in animal models suggest this may also be essential in 
development or promotion of Bregs. In BAFF-deficient mice there is impaired 
maturation of transitional B cells, (Schiemann et al., 2001) and BAFF-transgenic mice 
promote development of Tregs (Walters et al., 2009). Moreover, BAFF induced the 
differentiation of IL-10-producing B cells capable of suppressing T-cell proliferation and 
Th1 cytokine production, and their in vivo transfer inhibited arthritis (Yang et al., 
2010). The significance of BAFF and other cytokines in elevation of Bregs, and during 
their interaction with CD4
+
 T cells following renal transplantation to advocate a 
suppressive or regulatory response has yet to be addressed. 
  
In summary, research into human regulatory B cells has yielded diverse results and in 
the absence of a definitive phenotype it is difficult to unify a coherent function. 
However it is clear that, in the context of autoimmunity and observations in tolerant 
renal transplant recipients, B cells play an important role in maintaining and controlling 
the immune response.  
 
The purpose of this study was to identify IL-10-producing B cells, further define 
association with naïve, memory and transitional B cells and, progressing beyond the 
phenotypic level, to determine if regulation resides in CD19
+
CD24
high
CD38
high
 cells by 
assessing suppression of Th1 cell pro-inflammatory cytokines and explore secreted 
products during contact with CD4
+
 T cells. Collectively findings are related to the level 
of renal allograft function. 
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6.2 Materials and methods  
 
Materials and methods detailed in Chapter 2, General Methods (GM) are indicated. 
 
GM1  Recruitment of study patients 
 
GM2  Immunosuppressive regime  
 
GM3  Defining level of allograft function in patient cohorts  
 
GM4  Peripheral blood mononuclear cells (PBMC) separation  
 
GM5  CD19+ cell isolation from PBMC  
 
GM6  Phenotyping CD19+ cells by flow cytometry 
 
GM7  Polyclonal agonists applied during CD19+ cell culture 
 
GM8  Detection of HLA antibody in serum by Luminex technology 
 
GM10  Statistical analysis  
 
 
CD19+ cell culture 
 
CD19
+
 cells (1 x 10
6
/ml) in RPMI-1640/10% FCS with 5% L-glutamine, 5% penicillin and 
5% streptomycin (complete medium) were cultured with TLR agonists to induce 
proliferation and differentiation (GM 7, Table 2.2). This included R848 and IL-2, CpG 
alone or in combination with CD40L and anti-human IgG-IgM-IgA (anti-Ig). Cells were 
added at 100 µl/well to a 96-well U-bottom plate (Becton Dickinson; BD) and 
incubated at 37 
o
C in 5% CO2 for five days. 
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Stimulating CD19+ cells for intracellular cytokine detection 
 
Post-culture cells were transferred to FACS tubes (BD), washed, resuspended in 800 μL 
complete medium and stimulated for five hours with phorbol 12-myristate 13-acetate 
(PMA, 50 ng/ml; Sigma-Aldrich, UK) and ionomycin (500 ng/ml; Sigma-Aldrich). 
Brefeldin A (3 μg/ml; ebioscience, USA) and monensin (2 μM; ebioscience) were added 
for the last two hours. Tubes were centrifuged to collect the cells, the medium 
discarded, cells resuspended and washed in 1 ml FACS buffer (PBS/2% FCS).  
 
Post-culture extracellular staining of CD19+ cells for analysis by flow cytometry 
 
Following stimulation for intracellular cytokine analysis, cells were resuspended in 50 
μl FACS buffer and stained with the B-cell panel of antibodies as described in GM 6, 
Table 2.1. 
 
Post-culture intracellular staining of CD19+ cells for analysis by flow cytometry 
 
Following extracellular staining, cells were washed in 1 ml FACS buffer, resuspended in 
100 µl fixation buffer (4% formaldehyde; ebioscience) and incubated in the dark with 
shaking for 20 minutes at room temperature. Cells were washed and resuspended in 
50 µl permeabilisation buffer (0.1% saponin; ebioscience) with rat anti-human IL-10-
APC (0.5 μg/ml; Clone JES3-19F1, BD Biosciences) or for the negative control, a 
blocking antibody, rat anti-human IL-10 (0.5 μg/ml; Clone JES3-19F1, BD Biosciences), 
for 20 minutes in the dark at room temperature. The negative control was re-stained 
with anti-human IL-10-APC (0.5 μg/ml) to confirm efficacy of the blocking antibody. 
Cells were washed with 1ml permeabilisation buffer, resuspended in 500 µl fixation 
buffer and analysed on the flow cytometer. 
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CSFE staining of CD19+ cells 
 
100 µL of CD19+ cells (1 x 106/ml) were incubated with 5 µM CFSE (Molecular Probes, 
Life Technologies) in 1 ml FCS at 37 
o
C for six minutes with mixing every two minutes. 
Cells were quenched with 5 ml of ice-cold FCS for five minutes, washed and quenched 
again to remove any remaining CFSE. Cells for culture were resuspended in complete 
medium. 100 µl of stained cells were analysed at day zero and day five by flow 
cytometry.  
 
Functional assays – CD4+T: B-cell co-cultures 
 
PBMC and CD19+ cell isolation 
 
PBMC were isolated from peripheral whole blood (40 ml) within four hours of 
venesection as detailed in GM 4. For studies using the whole CD19
+
 cell fraction, CD19 
cells were isolated by magnetic bead separation as detailed in GM 5.  The positively 
selected CD19
+ 
cells were retained and the negative fraction was utilised to isolate 
CD4
+
CD25
- 
naïve T cells. For cell-sorting experiments, PBMC (5 x 10
6 
cells) were 
reserved for naïve T-cell isolation. 
 
Cell-sorting by Fluorescently Activated Cell Sorting (FACS) 
 
For cell-sorting experiments by FACS, PBMC were resuspended in 1 ml FACS buffer. 
20 μl was removed for isotype & single antibody-stained controls and the remaining 
stained with CD19-APC-H7, CD24-PerCP 5.5 and CD38-V450 for 30 minutes in the dark 
at room temperature. Cells were washed and resuspended in FACS buffer before 
analysis using a FACS Aria (BD Biosciences). Voltages and compensation parameters 
were set using the controls and CD19
+
 cells selected from the total lymphocyte 
population. From CD19
+
 cells, CD24 & CD38 cells were gated to distinguish three 
populations: transitional (CD19
+
CD24
high
CD38
high
), memory (CD19
+
CD24
high
CD38
-
) and 
mature naïve cells (CD19
+
 CD24
+
CD38
+
). FACS cells were collected under sterile 
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conditions into FACS tubes containing complete medium with FCS at 20%. At the end 
of the sort, cells were washed and resuspended in complete medium prior to cell 
culture. 
 
Naïve T-cell isolation 
 
Naïve T cells (CD4
+
CD25
-
) were isolated by magnetic-bead purification using naïve CD4
+ 
T cell microbeads (Miltenyi Biotec) as per manufacturer instructions. Briefly, PBMC (5 x 
10
6 
cells) were resuspended in 80 μl MACS buffer (PBS/0.5% FCS/0.05% EDTA), 10 μl 
microbeads and incubated for 20 minutes at 4 °C in a 15 ml Falcon tube. Cells were 
washed with 2 ml MACS buffer, resuspended in 80 μl MACS buffer and 20 μl biotin 
microbeads and incubated again for 20 minutes at 4 °C. Cells were washed in 2 ml 
MACS buffer and applied to a pre-prepared column (MS column; Miltenyi Biotec) on a 
magnetic plate to retain cells bound to the microbeads. The labeled PBMC suspension 
was allowed to run completely through the column before being washed three times 
with 500 μl MACS buffer. The negative fraction contained naïve T cells. After the flow 
through was complete, cells were washed and resuspended in complete medium at a 
concentration of 1 x 10
6
/ml. 
 
CD4+ T-cell suppression assay 
 
Pre-culture preparation for naive T-cell activation by CD3 antibody 
 
100 μl of anti-CD3 (10 μg/ml; clone HIT3a; BD Biosciences) in PBS was applied to a 96-
well round bottom microplate (BD) and incubated at 37 
o
C for a minimum of 
two hours. Immediately prior to naïve/B-cell subset transfer, the antibody solution was 
expelled from the plate and wells washed twice with PBS. After each wash the plate 
was inverted and blotted against clean paper towels to remove residual liquid. 
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Naïve T-cell co-culture with CD19, CD24, CD38 subsets 
 
CD19
+
 cells or CD19
+
CD24
high
CD38
high
; CD19
+
CD24
high
CD38
-
; CD19
+
 CD24
+
CD38
+
 FACS 
populations (1 x 10
6
/ml) were cultured 1:1 with CD4
+
CD25
-
 cells (1 x 10
6
/ml).  
CD4
+
CD25
-
 cells without CD19
+ 
cells or CD19
+
 subsets served as positive controls. Cells 
were cultured for 96 hours at 37 
o
C in 5% CO2. 
 
Post-culture analysis 
 
Cytokine detection in culture supernatant 
 
Supernatant was removed from culture wells without disturbing the cell pellet and 
stored at -20 
o
C until required. 
  
Stimulating cells CD4+ T cells for intracellular cytokine detection  
 
Post-culture cells were stimulated for intracellular cytokine analysis previously 
described. 
 
Extracellular staining of CD4+ T cells for analysis by flow cytometry 
 
Following stimulation for intracellular cytokine analysis, cells were resuspended in 50 
μl FACS buffer and stained with mouse anti-human CD4-eFluor 450 (0.2 μg/ml, Clone 
SK3; eBioscience) and CD69-FITC (0.2 μg/ml, Clone FN50; BD Biosciences) or isotype 
controls (eFluor 450 & FITC Mouse IgG1, κ) as previously described. 
 
Intracellular staining of CD4+ T cells for analysis by flow cytometry 
 
Following extracellular staining, cells were prepared for intracellular cytokine analysis 
as previously described. Expression of TNF-α-PE (0.5 μg/ml, Clone MAb11; BD 
Biosciences) and IFN-γ- APC (0.5 μg/ml, Clone B27; BD Biosciences) were investigated. 
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Cytokine detection in serum and culture supernatant 
 
IL-10 detecting ELISA 
 
IL-10 in serum and culture supernatant was investigated by ELISA following the 
manufacturer’s instructions (DuoSet ELISA System; R&D Systems). In brief, a 96-well 
flat-bottom microplate (BD Biosciences) was coated with 100 μl per well of mouse 
anti-human IL-10 antibody (2 μg/ml), sealed with paraffin film and incubated at room 
temperature overnight. Next day, the plate was washed three times with wash buffer 
(PBS/0.05% Tween 20). After each wash the plate was inverted and blotted against 
clean paper towels to remove any remaining wash buffer. A blocking solution (PBS/1% 
BSA) was applied and incubated at room temperature for one-hour. The plate was 
washed as outlined above and positive controls (recombinant human IL-10) prepared 
by serial dilution (decreasing from 2000 pg/ml) or samples (1:1 with PBS/1% BSA) 
applied to the plate, covered with paraffin film and incubated in the dark for two hours 
at room temperature. The plate was washed and biotinylated goat anti-human IL-10 
(150 ng/ml) added to each well before being sealed and incubated for two hours. The 
plate was decanted again, washed and 100 μl streptavidin conjugated to horseradish-
peroxidase (HRP) reagent applied to each well for 20 minutes in the dark at room 
temperature. After washing, the substrate solution (1:1; H2O2: Tetramethylbenzidine) 
was applied for 20 minutes in the dark at room temperature. This reaction was 
stopped with sulphuric acid (2N H2SO4) and the optical density (OD) of the developed 
colour analysed using a microplate reader (Labtech) set to 450 nm with a correction 
value of 540 nm. Data were exported to Excel and using the concentration of serially 
diluted positive controls against absorbance generated a linear regression curve used 
to estimate the concentration of IL-10 in the samples. 
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Human cytokine array assay 
 
Identification of cytokines in the B-T cell co-culture supernatant employed a Proteome 
Profiler, Human Cytokine Array assay (Panel A; R&D systems). This enabled detection 
of 36 cytokines and chemokines (anti-C5a, CD40 Ligand, G-CSF, GM-CSF, GRO, I-309, 
sICAM-1, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, p70, IL-13, IL-
16, IL-17, IL-17E, IL-23, IL-27, IL-32α, IP-10, I-TAC, MCP-1, MIF, MIP-1α, MIP-1β, Serpin 
E1, RANTES, CXCL12, TNF-α, sTREM-1) impregnated onto a nitrocellulose membrane. 
The method followed the manufacturer’s instructions. In brief, 500 μl of a blocking 
buffer was applied onto the membrane in a four-well multiplate and incubated at room 
temperature on a rocking platform for one-hour. Culture supernatant was centrifuged 
to collect cell debris and the upper fraction, together with the antibody detection 
cocktail (supernatant-antibody mixture) was incubated at room temperature for one-
hour. After incubation, the blocking buffer was removed from each membrane, the 
supernatant-antibody mixture applied, and the membranes incubated overnight at 4 
o
C 
on a rocking platform. Next day, membranes were removed and washed on a rocking 
platform; this was repeated for a total of three washes. The membranes were 
removed; excess buffer allowed to drain and placed back into the cleaned multiplate 
with streptavidin-HRP reagent (1:200) and incubated for 30 minutes at room 
temperature on a rocking platform. The membranes were washed again as described. 
After the third wash, each membrane was removed, allowed to drain and placed on a 
plastic sheet held in an autoradiography cassette. Chemi Reagent Mix was applied onto 
the membrane and covered with a plastic sheet. After one minute, excess Chemi 
Reagent Mix and any air bubbles between the plastic sheets were removed with 
smoothing. The membranes were exposed to X-ray film in a dark room and level of 
spot development assessed. Generally, one to three minutes was sufficient time. The 
X-ray film was scanned and the images analysed using Image J software (National 
Institutes of Health). 
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6.3 Results 
  
Identification of IL-10-producing B cells  
 
To evaluate if numbers of IL-10-producing B cells are associated positively with stable 
graft function, three groups of patients were investigated: those with stable (ST; n=5); 
slowly deteriorating (SD; n=5), and rapidly deteriorating (RD; n=6). The demographic 
and clinical characteristics of patients are shown in Table 6.1. 
 
 Stable 
(ST) 
Slowly 
deteriorating 
(SD) 
Rapidly 
deteriorating 
(RD) 
Total number of patients, n (%) 
 
5 (31.3) 5 (31.3) 6 (37.5) 
Recipient 
Gender (F,M) 
Age, mean (range; years) 
Time post-transplant, mean (range; years) 
  
 
1,4 
45 (31-57) 
6 (1-10) 
 
1,4 
45 (33-52) 
13 (1-24) 
 
1,5 
43 (32-55) 
11 (3-23) 
Type of allograft, n (%) 
Live donation 
DBD 
 
 
3 (60) 
2 (40) 
 
2 (40) 
3 (60) 
 
2 (30) 
4 (70) 
HLA mismatches, n ± sd 
A,  mean ± sd 
B, mean ± sd 
DR, mean ± sd 
 
 
1.2 ± 0.45 
1.4 ± 0.55 
0.8 ± 0.84 
 
0.75 ± 0.96* 
1 ± 0.82* 
0.5 ± 0.58* 
 
1.5 ± 0.55 
1.2 ± 0.41 
0.33 ± 0.52 
HLA antibody - post-transplant, n (%) 
Negative 
NDSA 
DSA 
 
 
3 (60) 
2 (40) 
0 
 
4 (80) 
1 (20) 
0 
 
3 (50) 
1 (20) 
2 (30) 
Cause of ESRF, n (%) 
IgA nephropathy 
FSGS 
GN 
Hypertension 
Other/Unknown aetiology 
 
 
0 
0 
4 (80) 
0 
1 (20) 
 
0 
0 
1 (20) 
0 
4 (80) 
 
1 (16.7) 
1 (16.7) 
1 (16.7) 
1 (16.7) 
2 (33.3) 
Table 6.1  Demographics of patient groups separated by allograft function  
Abbreviations: DBD, donation after brainstem death; DSA, donor-specific HLA antibody; 
NDSA, non-donor-specific HLA antibody; ESRF, end-stage renal failure; FSGS, focal 
segmental glomerulosclerosis; GN, glomerulonephritis; sd, standard deviation. *Donor 
type missing for one patient. 
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Phenotypic analysis of peripheral blood in study groups 
 
Total lymphocyte and CD19+ cell populations 
 
The total PBMC count was assessed following lymphocyte isolation by density-gradient 
centrifugation of peripheral whole blood within four hours of venesection (Figure 6.1). 
Minimal differences existed between groups (450 ± 169 cells/μl; 570 ± 84 cells/μl; and 
558 ± 198 cells/μl; p = 0.44, for ST, SD and RD groups respectively). Following PMBC 
isolation, CD19
+
 cells were positively selected by magnetic-bead separation. Patients 
with stable function seemed to have a higher percentage (5.14 ± 2.45%; 2.76 ± 1.89% 
and 3.55 ± 0.8%; p = 0.43 for ST, SD and RD groups respectively) and number (23.01 ± 
0.28 cells/μl; 15.13 ± 9.1 cells/μl and 20.09 ± 9.02%; p = 0.26 for ST, SD and RD groups 
respectively) of CD19
+
 cells, but in neither case was the difference statistically 
significant.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1  PBMC and CD19+ cell 
numbers were comparable between 
groups 
Dot-plots show mean PBMC count (A) for 
each patient group based on lymphocyte 
isolation by density centrifugation of 
fresh peripheral whole blood (40 ml) and 
the frequency (B) and number (C) of 
positively selected CD19+ cells. ST, stable 
(n = 5); SD, slowly deteriorating (n = 5); 
RD, rapidly deteriorating (n=6) graft 
function. p values all > 0.05 by Kruskal-
Wallis test. 
  A 
 B    C 
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Optimising cell-culture conditions to promote CD19+ cell expansion in 
peripheral blood of healthy controls 
   
CD19
+
 cells were investigated for IL-10 production post-culture with TLR agonists 
known to promote B-cell expansion and differentiation. This included the TLR7/8 
agonist, R848 (Pinna et al., 2009), and the TLR9 agonist, CpG-B (Bouaziz et al., 2010). 
The ability of these agonists, with combinations of additional stimulants, to promote IL-
10 production was assessed. First, expansion of CD19
+
 cells was determined in healthy 
controls (n = 3). CD19
+
 cells were labelled with CSFE to identity proliferation and 
cultured for five days in the presence of the following: R848 and IL-2; CpG-B; CpG-B and 
CD40L; or CpG-B 2006, CD40L and anti-human IgG-IgM-IgA (anti-Ig). Although small, 
the greatest proliferation of CD19
+
 cells was observed with a combination of CpG, 
CD40L and anti-Ig (Figure 6.2A & B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CpG 
   CpG & CD40L CpG, CD40L & anti-Ig 
Figure 6.2 Combined 
stimulation with CpG, 
CD40L and anti-Ig favoured 
expansion of CD19+ cells  
A. Representative flow-
cytometric plots showing 
CD19+ cells labelled with CSFE 
and cultured for five days. 
Post-culture cells were 
stained for CD19 and analysed 
by flow cytometry. The zebra 
plots show the frequency of 
CD19+ CSFE+ cells (%) for 
unstimulated cells or with 
R848 & IL-2; CpG; CpG & 
CD40L or CpG, CD40L & anti-
Ig. B. Histogram plot of CFSE 
fluorescence of CD19+ cells 
after culture with the various 
stimulants. 
 
 CD19 
CSFE 
% 
of 
max 
 Unstimulated 
   A 
 R848 & IL-2 
CSFE 
   B 
R848 & IL-2 
  CpG 
 CpG & CD40L 
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 CpG, CD40L  
& anti-Ig 
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Next, each TLR agonist was tested to establish optimal IL-10 production. Following 
culture and a short stimulation with PMA, ionomycin & monensin, expression of 
CD19
+
IL-10
+
 cells was assessed by flow cytometry. The gating strategy to determine 
CD19
+
IL-10
+
 cells employed a blocking antibody matched to the test antibody as the 
matched isotype control lacked specificity and could not be used for accurate 
discrimination. In agreement with CD19
+
 cell proliferation; the combination of CpG, 
CD40L and anti-Ig gave the highest percentage of CD19
+
IL-10
+
 cells and was used 
thereon in (Figure 6.3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD19 
IL-10 
 Unstimulated R848 & IL-2 
CpG CpG & CD40L CpG, 
CD40L 
&anti-
Ig 
Control 
Figure 6.3   Stimulating CD19+ cells with CpG, CD40L and anti-Ig promoted the 
highest frequency of IL-10-producing cells  
CD19+ cells were cultured for five days either alone; with R848 & IL-2; CpG; CpG & 
CD40L or CpG, CD40L & anti-Ig and with PMA, ionomycin & monensin for the last five 
hour. Post–culture, cells were assessed by flow cytometry for cell surface CD19 and 
intracellular expression of IL-10.  
Representative flow cytometry zebra plots show the percentage of IL-10 producing 
CD19+ cells for each condition. Culture with CpG, CD40L & anti-Ig promoted the 
greatest, albeit low, frequency of CD19+ IL-10+ cells. 
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Identifying IL-10-producing CD19+ cells in peripheral blood from patient 
groups 
  
The conditions optimised in healthy controls were applied to patient groups. Those 
with stable graft function had a higher percentage and number of CD19
+
IL-10
+
 cells 
(1.4% and 0.32 cells/μl; Figure 6.4A and B) than the SD group (0.37%; p = 0.06 and 
0.07 cells/μl; p = 0.06) and significantly more than the RD group (0.20%; p = 0.004 and 
0.04 cells/μl; p = 0.009). Investigating if a relationship existed between the percentage 
of CD19
+
IL-10
+ 
cells and level of graft function based on eGFR measurements taken 
over time found there was significant correlation between elevated frequency and 
superior graft function (R
2 
= 0.36, p = 0.02; Figure 6.4C). 
 
         
 
 
 
 
 
 
 
 
  
 
   
 
 
                      
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
Figure 6.4 Patients with stable graft function had significantly higher frequency 
and number of CD19+IL-10+ cells 
CD19+ cells were cultured for five days in the presence of CpG, CD40L & anti-Ig and 
assessed for cell surface CD19 and intracellular expression of IL-10 by flow cytometry. 
The dot plots show the percentage (A) and number (B) of CD19+IL-10+ cells for each 
group. The stable (ST; n = 5) group have a higher number and percentage of CD19+IL-
10+ cells compared to those with slowly deteriorating (SD; n = 5) graft function, and this 
is significantly so when compared to the rapidly deteriorating (RD; n = 6) group. P 
values shown are derived from Mann-Whitney tests.  
(C) Linear regression analysis demonstrated significant correlation between CD19+IL-
10+ cell frequency (all patients) and the rate of allograft deterioration extracted from 
measuring eGFR over time. 
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Phenotypic characteristics of CD19+IL-10+ cells 
  
IL-10-producing CD19
+
 cells were examined for expression of cell surface markers 
associated with naïve, memory and transitional B cells. 
 
CD19+IL-10+ transitional B cells  
 
Transitional B cells are defined as expressing high levels of CD24 and CD38 (Carsetti et 
al., 2004). Previous studies in autoimmunity and during infection show CD19
+
IL-10
+
 
cells are enriched within the CD24
high
CD38
high
 subset (Blair et al., 2010, Flores-Borja et 
al., 2013, Bouaziz et al., 2010, Das et al., 2012). This was also demonstrated in renal 
transplant recipients. Post-culture analysis by flow cytometry showed CD19
+
IL-10
+
 cells 
expressed CD24
 
and CD38 at high levels compared to CD19
+
IL-10
-
 cells (Figure 6.5). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 CD19+IL-10+ cells were 
enriched in the transitional B-cell 
compartment 
Representative flow cytometric zebra 
plots for a patient with stable graft 
function showing the gating strategy 
used to measure expression of CD19+ 
cells intracellularly stained for IL-10.  
The expression of CD24high & CD38high is 
shown as a percentage of total CD19+ 
cells; CD19+IL-10- cells and CD19+IL-10+ 
cells. CD24high & CD38high cells were 
enriched in IL-10-producing cells. 
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In addition, regardless of graft function, CD19
+
IL-10
+
 cells were enriched within the 
CD24
high
 CD38
high
 subset (18.57% vs. 8.42% and 9.64% for ST, SD and RD groups 
respectively; Figure 6.6).  While there was no significant differences found between 
groups (p = 0.8); both the ST group (18.57% vs. 5.73%; p = 0.03) and the RD group 
(9.64% vs. 2.62%; p = 0.009) had a significantly greater representation of this subset by 
IL-10 positive compared to IL-10 negative cells  
 
To determine if a lower percentage of IL-10 producing CD24
high
 CD38
high
 cells correlated 
with rate of deterioration, eGFR was measured over time and linear regression analysis 
performed. No significant correlation was found (R
2 
= 0.04, p = 0.46; data not shown), 
this was likely due to variance in the percentage of IL-10-producing CD24
high
 CD38
high
 
cells expression between patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6    CD19+IL-10+ cells were enriched within the CD24high CD38high 
subset in all patient groups 
CD19+ cells were cultured with CpG, CD40L & anti-Ig for five days with PMA, 
ionomycin and monensin added for the last five hours. Cells were surface stained for 
CD24 and CD38 prior to intracellular staining for IL-10 and analysed by flow 
cytometry.  
The dot-plot shows the frequency (%) of CD19+IL-10+CD24highCD38high cells post-
culture in patients with stable (ST; n = 5), slowly deteriorating (SD; n = 5) and rapidly 
deteriorating (RD; n = 7) graft function. No significant difference was found between 
groups (p=0.8).  CD24highCD38high cells were expanded in IL-10-producing B cells in 
all patient groups, and to a significant level in the ST and RD groups. Comparison 
between CD24high CD38high cell expression and 1) CD19+IL-10+ or CD19+IL-10- 
populations was performed using Mann-Whitney test, and 2) CD19+IL-
10+CD24highCD38high cells between patient groups by Kruskal-Wallis test. 
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CD19+IL-10+ naïve and memory B cells 
 
Expression of naïve and memory cell phenotypes within IL-10
+
 and IL-10
-
 B-cell 
populations was investigated by flow cytometry using CD27 and IgD as extracellular 
markers to distinguish naïve, CD19
+
CD27
-
IgD
+
, from memory, CD19
+
CD27
+
IgD
-
, cells 
(Sanz et al., 2008). The gating strategy employed is shown in Figure 6.7. The 
composition of these phenotypes was found to be differentially expressed depending 
on level of allograft function. 
 
 
  
 
 
 
 
 
 
      
 
 
 
  
  
 
 
 
 
 
 
 
Naïve and memory B cell expression on CD19+IL-10+ cells  
 
The expression of IL-10
+
 and IL-10
-
 naïve B cells between patient groups was compared 
and did not show any statistically significant difference (p = 0.3). In stable patients, 
naïve B cells were present in equal proportions in both IL-10
+
 and IL-10
-
 B-cell 
populations (51.05 ± 25.41%; vs. 48.92 ± 20.42%; p = 0.89). The IL-10
+
 B-cell population 
Figure 6.7     The frequency of naïve and memory B cells differed depending on 
the level of graft function 
Naïve (CD19+CD27-IgD+) and memory (CD19+CD27+IgD-) B cells were evaluated by 
analysing cell surface expression of CD27 and IgD.  
Representative flow cytometric zebra plots show the percentages of naïve and memory 
B cells for a patient with stable graft function and a patient with rapidly deteriorating 
graft function. The frequency of memory B cells was lower, while naïve B cells were at a 
greater frequency in this patient with stable function compared to a patient with 
deteriorating function. This pattern of expression was seen within the groups and are 
shown in Figure 6.8 
Memory  Non-switched 
memory 
Naïve  
 CD27 
IgD 
 2.8 
    2.1 
   62.9 
 28.9   2.3 
  9.6 
Gated on CD19
+ 
cells A stable patient 
A rapidly deteriorating 
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representation was lower in the RD groups, albeit not to the level of statistical 
significance (17.91 ± 21.41% vs. 40.60 ± 25.11%; p = 0.09, Figure 6.8A).  
 
The frequency of IL-10
+
 memory cells was reduced in the ST group (6.09 ± 4.76%; 15.54 
± 9.16% and 26.44 ± 21.60% for ST, SD and RD groups respectively, Figure 6.8B), 
however expression was variable within groups and statistically significance differences 
were not found (p = 0.2). Comparing for differences in memory B-cell populations that 
produced IL-10 within groups, found there was little difference in the proportions of IL-
10
+ 
and IL-10
-
 cells in all three groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 6.8 The frequency of CD19+IL-10+ naïve and memory B cells were not 
significantly altered with level of allograft function 
CD19+ cells were cultured with CpG, CD40L and anti-Ig for five days with PMA, 
ionomycin and monensin added for the last five hours. Cells were surface stained for 
CD27 & IgD to distinguish naïve (CD27-IgD+) from memory (CD27+IgD-) prior to 
intracellular staining for IL-10 and analysed by flow cytometry.  
The dot-plots show the frequency of naïve (A) and memory (B) B cells separated by 
their capacity to produce IL-10 in patients with stable (ST; n = 5), slowly deteriorating 
(SD; n = 5) and rapidly deteriorating (RD; n = 6) graft function. Comparing CD19+IL-10 
positive and negative naïve and memory B cell populations in each group by Kruskal-
Wallis test did not show any significant differences. Similarly, comparing CD19+IL-10 
positive and negative cells within each group by Mann-Whitney test did not show any 
significant differences. 
 
 
  Memory B cells 
   Naïve B cells 
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Expression of BAFF receptor on IL-10 producing cells 
 
Chapter 5 reported that stable patients had a higher percentage of CD19
+
BAFF-R
+
 cells. 
Here, the ST group also had a significantly higher percentage of B cells expressing 
BAFF-R than the RD group (92.53 ± 3.11%, 62.25 ± 30.78%; p = 0.09 and 58.08%; p = 
0.004, ST, SD and RD, respectively, Figure 6.9). The percentage of CD19
+
BAFF-R
+
 cells 
was also significantly reduced for IL-10 producing cells in the SD compared to the ST 
group (95.39 ± 4.5% vs. 66.55 ± 18.78%; for ST and SD groups respectively; p = 0.009).  
 
The level of BAFF-R positivity was evaluated in IL-10-producing transitional B cells. 
Both the ST and SD group demonstrated that BAFF-R was expressed on virtually all 
cells (98.71 ± 1.98% and 99.04 ± 1.93% for ST and SD groups respectively). In the RD 
group, expression was significantly less frequent than the ST group (79.15 ± 21.79%; p 
= 0.04). Moreover, there was a significant difference when comparing the frequency of 
total CD19
+
BAFF-R
+
 cells against the IL-10-producing transitional B-cell population in 
the SD group (p = 0.02).  
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 The level of BAFF-R positivity by CD19+IL-10+ cells was associated 
with stable graft function  
CD19+ cells cultured with CpG, CD40L and anti-Ig for five days were surface-stained 
for BAFF-R, CD24 & CD38 prior to intracellular IL-10 and analysed by flow cytometry.  
The dot-plot shows the percentage of CD19+ BAFF-R+ cells for total CD19+, CD19+IL-
10+ & CD19+ IL-10+ CD24high CD38high cells in each patient group. BAFF-R+ cells were 
expanded in the unselected B-cell population in patients with stable (ST; n = 5) graft 
function. p values (*) derived from Mann-Whitney test by comparing percentage of 
total CD19+, CD19+IL-10+ & CD19+ IL-10+ CD24high CD38high cells in the ST group against 
the slowly deteriorating (SD; n = 5) group and the rapidly deteriorating group (RD; n 
=6). CD19+ BAFF-R+ IL-10+ CD24high CD38high cells were elevated in the SD group when 
compared to total CD19+ cells (p=0.02 by Mann-Whitney test). 
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The frequency of IL-10-producing B cells and presence of HLA antibody 
 
A relationship between an increased frequency of IL-10-producing B cells and absence 
of HLA antibody was investigated. Patients from all study groups were examined for 
presence of HLA antibody (Figure 6.10A). Those without HLA antibodies (negative) did 
not have a significantly higher percentage of IL-10-producing B cells than those with 
DSA (0.61%, 0.87%; and 0.39%; p = 0.4, negative, NDSA and DSA respectively). When 
patients with DSA were examined further, all had rapidly deteriorating graft function 
(100%; p = 0.07) compared to those with NDSA (20%), and those without antibody 
(33%; Figure 6.10B). 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 6.10   Comparing the frequency of IL-10 producing B cells and presence of 
HLA antibodies 
Serum samples were analysed for HLA Class I & II antibodies by Luminex technology. 
Patients were divided into three groups; those with donor-specific HLA antibodies 
(DSA; n = 2) non-DSA (NDSA; n = 5) and no detected HLA antibodies (Neg; n = 10). 
A. The dot-plot shows percentage of CD19+IL-10+ cells and HLA antibody status for all 
study patients. There was no significant difference between groups when compared by 
Kruskal-Wallis test (p=0.4). 
B. The study groups were separated based on presence or absence of serum HLA 
antibodies. Those with DSA were all categorised as having rapidly deteriorating (RD) 
graft function (p=0.07 by Chi squared test) unlike those with slowly deteriorating (SD) 
or stable (ST) graft function.  
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Investigating the suppressive capacity of CD19+CD24highCD38high cells 
 
The relevance of CD19
+
CD24
high
CD38
high
 cells as important regulators during the 
immune response has emerged to represent regulatory B cells, which in SLE (Blair et 
al., 2010) and rheumatoid arthritis (Flores-Borja et al., 2013) lack suppressive capacity. 
Their functional role was investigated in patients grouped by allograft function. The 
demographics and clinical characteristics are shown in Table 6.2. 
 
  
Stable 
(ST) 
Slowly 
deteriorating 
(SD) 
Rapidly 
deteriorating 
(RD) 
Total number of patients, n (%) 5 (33.3) 5 (33.3) 5 (33.3) 
Recipient 
Gender (F,M) 
Age, mean (range) (years) 
Time post-transplant, mean (range) 
(years) 
 
2,3 
48 (46-52) 
7 (1-20) 
 
2,3 
47 (35-53) 
9 (2-24) 
 
1,4 
47 (33-56) 
14 (6-23) 
Type of allograft, n (%) 
Live donation 
DBD 
DCD 
 
2 (40) 
2 (40) 
1 (20) 
 
4 (80) 
1 (20) 
0 
 
2 (40) 
3 (60) 
0 
HLA mismatches, n ± sd 
A, mean ± sd 
B, mean ± sd 
DR, mean ± sd 
 
1 ± 0.71 
1 ± 0.71 
1 ± 0.71 
 
1.25 ± 0.5* 
1.25 ± 0.5* 
1.25 ± 0.96* 
 
1.2 ± 0.84 
1.2 ± 0.45 
0.8 ± 0.45 
HLA antibody - post-transplant, n (%) 
Negative 
NDSA 
DSA 
 
4 (80) 
0 
1 (20) 
 
3 (60) 
0 
2 (40) 
 
3 (60) 
2 (40) 
0 
Cause of ESRF, n (%) 
Diabetes 
IgA nephropathy 
FSGS 
GN 
Hypertension 
PKD 
Other/Unknown aetiology 
 
 
1 (20) 
1 (20) 
2 (40) 
0 
0 
1 (20) 
0 
 
1 (20) 
0 
0 
0 
0 
1 (20) 
3 (30) 
 
0 
1 (20) 
0 
1 (20) 
1 (20) 
0 
2 (40) 
 
Table 6.2 Demographics of patient groups separated by allograft function 
Abbreviations: DBD, donation after brainstem death; DCD, donation after circulatory 
death; DSA, donor-specific HLA antibody; NDSA, non-donor-specific HLA antibody; ESRF, 
end-stage renal failure; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; 
PKD, polycystic kidney disease; sd, standard deviation. *Donor type missing for one 
patient 
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Establishing methods to investigate suppression of pro-inflammatory T-cell 
cytokines by CD19+ cells in healthy controls   
 
The effect of CD19
+ 
cells on the production of the pro-inflammatory T-cell cytokines, 
TNF-α and IFN-γ was investigated initially using peripheral blood from healthy controls 
(n = 4) to establish methods. To maximise available cell number, the whole B-cell 
fraction was used as opposed to CD19, CD24 & CD38 subsets. 
 
Optimising T-cell activation from naïve to effector cells 
 
Anti-CD3 antibodies, immobilised on a tissue culture plate were used to induce 
activation of naïve T cells (CD4
+
CD25
-
) via the TCR. Optimal proliferation required a 
higher concentration of antibody (10 μg/ml) than the range (0.5-2 μg/ml) suggested in 
previous publications (Flores-Borja et al., 2013, Abraham et al., 2008, Paulsen et al., 
2011). In addition the co-stimulatory molecule, CD28, was included as this enhanced 
proliferation of effector T cells (Figure 6.11). 
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CSFE 
CD4 
0.44% 
3.46% 
20.69% 15.91% 
7.06% 
Unstimulated  
+ anti-CD3 (1 µg/ml)  + anti-CD3 (10 µg/ml)  
+ anti-CD3 (1 µg/ml), 
CD28 (1 µg/ml) 
+ anti-CD3 (10 µg/ml), 
CD28 (1 µg/ml) 
Figure 6.11   Combining anti-CD3 antibody and CD28 gave optimal T-cell 
activation  
Autologous naïve T cells (CD4+CD25-) labelled with CSFE were cultured with plate-
bound anti-CD3 and CD28 for 96 hours. Post-culture, cells were stained with CD4 and 
analysed by flow cytometry.  
Representative CSFE profiles of CD4+ T cell proliferation are shown with percentage 
of CD4+CSFE+ cells for unstimulated CD4+ T cells; with anti-CD3 (1 μg/ml); anti-CD3        
(10 μg/ml); anti-CD3 (1 μg/ml) & CD28 (1 μg/ml) or anti-CD3 (10 μg/ml) & CD28         
(1 μg/ml). The last gave optimal naïve T-cell activation and was used thereon in.   
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Suppression of CD4+ T-cell proliferation during co-culture with CD19+ cells  
 
Purified CD19
+
 cells were co-cultured with autologous naïve T cells activated with anti-
CD3 and CD28 to investigate any inhibitory effects. The frequency of effector T cells 
post-culture with CD19
+
 cells together with CpG, CD40L and anti-Ig was reduced when 
compared to naive T cells cultured alone (Figure 6.12). Although the reduction was 
small, these data demonstrated a level of CD4
+
 T-cell reduction in the presence of 
CD19
+
 cells and justified further investigation to determine if CD24
high 
CD38
high
 B cells 
were responsible. 
 
     
   
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CSFE 
CD4 20.69% 15.05% 
Figure 6.12   Proliferation of CD4+ T cells was marginally reduced in the 
presence of CD19+ cells in healthy controls 
Autologous naïve T cells (CD4+CD25-) from healthy controls (n = 4) were activated 
with anti-CD3 and CD28 for and cultured in the presence or absence of CD19+ cells for 
96 hours. Post-culture CD4+CSFE+ cells were assessed by flow cytometry. 
Representative CSFE profiles of effector T-cell proliferation ± CD19+ cells are shown 
with percentage of proliferating T cells. Co-culture with CD19+ cells demonstrated a 
small reduction in the frequency of CD4+ T cells.  
Unstimulated  
CD4+ T cells  Activated T cells + CD19+ cells 
20.68% 0.44% 15.5 % 
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Rational for including polyclonal B-cell agonists in T: B co-culture assay 
 
As described, the frequency of IL-10-producing CD19 cells was maximised in the 
presence of CpG, CD40L and anti-Ig. To promote expansion of these cells, CpG, CD40L 
& anti-Ig were included within the T: B cell co-culture environment. Investigations 
found in their absence, CD4
+
 T cell frequency went up (Figure 6.13). In addition, the 
ratio of CD4
+
: CD19
+
 cells were more effective at 1:1 (1 x 10
6
/ml) compared to 1:2 
(13.95% & 4.93%, 1:1 & 1:2 respectively). These were not significant findings (p = 0.8), 
however the B-cell agonists were included in all co-culture conditions at a 1:1 ratio 
with naïve CD4
+
 T cells. 
 
 
       
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 Reduced frequency of 
CD4+ T cells with inclusion of B-cell 
agonists in co-culture assays 
Autologous naïve T cells (CD4+CD25-) from 
healthy controls (n = 4) were activated by 
anti-CD3 and CD28 in the presence of 
CD19+ cells +/-  CpG, CD40L and anti-Ig for 
96 hours.  
The bar-chart shows post-culture staining 
with CD4 antibody and analysis by flow 
cytometry. The percentage reduction 
subtracts frequency of CD4+ T cells cultured 
alone from other conditions which included 
CD19+ cells. Co-culture of CD4+ T cells with 
equal number of CD19+ cells and inclusion 
of CpG, CD40L and anti-Ig was most 
effective. However there was no significant 
difference found (p = 0.8 by Kruskal-Wallis 
test). 
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Suppression of TNF-α-secreting CD4+ T cells in the presence of CD19+ cells  
 
Next, suppression of TNF-α and IFN-γ by CD19
+
 cells was investigated (Figure 6.14). The 
frequency of CD4
+
TNF-α
+
 cells was not significantly reduced (41.09 ± 12.28% to 29.46 ± 
10.92%; p = 0.1). CD4
+
IFN-γ
+
 cells were unaffected (34.97 ± 2.96% increased to 37.16 ± 
9.35%). 
  
  
                                          
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
In summary, these data demonstrated the principle of the impact of CD19
+
 cells on 
naïve CD4
+
 cells activation, and the detection of pro-inflammatory Th1 cytokines by 
flow cytometry; these methods were then applied to patient groups.  
 
 
 
 
A B 
Figure 6.14  Reduced expression of TNF-α but not IFN-γ by CD4+ T cells 
following culture with CD19+ cells from healthy controls 
Autologous naïve T cells (CD4+CD25-) from healthy controls (n = 4) were activated by 
anti-CD3 and CD28 and co-cultured ± CD19+ cells for 96 hours. Post culture cells were 
surface stained for CD4 and intracellularly for TNF-α and IFN-γ for analysis by flow-
cytometry. 
The dot-plots show the percentage of CD4+TNF-α+ cells (A) and CD4+IFN-γ+ cells (B) 
post-culture. CD4+TNF-α+ cells were marginally reduced in the presence of CD19+ cells 
compared to CD4+ T cells cultured alone (p = 0.1 by Mann-Whitney test). There was no 
reduction in the frequency of CD4+IFN-γ+ cells post-culture with CD19+ cells. 
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Evaluating suppression of pro-inflammatory T-cell cytokines by subsets 
defined by CD19, CD24 and CD38 phenotypes in patient groups 
 
To determine if functional regulatory properties resided in CD19
+
CD24
high
CD38
high 
cells, 
these populations were isolated by flow cytometry using fluorescently activated cell-
sorting (FACS) based on cell surface marker expression of CD19, CD24 and CD38.  
 
Phenotypic analysis of peripheral blood in study groups 
 
Total lymphocyte and CD19+ cell populations 
 
Total PBMC were isolated from peripheral whole blood and a total lymphocyte count 
calculated. No significant difference existed between groups (770 ± 276 cells/μl, 647 ± 
223 cells/μl and 965 ± 263 cells/μl; p = 0.22 for ST, SD and RD groups, respectively, 
Figure 6.15A). Likewise, the percentage (4.82 ± 3.53%, 2.36 ± 1.77% and 5.43 ± 3.99%; 
p = 0.11 for ST, SD and RD groups respectively, Figure 6.15B) and number of CD19
+
 cells 
was not significantly different between groups (38 ± 35 cells/μl, 8 ± 17 cells/μl and 40 ± 
34 cells/μl; p = 0.24 for ST, SD and RD groups respectively, Figure 6.15C). Therefore any 
differences in the suppressive capacities of B cells were not attributed to the initial 
lymphocyte or CD19
+
 cell constitution. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15  PBMC and CD19+ cell numbers were comparable between groups 
Dot-plots show mean PBMC count (A) for each patient group based on lymphocyte 
isolation by density centrifugation of fresh peripheral whole blood (40 ml) and the 
frequency (B) and number (C) of positively selected CD19+ cells. ST, stable (n = 5); SD, 
slowly deteriorating (n = 5); RD, rapidly deteriorating (n = 5) graft function. p values 
all > 0.05 by Kruskal-Wallis test. 
 
Ga
     B   C   A 
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Characterisation of transitional, memory & mature naïve B cells in healthy 
controls 
 
PBMC were separated into three populations based on expression of CD19, CD24 and 
CD38 by FACS (Figure 6.16). This was first optimised in healthy controls and analysis 
revealed three distinct subsets consistent with that shown by others (Carsetti et al., 
2004, Blair et al., 2010, Flores-Borja et al., 2013).  These populations have been 
defined as: transitional, CD19
+
 CD24
high
CD38
high
; memory, CD19
+
 CD24
high
CD38
-
; and 
mature naïve cells; CD19
+
 CD24
+
CD38
+
. 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
                                                                                               
           
                                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48.
5% 
 
DC
14.2% 
48.5% 
 
 Figure 6.16 Characterisation by FACS of transitional, memory & mature naïve 
B cells in healthy controls 
CD19+CD24highCD38high, CD19+CD24highCD38- & CD19+CD24+CD38+ cells were isolated 
from PBMC by FACS using a gating strategy to identify B cell subsets (A).  
Representative zebra plots showing the isotype control (B) and test sample (C) and 
post-cell sort CD19, CD24 & CD38 purity (D). CD24 & CD38 populations were gated 
from total CD19+cells and the percentage of subset of each subset is shown. 
 
 Memory 
 CD38 
  CD24 
 Mature 
naive 
     CD38 
  CD24 
   Gated on CD19
+
 cells   B 
   D 
  C   A 
48.5% 
 14.2%   24.9% 
    Transitional 
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Identifying transitional, memory & mature naïve B cells in study groups 
 
FACS analysis of CD19, CD24 & CD38 subsets in healthy controls identified three 
distinct populations (Figure 6.16C). However, in transplanted patients, these 
populations were not always evident; in particular, the mature naïve subset was often 
unclear (Figure 6.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Slowly deteriorating 
 
  Stable  Rapidly deteriorating 
 CD24 
CD38 
 
 4.7% 
24.2%   22.4% 
  2.6% 
  
11.4% 
    1.1% 
5.7% 
Figure 6.17     Variation in the constitution of transitional, memory & mature 
naïve B cells between study groups  
Representative zebra plots of CD19+, CD24 & CD38 populations following FACS for a 
patient from each study group.  
CD19+CD24highCD38high, CD19+CD24highCD38- & CD19+CD24+CD38+ populations varied 
depending on graft function. The frequency (%) of each subset is shown. Overall the 
percentage of CD19+CD24highCD38high cells was lower in patients with deteriorating 
graft function (slow and rapid). 
 
 
  11.4%  25.3% 
 53.3% 
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Transitional B-cell populations 
 
The frequency of transitional B cells was significantly lower in patients with 
deteriorating graft function (4.2 ± 0.64%; 2.54 ± 0.7%; p = 0.02 and 2.13 ± 0.45%; p = 
0.008, for ST, SD and RD groups respectively, Figure 6.18A). This reduction appears a 
feature of graft dysfunction as both SD and RD groups have significantly lower 
expression. However even the ST group had a numerical deficit compared to healthy 
controls (13.95 ± 0.25%). Although only reflective of two individuals, these data are 
consistent with others reporting expression of approximately 10% (Blair et al., 2010, 
Flores-Borja et al., 2013). 
 
The expression CD24
high
 CD38
high
 cells was examined in relation to level of graft 
function. There was significant correlation between elevated frequency and superior 
graft function by linear regression analysis of eGFR over time (R
2 
= 0.67, p = 0.0002; 
Figure 6.18B). 
 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  B 
Figure 6.18          Patients with stable function had significantly higher 
frequency of CD19+CD24highCD38high cells than those with deteriorating function 
PBMC stained with CD19, CD24 and CD38 were analysed by FACS.   
A. Dot-plot shows mean percentage of CD19+CD24highCD38high cells for each group. 
The stable (ST; n = 5) group had significantly higher frequency compared to both 
slowly deteriorating (SD; n = 5) and rapidly deteriorating (RD; n = 5) patients (p 
values by Mann-Whitney test). B. Linear regression analysis demonstrated a 
significant correlation between CD19+CD24highCD38high cell frequency (all patients) 
and the rate of allograft deterioration extracted from measuring eGFR over time. 
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Mature naïve and memory B cell populations 
 
Memory and mature naïve B cell frequencies were not significantly different in groups 
with different allograft function. The memory B-cell population was elevated in 
patients with rapidly deteriorating function (28.05 ± 7.72%; 27.38 ± 11.37% and 48.63 
± 8.2%; p = 0.07 for ST, SD and RD groups respectively, Figure 6.19A). Accordingly, 
naïve B cells were reduced (30.66 ± 20.24%; 18.71 ± 8.95% and 8.69 ± 2.3%; p=0.08 for 
ST, SD and RD groups respectively, Figure 6.19B). 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
CD19+CD24-CD38high cell population in deteriorating function groups 
 
A number of patients had a fourth distinct population of B cells, with no CD24
 
but 
highly expressed CD38 (seen in the SD patient shown in Figure 6.17). Interestingly 80% 
of the RD group and 60% of the SD group presented this phenotype compared to only 
20% of the ST group. Although more of the RD group had this population, as a 
percentage of total cells, when it was present, it was found at higher frequency in SD 
patients (10.49 ± 6.29% vs. 3.22 ± 2.3%, SD vs. RD; p = 0.105). This population was not 
included in the subsequent functional analysis as it was identified too late in the study, 
but it may be of interest in further investigations.  
B A 
Figure 6.19   Memory and naive B cells were not significantly altered as a factor 
of allograft function 
PBMC were stained for CD19, CD24 and CD38 were analysed by FACS. Dot-plots 
show percentage of memory B cells; CD19+CD24highCD38- (A) and naïve B cells; 
CD19+CD24+CD38+cells (B). The frequency of naïve (p = 0.08) and memory (p = 0.07) 
did not significantly alter when comparing the stable (ST; n = 5), slowly deteriorating 
(SD; n = 5) and the rapidly deteriorating (RD; n = 5) function groups by Kruskal-
Wallis test. 
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Investigating suppression of activated T cells by CD19+CD24highCD38high 
cells 
 
To investigate potential suppressive capacity of CD19
+
CD24
high
CD38
high
 cells, FACS-
separated subsets expressing CD19, CD24 & CD38 were co-cultured with naïve 
autologous T cells activated with anti-CD3 & CD28 using methods optimised in healthy 
controls as previously described. Activated CD4
+ 
T-cell frequency was assessed in 
conjunction with the activation marker, CD69. CD69 is one of the earliest cell surface 
antigens expressed by T cells following activation and is detectable within an hour of 
ligation of the TCR/CD3 complex. (Ziegler et al., 1994). The extent of T-cell suppression 
by each B-cell subset was investigated for each group by identifying the difference in 
the frequency of CD4
+
CD69
+ 
T cells cultured in the absence and presence of B-cell 
subsets (Figure 6.20). Overall there was a significant difference between groups (p = 
0.01). Examining this further, CD4
+
CD69
+
 T cells were reduced to the greatest extent in 
the ST group when co-cultured with CD19
+
CD24
high
CD38
high 
cells (10.00 ± 4.69%, 1.07 ± 
11.13%; p = 0.3 and 1.99 ± 5.27%; p = 0.09 for ST, SD and RD groups respectively). 
However due to the small sample size, the number of variables and wide variance in 
the frequency CD4
+
CD69
+
 T cells between patients, no statistically significant 
differences are found. 
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Figure 6.20    Reduced frequency of activated T cells in the presence of 
CD19+CD24highCD38high cells from patients with stable graft function 
FACS-separated subsets (defined by various CD19, CD24 and CD38 phenotypes) were 
cultured 1:1 with autologous naïve T cells activated with anti-CD3 antibody & CD28 
for 96 hours. Post-culture cells were stained with CD4 & CD69 and analysed by flow 
cytometry.  
The bar-graph shows the mean percentage of CD4+CD69+ T cells (error bars represent 
standard deviation) for each patient group; stable (ST; n = 5); slowly deteriorating 
(SD; n = 5) and rapidly deteriorating (RD; n = 5) graft function following culture with 
the various B-cell subsets. Comparing culture of CD4+ cells alone against culture in the 
presence of the B-cell subsets showed a significant difference by Kruskal-Wallis test 
(p = 0.01). In the ST group, there was the greatest reduction in the frequency of 
CD4+CD69+ T cells during co-culture with CD19+CD24highCD38high cells, however 
examining this further by Mann-Whitney test did not show a significant differences 
when compared to either the SD and RD groups.  
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Investigating suppression of pro-inflammatory cytokines, IFN-γ and TNF-α 
by CD19+CD24highCD38high cells 
 
Suppression of IFN-γ-secreting CD4+ T cells was pronounced in patients with 
stable graft function but not restricted to CD19+CD24highCD38high cells 
 
The isolated subsets defined by pattern of expression of CD19, CD24 & CD38 were next 
investigated to determine if a particular population was responsible for increased 
capacity to supress the production of the Th1 pro-inflammatory cytokine, IFN-γ (Figure 
6.21A). By examining the level of reduction of CD4
+
IFN-γ
+
 T cells when CD4
+
 T cells 
were cultured alone or with B-cell subsets, there was a significant difference between 
groups (p = 0.03). The ST group demonstrated the greatest reduction with all subsets 
(CD24
high
CD38
high
: 12.32 ± 2.5%, CD24
high
CD38
-
: 11.76 ± 4.13% and CD24
+
CD38
+
: 10.86 
± 4.43%). Further examination did not reveal any statistically significant differences 
between groups. As with CD4
+
CD69
+
 T-cell reduction, this study lacked the statistical 
power to find statistically significant difference at this level. However, since the largest 
median difference between groups existed when comparing the ST group against the 
RD group following culture with either CD24
high
CD38
high 
(p = 0.09) or CD24
high
CD38
- 
(p = 
0.06) B cells; an increase of statistical power in this analysis through a greater sample 
size may have demonstrated enhanced suppressive capability of IFN- γ and stable graft 
function. 
 
Suppression of TNF-α-secreting CD4+ T cells by CD19+CD24highCD38high cells was 
greatest in patients with stable allograft function 
 
Next the capacity of CD19
+
 cells of various subsets defined by their expression of CD24 
and CD38 cells to suppress TNF-α secretion by CD4
+ 
T cells was investigated. Again for 
each group the frequency of CD4
+
TNF-α
+
 T cells following co-culture with the B-cell 
subsets was compared (Figure 6.21B). As the bar graph shows, there was considerable 
variation between patients in the reduction of CD4
+
TNF-α
+
 T cells and no statistically 
significant difference was found (p = 0.13). However, in contrast to the suppression of  
IFN-γ-secreting CD4
+ 
T cells, the ST group demonstrated maximal suppressive capacity 
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in the presence of the CD24
high
CD38
high
 subset (CD24
high
CD38
high
: 10.24 ± 2.71%, 
CD24
high
CD38
-
: 7.42 ± 4.87% and CD24
+
CD38
+
: 7.2 ± 4.23%). Again, this data may be 
enriched by the inclusion of additional patients to the study to increase the statistical 
power. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Figure 6.21    Suppression of IFN-γ and TNF-α-producing CD4+ T cells by subsets 
of CD19+ CD24 and CD38 expressing cells 
CD19, CD24 & CD38 subsets were separated by FACS and cultured 1:1 with autologous 
naïve T cells activated with anti-CD3 antibody & CD28 for 96 hours. Post-culture cells 
were stimulated with PMA, ionomycin & monensin for five hours and analysed by 
flow cytometry for expression of CD4 and intracellular IFN-γ and TNF-α. 
The bar-graphs show the mean level of CD4+IFN-γ+ (A) and CD4+ TNF-α+ (B) cell 
reduction (error bars represent standard deviation) during co-culture with CD19, 
CD24 & CD38 subsets compared to CD4+ T cells cultured alone.  
There was a significant difference in the level of CD4+IFN-γ+ reduction between 
groups (p = 0.03) but not CD4+ TNF-α+ (p = 0.13) by Kruskal-Wallis test. Further 
examination of CD4+IFN-γ+ reduction by Mann-Whitney test could not find any 
statistically significant differences between groups due to the lack of statistical power; 
potentially attributable to the small sample size and number of variables. 
 
B 
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Suppression of activated CD4+ T cells and pro-inflammatory cytokines by 
CD19+CD24highCD38high cells was maximal in patients with stable graft function 
 
To summarise the suppressive capacity of CD19
+
CD24
high
CD38
high 
cells on T-cell 
activation and pro-inflammatory cytokine secretion by each group (Figure 6.22), 
patients with stable graft function demonstrated the highest reduction in the 
frequency of activated T cells and both TNF-α
 
and IFN-γ producing T cells. The 
difference between groups did not quite reach a level of statistical significance (p = 
0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.22     Greater reduction of activated T cells, TNF-α and IFN-γ producing 
T cells following CD4+: CD19+CD24highCD38high cell co-culture in stable patients   
Investigating the reduction of CD4+ T cells expressing CD69, IFN-γ and TNF-α in 
patients with stable (ST) compared to slowly deteriorating (SD) and rapidly 
deteriorating (RD) graft function following co-culture with CD19+CD24highCD38high 
cells. 
The bar-chart shows the mean percentage (error bars represent standard deviation) 
of CD4+ T-cell reduction post-culture. Reduction is based on the difference of CD4+ 
cells cultured alone compared with CD19+CD24highCD38high cells. The ST group 
demonstrated higher reduction of all CD4+ T cell subsets. There was no significant 
difference in the frequency of CD4+ T-cell subsets between groups (p=0.05 by 
Kruskal-Wallis test). 
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Profiling cytokine expression following CD4+: B cell subset co-culture 
 
Analysing serum and culture supernatant for IL-10 
 
Secretion of IL-10 is a primary mechanism of suppression by B cells. To assess if IL-10 
was elevated during CD4
+
 T cell-culture with CD19
+
CD24
high
CD38
high 
cells, supernatant 
was collected and analysed by ELISA (Figure 6.23). A uniform observation in all patient 
groups was that activated T cells produced high levels of IL-10. This was reduced in all 
the B-cell subset cultures but there was no significant difference between the different 
subsets or patient groups. Serum samples were also analysed and interestingly IL-10 
was only detected in patients with rapidly deteriorating function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.23    Levels of IL-10 in post-culture supernatant were not elevated in 
the presence of CD19+CD24highCD38high cells for any group 
Serum and post-culture supernatant were analysed for IL-10 by ELISA for patients 
with stable (ST), slowly deteriorating (SD) or rapidly deteriorating (RD) graft 
function. 
The bar-chart shows the mean level of IL-10 (error bars represent standard 
deviation) in serum or following cell culture for CD4+ T cells alone or in the presence 
of subsets isolated from CD19+ cells with different patterns of CD24 and CD38 
expression. Activated CD4+ T cells cultured alone produced the highest levels and no 
significant difference existed between patient groups by Kruskal-Wallis test (p = 0.6). 
Serum IL-10 was only detected in the RD group. 
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Analysing culture supernatant by cytokine array 
 
Analysis of IL-10 in serum or post-culture supernatant did not reveal any clear 
distinction between the cell subsets. Therefore, a wider approach was taken and 
supernatant was assessed against a panel of cytokines and chemokines associated with 
T-cell activation. A marked difference was observed in the overall presence of cytokines 
in supernatant from patients in the ST group (n = 3) compared to the RD group (n = 3, 
Figure 6.24). The SD group were not included in this analysis due to financial 
constraints on the project. 
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Figure 6.24  Analysis of culture supernatant by cytokine array assay showed 
heightened reactivity in those with rapidly deteriorating graft function 
Post-culture supernatant from CD4+ T cells cultured alone or with CD19, CD24, CD38 
subsets were analysed for the presence of cytokines and chemokines by cytokine array 
in patients with stable (n = 3) and rapidly deteriorating graft function (n = 3). 
Supernatant was applied to membranes containing anti-cytokine antibodies. After 
detection by secondary antibody, a chemiluminiscence signal of the membranes was 
captured and the intensity of each spot was estimated by densitometric analysis. 
Representative data are shown from a patient with stable and deteriorating graft 
function. The table shows the panel of cytokines included in array analysis and the 
coloured boxes show those significantly reduced (red, IL-2; yellow, TNF-α and blue; IL-
17).  
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Figure 6.25     Increased range and heightened production of cytokines and 
chemokines during CD4+ T cell: CD19, CD24, CD38 subset co-culture in patients 
with rapidly deteriorating graft function 
The bar graphs shows mean pixel density (arbitrary units; AU) for each cytokine 
ranging from high (pixel density = 4) to low (pixel density = 1) for stable and rapidly 
deteriorating patients as derived from the cytokine array assay. Cytokines not 
detected are listed in the tables. 
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The assay is semi-quantitative and relative expression levels were determined by 
analysing pixel density of each spot (Figure 6.25). Cytokines detected in supernatant 
from the RD group demonstrated reactivity against the majority of the panel and there 
were no significant differences found when comparing cultures with B-cell subsets to 
CD4
+
 T cells alone.  
 
In contrast, the ST group demonstrated less reactivity to the panel. This included IL-10, 
supporting the previous findings using ELISA. However there was marked reduction of 
IL-2, TNF-α and IL-17, particularly by CD19
+
CD24
high
CD38
high
 cells when compared with 
the level of pixel density of CD4
+
 T cells cultured alone (p=0.003; Figure 6.26). It was 
not possible to apply any further statistical analysis due to the lack of statistical power 
governed by the small sample size and number of variables. Figure 6.26 clearly 
demonstrates that IL-2, TNF-α and IL-17 expression are reduced in the presence of 
CD19
+
CD24
high
CD38
high
 cells, to a greater extent than co-culture with 
CD19
+
CD24
high
CD38
- 
and CD24
+
CD38
+
 cells.  
 
  
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.26      IL-2, IL-17 and TNF-α were significantly reduced during CD4+ T 
cell: CD19+CD24highCD38high co-culture in patients with stable graft function 
The bar–chart shows the mean pixel density (error bars represent standard 
deviation) for each cytokine analysed by human cytokine array assay for stable 
patients (n = 3).  
Co-culture with CD19+CD24highCD38high cells caused the greatest reduction in IL-2, 
TNF-α and IL-17. Comparing CD4+ T cells alone with co-culture with CD19, CD24, 
CD38 cell subsets was statistically significant by Kruskal-Wallis test (p = 0.0003), 
however the small sample size lacked the statistical power to perform any further 
statistical analysis.  AU= arbitrary units. 
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6.4 Discussion 
 
Promoting the longevity of renal allograft survival will prevent patients returning to 
dialysis and potentially awaiting re-transplantation. The composition of the B-cell 
compartment may influence a favourable outcome post-transplantation through the 
suppressive function of IL-10-producing and transitional B cells. This study sought to 
establish if their prevalence increased in those with stable graft function, and if there 
was capacity in these cells to attenuate an inflammatory immune response by CD4
+ 
T 
cells. 
 
IL-10 secretion by B cells is a primary mechanism to suppress other immune cells. This 
study showed that by stimulating CD19
+
 cells via TLR-9 it was possible to detect IL-10-
producing B cells at low frequency, and the most effective expansion included CD40 
and anti-Ig. The mechanism for this would follow the two-step model proposed by 
Lampropoulou et al., that first TLR stimulation primes B cells towards IL-10 production 
and second, this is potentiated towards a regulatory phenotype upon BCR and CD40 
ligation (Lampropoulou et al., 2010). There are conflicting reports as to the 
requirement for CD40-CD40L interactions. In animal models of autoimmune disease, 
CD40 stimulation was critical for suppressive capacity, (Mauri et al., 2003) and mice 
with CD40-deficent B cells did not recover from experimental autoimmune 
encephalomyelitis (EAE; (Fillatreau et al., 2002)). In contrast, investigating human IL-
10-producing cells found only CpG and anti-Ig were necessary (Bouaziz et al., 2010). In 
this study, CD19
+
 cells were stimulated for five days rather than two days as shown by 
Bouaziz and colleagues. It is possible that cells respond via the innate pathway in the 
short-term and later by the CD40-dependent adaptive pathway.  
 
The frequency of IL-10-producing B cells was lower in renal transplant recipients than 
figures reported in the peripheral blood of healthy controls (~5%) (Bouaziz et al., 2010, 
Iwata et al., 2011, Blair et al., 2010, Das et al., 2012), and is what would be expected 
given the overall relative lymphopenic state of transplant recipients. When lymphocyte 
constitution was evaluated, this did not identify any differences between the three 
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groups of patients. It did however highlight the level of lymphopenia still present at a 
considerable period of time post-transplantation. With a median of seven years, and a 
number of patients over twenty years, the average lymphocyte count (~600 cells/μl) 
remains below the normal range (1000-4800 cells/μl). This is interesting since 
induction therapy with basiliximab is non-depletional with its target being the IL-2 
receptor on activated T cells. It is possible lymphopenia is a consequence of 
maintenance immunosuppression with MMF, which is known to affect lymphocyte 
constitution (Heidt et al., 2008). Similarly reconstitution of B cells does not return to 
the normal range and patients with stable graft function did not display any significant 
differences in percentage or number of cells. This agrees with data following a larger 
cohort of renal transplant recipients where B-cell counts were low regardless of 
allograft stability, even in patients experiencing either subclinical or acute rejection 
(van de Berg et al., 2012).  
 
For frequency of IL-10-producing B cells, it is difficult to draw a perfect comparison 
with other studies since the methods used to stimulate cells, culture time and details 
of analysis by flow cytometry differ. There may also be bias towards certain 
phenotypes as a consequence of the nature of the stimulation employed. For example 
in this study and that of Bouaziz and colleagues, anti-Ig stimulation of B cells was 
included, (Bouaziz et al., 2010) where in others it was not (Das et al., 2012, Iwata et al., 
2011). Also as previously mentioned, CD40 is not always included, so there is variation 
in the methods employed to promote and identify CD19
+
IL-10
+
 cells. 
 
Comparing the frequency of IL-10-producing B cells between groups presented clear 
associations with stable graft function which diminished with deteriorating graft 
function. A correlation between their presence and a positive impact on disease has 
also been reported in autoimmunity where patients with SLE (Blair et al., 2010) and 
multiple sclerosis (Duddy et al., 2007) exhibited reduced frequency. In the temporal 
setting of viral infection, IL-10-producing B cells were enriched during active flares of 
hepatitis B (Das et al., 2012). Furthermore in ‘tolerant’ renal transplant recipients, 
those with stable function in the absence of immunosuppression, there was increased 
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frequency of IL-10-producing B cells (Newell et al., 2010). In addition they reported IL-
10-producing B cells as enriched in the CD24
high
CD38
high 
cell
 
subset. We also found this 
association, as have others (Blair et al., 2010, Duddy et al., 2007). As to why IL-10-
producing cells reside within this phenotype is not clear; possibly this subset expresses 
receptors to efficiently stimulate IL-10 secretion. Interestingly in this study, expression 
of BAFF-R was significantly higher on IL-10
+
 B cells in stable patients, suggesting 
transitional cells may be at a higher state of activation.
 
 
Assignment of a distinct phenotype demonstrated IL-10-producing B cells were 
predominantly naïve in stable patients but in other patient groups were at a lower 
frequency. Naïve B cells constitute a major type in peripheral B cells and may be 
important in promoting allograft survival. Although ineffective APC for naïve T cells, 
they are not quiescent as shown in animal models: antigen presented by these cells 
can induce a tolerant state (Fuchs and Matzinger, 1992) or promote development of 
Tregs (Reichardt et al., 2007). In renal transplant recipients, an increased number of 
naïve cells has been associated with tolerance (Newell et al., 2010). Furthermore, 
following treatment for acute rejection with rituximab, a higher number of naïve B 
cells correlated with graft survival (Zarkhin et al., 2011). IL-10-producing memory B 
cells were also investigated and increased frequency was associated with patients with 
deteriorating function – in both the IL-10
+ 
and total B-cell population. This pattern was 
a reverse to the observed increased frequency of naïve B cells in the stable group. This 
shift from naïve to memory B-cell constitution marked declining graft function and 
could be applied as a negative prognostic marker post-transplantation. Indeed, 
increased circulating memory B cells have been found during ESRF, (Kim et al., 2012) 
and associated with the incidence of acute rejection (Zarkhin et al., 2011). However, 
interpretation may be difficult in immunosuppressed patients who suffer persistent 
infections. 
 
IL-10 secretion by B cells is a hallmark feature of their regulatory properties and is 
utilised to identify them in peripheral blood. This requires intracellular analysis, 
limiting functional investigations due to the fixation and permeabilisation process. To 
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circumnavigate this, CD19
+
CD24
high
CD38
high 
cells are reported to have regulatory 
capacity (Blair et al., 2010, Flores-Borja et al., 2013) and were selected in this study to 
investigate functional suppressive properties of B cells. A reduced frequency of 
CD19
+
CD24
high
CD38
high 
cells was a feature of graft dysfunction as patients with 
deteriorating graft function (slow or rapid) had significantly lower expression 
compared to stable patients. However even stable patients had a numerical deficit 
relative to healthy controls. Although only reflective of two individuals, this is 
consistent with others citing re-constitution at approximately 10% (Blair et al., 2010, 
Flores-Borja et al., 2013). A reduction in transitional B cells was also observed during 
ESRF (Kim, Chung et al. 2012), and post-renal transplantation correlated with 
significantly worse graft function (Cherukuri, Salama et al. 2012). The latter study also 
measured reconstitution of B-cell subsets following induction with either alemtuzumab 
or basiliximab and reported an association between higher expression of transitional 
and naïve B cells with stability of graft function following alemtuzumab. Similarly Heidt 
et al., report dominance of these B-cell subsets with alemtuzumab and not basiliximab 
induction (Heidt et al., 2012a). Together these studies suggest alemtuzumab rather 
than non-depletional induction therapy favours transitional and naïve B cell 
reconstitution and presumably due to the more profound lymphocyte depletion. In 
contrast, this study demonstrated correlation of these B-cell subsets and stable graft 
function following basiliximab induction. A possible explanation is the relatively short 
post-transplant follow-up time monitoring B-cell repopulation (Cherukuri et al., at 2 
years and Heidt et al., up to 12 months post-transplantation). In this study, the median 
time was seven years and, perhaps given time and favourable conditions, the B-cell 
compartment will reach a level of homeostasis independent of induction therapy. 
 
As a consequence of identifying CD19
+
CD24
high
CD38
high
 cells in the patient groups, an 
additional subset of cells expressing low levels of CD24 and high levels of CD38 were 
noted; predominantly in those with deteriorating (slow and rapid) graft function. 
These CD19
+
CD24
-
CD38
high
 cells could be plasmablasts or circulating plasma cells. The 
inclusion of additional B-cell markers such as CD27 would confirm this as most 
plasmablasts express high levels of both CD27 and CD38 (Wirths and Lanzavecchia, 
CHAPTER 6 
 
215 
2005). Plasma cells can then be distinguished from plasmablasts through expression of 
CD138 (Medina et al., 2002, Oracki et al., 2010). Further refinement for transitional B-
cell selection may include CD10 and IgD as both are associated with T1 and T2 
transitional B cells (Blair et al., 2010, Wirths and Lanzavecchia, 2005). Together these 
markers could provide information as to the possible origin of CD19
+
CD24
-
CD38
high
 
cells; this may warrant further analysis as to their function and apparent association 
with deteriorating allograft function. 
 
Evaluating the functional suppressive capacity of transitional B cells demonstrated the 
CD19
+
CD24
high
CD38
high
 cell subset as the most effective inhibitors of T-cell activation in 
patients with stable graft function and in agreement with observations in healthy 
individuals (Blair et al., 2010). However while pro-inflammatory cytokines, in 
particular,  IFN-γ, were reduced to the greatest extent in stable patients, this was not 
entirely  restricted to the CD19
+
CD24
high
CD38
high
 subset for either IFN-γ or TNF-α 
production by Th1 cells. These data suggested all of the B-cell subsets had the 
functional capacity to control excessive production of IFN-γ by inhibiting activation of 
naïve to effector Th1 cells, and this declined with the rate of deteriorating graft 
function (slow to rapid). The small sample size number in this study together with the 
number of variables within the analysis, restricted gaining more detailed statistical 
information, and the inclusion of more patients in this study may have enriched the 
data.  
 
While lacking any statistical significance, it was noted that the reduction in CD4
+
TNF-α
+
 
cells was at its greatest during co-culture with the CD19
+
CD24
high
CD38
high
 subset in 
patients with stable function. It is possible that within the transitional B-cell phenotype 
there are distinct populations: those which develop into mature B cells and those 
which assume a regulatory capacity. Perhaps the environment experienced by those 
with declining graft function favours the promotion of mature cells but without a 
definitive marker uniquely expressed by Bregs it is difficult to dissect this further. It 
would also be interesting to explore if effector T cells are converted into Tregs at an 
increased rate in stable patients, promoting a balance between effector responses and 
CHAPTER 6 
 
216 
immune tolerance. In patients with rheumatoid arthritis, CD19
+
CD24
high
CD38
high
 cells 
failed to convert naïve T cells to Tregs or suppress Th17 development as is seen in 
healthy controls (Flores-Borja et al., 2013). It is therefore reasonable to suppose this 
mechanism is disrupted following transplantation. 
 
The suppressive activity of CD19
+
CD24
high
CD38
high 
cells to inhibit Th1 cell differentiation 
in vitro is mediated by the release of IL-10 (Blair et al., 2010). In this study the 
concentration of IL-10 following co-culture with naïve T cells was not restricted to this 
subset. Activated T cells were the highest producers, presumably as a result of the 
intense method used to promote naïve to effector cells, driving expression of this 
classically Th2 type cytokine. Interestingly, IL-10 was only detected in serum from 
patients with rapidly deteriorating graft function which does not correlate with the low 
frequency of IL-10-producing cells seen in this group, but this may reflect the general 
immune environment in these patients. As shown by the cytokine array assay, these 
patients displayed high reactivity to almost the entire panel, suggesting dysregulation 
of the cytokine network implying an environment which may be hostile for Bregs to 
reside, affecting stability, rendering the capacity of cells to act in a suppressive manner 
or promoting differentiation to a mature B-cell phenotype rather than a regulatory 
one. In contrast, cytokine expression in stable patients demonstrated a much less 
reactive pattern and importantly indicated CD19
+
CD24
high
CD38
high 
cells as mediators in 
the reduction of TNF-α, IL-2 and IL-17. The reduction of TNF-α supports our previous 
finding that inhibition of TNF-α–producing CD4
+
 T cells occurs during co-culture with 
this B-cell subset. In a wider context, the identification of these three cytokines could 
provide information of the potential mechanisms involved in immune suppression. For 
example, IL-2 is a key cytokine necessary for proliferation and differentiation of T cells. 
The involvement of IL-17 has been associated with renal allograft rejection where 
increased CD4
+
IL-17
+
 T cells are described in renal biopsies from patients undergoing 
acute T-cell-mediated rejection (Loverre et al., 2011). Moreover, serum IL-17 
expression is increased in acutely rejecting liver and renal allografts (Crispim et al., 
2009, Fabrega et al., 2009).  
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An important mediator in transplant rejection is the development of HLA antibodies, 
especially those that are donor-specific. In this small cohort, patients with DSA had a 
lower frequency of IL-10-producing B cells. This analysis could not be applied to 
transitional B cells as only two of the fifteen patients studied had DSA. In a larger 
cohort of renal transplant patients, those with DSA had a significantly lower number of 
transitional B cells (Cherukuri et al., 2012). It is an attractive possibility that regulatory 
B cells suppress development of HLA antibodies directed against the allograft.  
 
Concluding remarks 
 
In summary, this study defined an association between increased frequency of IL-10-
producing cells and transitional B cells with stable graft function, where in both cases 
elevated cell frequency correlated with superior graft function. Furthermore 
transitional B cells from those with stable graft function had superior ability to 
suppress T-cell activation and secretion of the Th1 cell pro-inflammatory cytokine, TNF-
α. These data raise the possibility of analysing and monitoring B-cell phenotypes to 
predict renal allograft function, and potentially guide immunosuppressive therapy. In 
addition, heightened activity in the cytokine milieu was characteristic of declining 
allograft function, suggesting dysregulation of B cells in their ability to restrain 
inflammation by promoting differentiation of pro-inflammatory over 
immunoregulatory T cells. 
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7.1 Concluding remarks  
 
B cells are increasingly recognised as important mediators in renal transplantation, not 
only in facilitating AMR, but also in their role in potentially promoting allograft survival. 
This study aimed to gain a better understanding of the biology that governs the 
function of these cells by investigating their phenotypic and functional characteristics. 
 
Given the well-defined detrimental effect of HLA antibodies on allograft survival, over 
the past decade there has been considerable refinement in the methodology to aid 
their definition. This has benefited patients pre-transplantation through avoidance of 
DSA, or where DSA cannot be avoided, has allowed monitoring of DSA levels during 
desensitisation protocols, such that where possible transplantation can proceed if 
levels are sufficiently reduced. In the post-transplantation period, their identification 
has allowed for appropriate treatment. These scenarios demonstrate how AMR is 
effectively avoided and managed. However there are limitations to the approach of 
assessing B-cell responses by serological measurement of HLA antibody, and this study 
looked beyond B cells actively secreting antibodies against the allograft. 
 
Limiting analysis of B-cell activity to serum measurement for DSA could be misleading, 
as it excludes detection of memory B cells which can exist in the absence of detectable 
levels in serum, as demonstrated against hepatitis B antigen (West and Calandra, 1996, 
Bauer and Jilg, 2006). In Chapter 3, a method was described to detect antibody-
secreting cells directed against HLA molecules expressed on donor cells using an IgG-
detecting ELISPOT. This was an attractive approach allowing memory B cells to be 
detected prior to transplantation, and identify those patients potentially at risk of 
developing AAMR.  However as the results demonstrated, this method failed to 
effectively discriminate the B-cell response to donor cells from that of third-party cells. 
Although these data were reflective of a very small cohort, results were not 
encouraging to pursue further. Since this project progressed to investigate other 
aspects of the B-cell compartment, Heidt and colleagues published their method of 
detecting HLA-specific B cells by ELISPOT (Heidt et al., 2012b), demonstrating a 
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superior approach to the one we described by refining the characterisation of 
antibody-secreting cells to include details of HLA specificity. However, neither method 
would be especially adaptable to clinical laboratory practice. Accessibility of donor 
cells, coupled with a means of irradiation limit the feasibility of these ELISPOT 
applications, and the approach described in Chapter 4, where HLA-specific B cells were 
identified from peripheral blood, would be more amenable to routine clinical practice.  
 
Measuring the presence of circulating B cells with donor-antigen specificity is an 
attractive concept to assess the risk of rejection, and may influence decision-making in 
the type and amount of immunosuppression. Using the methods described in Chapter 
4, donor HLA-specific B cells (DS-B) cells could be effectively identified in sensitised 
recipients. The further demonstration that their frequency correlated with level of 
serum HLA antibody suggested a level of both sensitivity and specificity. Once methods 
to detect DS-B cells had been established and optimised in patients with serum HLA 
antibodies against HLA-A*0201, it was of interest to investigate DS-B cells from 
patients transplanted with an allograft expressing HLA-DQB1*0301 (DQ7) who had 
developed de novo donor-specific HLA antibodies (dnDSA).  In our centre, and also 
reported by DeVos and colleagues (DeVos et al., 2012), this was the most common DQ 
antibody in those with dnDSA. Again the frequency of DS-B cells correlated with the 
level of serum anti-HLA-DQ7. While there was no specific phenotypic signature 
associated with these cells, they were present at significantly higher frequency  than 
DS-B cells from patients with dnDSA against HLA-A2. Moreover the frequency of 
transitional B cells, attributed with regulatory capacity (Blair et al., 2010, Flores-Borja 
et al., 2013) were reduced in patients with dnDSA against HLA-DQ7, and the 
proportion of patients with rapidly deteriorating graft function was greater compared 
to those with dnDSA against HLA-A2. Together these data suggest transitional B cells 
may serve to protect allograft survival. However investigating if the DQ7 allele was 
perhaps more immunogenic than others by measuring clinical outcomes in a larger 
cohort with dnDSA did not suggest anti-DQ7 DSA were more pathogenic than dnDSA of 
other specificities. However it did suggest that HLA-DQ antibodies require equal 
consideration as is currently given to those with HLA-A, -B and –DR. As routine 
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monitoring of HLA antibodies becomes more frequent, the long-term impact of HLA-
DQ DSA will become clearer.  
 
Measuring a product of B-cell activation in serum could allow for monitoring of an 
evolving B-cell compartment, and BAFF is an attractive candidate for this given its 
essential role in B-cell maturation and survival (Mackay et al., 2003, Groom et al., 
2007). Excess serum BAFF has been associated with rejection
 
and the development of 
DSA (Thibault-Espitia et al., 2012, Banham et al., 2013a, Xu et al., 2009b), and Chapter 
5 described how levels of BAFF were investigated in transplanted patients, to identify if 
a relationship existed between differential expression and level of allograft function. 
The data demonstrated that elevated serum BAFF, low BAFF-R
 
and
 
DSA were all 
associated with deteriorating graft function. While serum BAFF was elevated in those 
with both slowly and rapidly deteriorating allografts, the reduced percentage of BAFF-
R expressing B cells was restricted to those with rapidly deteriorating graft function. 
This suggests that serum BAFF levels may be governed by allograft stability rather than 
the quality of graft function, and for BAFF-R expressing B cells it is the quality of graft 
function that is important.  
 
This study provides evidence for measuring BAFF as a biomarker of deteriorating graft 
function. In addition, the prevalence of DSA in patients with elevated serum BAFF is 
suggestive of deregulated homeostasis in the B-cell compartment. To support the 
clinical application of measuring serum BAFF levels, a number of investigations were 
performed. First, the ability to demonstrate serum BAFF levels increased prior to 
serum creatinine was not successful due to the limited number of stored samples 
available for the duration of a patient’s functioning allograft. However, the increased 
surveillance of DSA in patients over recent years will result in more detailed collections 
of stored serum and this question may be addressed. Second, as to whether levels of 
serum BAFF increased as a potential bystander effect of raised creatinine were 
investigated. By measuring levels in patients with diseases lacking B-cell involvement 
this was eliminated as a contributing factor. Finally, expression of CD19, BAFF and 
BAFF-R were examined at the intrarenal level. The identification of BAFF and BAFF-R 
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within lymphoid aggregates of renal biopsy tissue in patients with AAMR placed BAFF 
at the site of renal injury. Together, these data promote the concept of serum BAFF as 
a marker of B-cell mediated pathology, and future studies in larger cohorts of patients 
could add validity to these findings. 
 
The final chapter of this thesis investigated B cells in a protective, rather than 
pathological role. The recent identification of a small population of human B cells with 
suppressive capacity, (Blair et al., 2010, Flores-Borja et al., 2013, Iwata et al., 2011, 
Yanaba et al., 2008) prompted the question as to their prevalence in patients with 
stable compared to deteriorating graft function. Since a definitive phenotype of Bregs 
is yet to be demonstrated, methods for identification of IL-10-producing B cells 
followed those previously described (Bouaziz et al., 2010, Das et al., 2012). These cells 
associated with stable graft function and their predominance with transitional & naïve 
B cells and a paucity of memory B cells suggested a regulatory response serving to limit 
immunopathology to prevent rejection. However, the lack of IL-10 in both serum and 
supernatant from subsets of cells expressing CD19, CD24 and CD38 cultured with CD4
+
 
T cells were not supportive of a role of IL-10, and it is possible other mechanisms 
served by B-cell subsets contribute to immunological graft stability. This was 
highlighted by the identification that levels of IL-2 and IL-17 were reduced in CD4
+
 T 
cells co-cultured with CD19
+
CD24
high
CD38
high 
cells.  
 
The role of B cells beyond antibody production or antigen-presentation to promoting 
allograft survival has only re-emerged in recent years, and whether these positive 
attributes of only a very small number of cells can supersede negative pro-
inflammatory effects are largely unknown. Further investigations into whether Bregs 
can promote Tregs, which in turn prevail over Th1 or Th17 activation could provide 
more detailed information of the role of Bregs, and may suggest that targeting B cells 
for depletion may be detrimental for long-term allograft survival. 
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In summary, this study has demonstrated methods for: effective detection and 
phenotyping of HLA-specific B cells, measuring serum BAFF levels as an indication of 
graft function and identifying populations of B cells described to have regulatory 
capacity. Together these data increase our understanding of B cells in renal transplant 
recipients, and may have important implications in the clinical setting for predicting 
the risk of rejection thus dictating immunosuppressive therapy and ultimately 
promoting allograft function and survival. However it is recognised that graft outcomes 
are affected by non-immunological mechanisms. It is also recognised that the studies 
described in this thesis are representative of a small number of patients, at a single 
time-point post-transplantation. On several occasions during this study, the small 
sample size together with the number of variables to assess resulted in a lack of 
statistical power to perform analysis which may have otherwise been significant had 
the sample size been larger. Therefore future studies should include larger cohorts, to 
monitor phenotypic stability or changes in the B-cell compartment over a longer time-
frame, and to explore the functional versatility of B cells. This would benefit our 
knowledge of how the favourable attributes of B cells could be promoted, while 
targeting their harmful effects.  
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B1 Abstracts arising from the thesis 
 
 
World Transplant Congress, San Francisco, July 2014 
 
Oral presentation 
 
RENAL TRANSPLANT STATUS CORRELATES WITH EXPRESSION OF BAFF AND 
LOCALISES WITHIN INTRA-GRAFT LYMPHOID AGGREGATES DURING ACUTE 
ANTIBODY-MEDIATED REJECTION 
 
Louise Onions, MSc
1
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4
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5
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Purpose of Study: To measure serum and intra-renal expression of B cell-activating 
factor (BAFF) as a marker of B cell-mediated pathology. 
 
Methods: CD19+ cells from patients with deteriorating (n=33), stably-impaired (n=29) 
and stable (n=31) grafts were examined for CD19, CD27, IgD & BAFF-receptor (BAFF-R) 
expression by flow cytometry. Serum BAFF (sBAFF) levels were measured by ELISA and 
HLA antibodies using Luminex technology. Renal biopsy sections from cohorts with 
(n=16) and without (n=11) acute antibody-mediated rejection (AAMR) were studied by 
immunohistochemistry. 
 
Results: The stable group had significantly lower sBAFF and more CD19+BAFF-R+ cells. 
Those with above average sBAFF (sBAFFhigh) had a higher rate of allograft 
deterioration and greater prevalence of donor-specific HLA antibody compared to 
those with below average sBAFF levels. Moreover, naïve B cells (CD19+CD27-IgD+) 
were reduced and memory B cells (CD19+CD27+IgD-) increased in sBAFFhigh patients. 
Examination of biopsy sections demonstrated a higher frequency of CD19+ cells 
associated with small populations of sub-capsular interstitial lymphoid aggregates in 
patients with AAMR. BAFF-R expression showed a similar distribution to CD19, but 
BAFF more often had a diffuse distribution across the core. The presence or absence of 
AAMR made no difference to sBAFF levels. 
  
Conclusion: BAFF is a central component of the B cell compartment regulating cell 
maturation and survival. Here elevated expression of sBAFF and low frequency of 
BAFF-R on CD19 cells correlate with deteriorating graft function and intra-renal 
expression of CD19, BAFF-R and BAFF is increased during AAMR. These data provide 
2 
 
direct evidence of BAFF expression on infiltrating B cells during humoral rejection, and 
a rationale for measuring expression levels of BAFF as a biomarker of allograft 
function. 
 
 
European Society for Organ Transplantation, Vienna, September 2013 
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RENAL TRANSPLANT STATUS CORRELATES WITH EXPRESSION OF BAFF AND 
REGULATORY B CELLS 
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1
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Dentistry, Queen Mary, University of London, London; 
2
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Laboratory, The Royal London Hospital, Barts Health NHS Trust, London; 
3
 
Histocompatibility & Immunogenetics Laboratory, NHSBT Colindale Centre, London 
 
Background: Dysfunction in the B cell compartment may contribute to chronic 
allograft deterioration. B cell activating factor (BAFF), if in excess, has been associated 
with rejection and development of donor-specific antibody (DSA). Here we examined 
BAFF and regulatory B cells (Breg) to identify the relationships between differential 
expression and level of function of the allograft.  
 
Methods: CD19+ cells from patients with deteriorating (gp 1), stably-impaired (gp 2) 
and well-functioning (gp 3) grafts were examined for CD19 & BAFF-R or cultured for 
Breg analysis and stained for CD19, CD24, CD38, IL-10. FACS-sorted-cells were stained 
with CD19, CD24 & CD38. Serum BAFF (sBAFF) levels were measured by ELISA. HLA 
antibodies were assessed using Luminex technology. 
 
Results: Gp 1 had higher sBAFF and lower CD19+BAFF-R+ cells. DSA with elevated 
sBAFF or low BAFF-R were only detected in gp 1. IL-10 producing-B cells, enriched in 
the CD24highCD38high compartment were lower in gp1 and cell-sorting showed the 
distinct CD19+CD24highCD38high subset was minimal. 
 
Conclusion: The expression of BAFF and Bregs correlates with deteriorating graft 
function, suggesting important roles in regulating B cell homeostasis. We are currently 
examining functional regulatory properties. 
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Introduction: B cells have multiple immunological functions. In transplantation their 
defining role has been the secretion of HLA antibody against the allograft. However 
more detailed analysis of these cells suggests additional factors may contribute to 
dysfunction in the B cell compartment. Here we investigate expression of the B cell 
activating factor (BAFF), a member of the TNF family essential for B cell selection, 
differentiation and survival. Excessive BAFF production has been associated with the 
development of autoimmune disorders and recent studies in renal transplant 
recipients show elevated serum BAFF (sBAFF) to be associated with rejection and the 
development of donor-specific antibody (DSA). In this study we measured sBAFF and 
the receptor to identify any differential expression depending on the level of function 
of the allograft. In addition we investigated if the presence of regulatory B cells, 
thought to play an important role in B cell homeostasis, would also differ depending on 
graft function. 
 
Method: Peripheral whole blood was collected from renal transplant recipients with 
deteriorating (gp 1), stably impaired (gp 2) and well-functioning (gp 3) grafts a 
minimum of one year post-transplant. CD19+ cells were isolated by positive selection 
and stained with anti-human CD19 & BAFF-R. CD19+ cells for Breg analysis were 
cultured for 5 days in the presence of CpG-B 2006 (3ug/ml). Post culture cells were 
treated with PMA (50ng/ml), ionomycin (500ng/ml) and monensin (2mM) stained with 
CD19, CD24, CD38, washed, fixed, permeabilised and stained with intracellular IL-10 
and analysed by flow cytometry. sBAFF levels were measured by ELISA. HLA antibodies 
were assessed using Luminex technology and HLA Single Antigen beads.  
 
Results: Patients in gp1 (n=20) had significantly higher sBAFF levels than those in gp 2 
(n=10) and gp 3 (n=16) (mean values 1005.66, 681.74, 664.70pg/ml respectively; gp 1 
vs. gp 2 p=0.047, gp 1 vs. gp 3 p=0.125). In addition, expression of BAFF-R on CD19+ 
cells is downregulated in gp 1 patients (62.87%) compared to gp 2 & 3 (86.71 & 
87.54%; p<0.001). DSA with elevated sBAFF level (higher than the overall mean; 
>784.03pg/ml) or low BAFF-R (lower than the overall mean; 79.03%) were only 
detected in gp 1 patients. Furthermore the rate of graft deterioration showed a 
significant correlation with elevated sBAFF level (p=0.004) but not with decreased 
expression of BAFF-R. In a smaller cohort of patients (n=5) there was an increase in IL-
10 producing B cells in gp 3 patients compared to gp 1 (1.09 vs. 0.27%; p=0.04). In 
4 
 
addition these cells were enriched in the CD24highCD38high compartment (gp 1; 31.84 
vs. 5.18% & gp 3; 30.66 vs. 5.51%) 
 
Conclusion: These data show that expression of sBAFF and the receptor correlate with 
deteriorating graft function suggesting an important role in regulating B cell 
homeostasis. In addition, preliminary data shows cells with a regulatory B cell 
phenotype are associated with stable graft function but further investigations are 
necessary to link these cells with down regulation of the immune response. 
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Introduction: The B cell activating factor (BAFF) of the tumour necrosis family is 
essential for B cell selection, differentiation and survival
1
 and therefore an important 
regulator of B cell immunity. In animal models, it has been shown that excess BAFF can 
lead to the development of autoimmune disorders
2
 and that BAFF is upregulated in 
patients with SLE
3
. In renal transplant patients, increased levels of BAFF were detected 
in those treated with Campath-1H
4
. However, a key question remains as to whether 
the dysregulation of B cell activation could be a contributing factor in alloantibody 
production and if aberrant expression of BAFF correlates with allograft function. Given 
this and the association of B cells in renal allograft rejection, we investigated if BAFF 
and its receptor are differentially expressed depending on the level of function of the 
allograft. 
 
Method: Peripheral whole blood was collected from renal transplant recipients with 
deteriorating (gp 1), stably impaired (gp 2) and well-functioning (gp 3) grafts a 
minimum of one year post-transplant. CD19
+ 
cells were isolated by positive selection, 
stained with anti-human CD19 & BAFF-R (BD Biosciences) and analysed by flow 
cytometry. Serum BAFF levels were measured by ELISA (R&D Biosysytems). The 
presence of HLA antibodies were assessed using Luminex technology and HLA Single 
Antigen beads (One Lambda). 
 
Results: Patients in gp1 (n=23) had significantly higher serum BAFF levels than those in 
gp 2 (n=8) and gp 3 (n=14) (mean values 1706pg/ml, 675pg/ml, 774pg/ml respectively; 
gp 1 vs. gp 2 p=0.04, gp 1 vs. gp 3 p=0.02). In addition, expression of BAFF-R on CD19
+
 
cells is downregulated significantly in gp 1 patients (60%) compared to gp 3 patients 
(73.7%; p=0.02) but not gp 2 patients (69.8%; p=0.27). Stratified by HLA antibody 
5 
 
status of study patients, donor-specific antibodies (DSA) were only detected in gp 1 
patients (DSA, 41%, non-DSA 27%, negative 32%) compared to gp 2 (non-DSA 14%; 
negative 86%) and gp 3 patients (non-DSA 21%; negative 79%). However, no 
correlation was found between the presence of HLA antibody (DSA or non-DSA) and 
high expression BAFF (>1223pg/ml, the overall mean) or downregulation of BAFF-R 
(<68.3%, the overall mean). 
 
Conclusion: B cells are increasingly recognised as key mediators in allograft injury. 
These data show that expression of BAFF and its receptor significantly correlate with 
renal graft function, suggesting that measurement of BAFF could act as a biomarker of 
deteriorating graft function. However, it does not appear that BAFF is a mediator in 
enhanced alloantibody production. Further research into B cell regulation and their 
dependence on BAFF expression could provide important information as to whether B 
cell survival factors should be utilised as potential markers of humoral rejection. 
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Introduction:  
The presence of donor-specific HLA antibodies is associated with acute and chronic 
renal allograft rejection. In an effort to minimise their damaging effects, highly 
sensitive and specific solid-phase assays have been developed to aid their detection in 
patient serum. However, investigating HLA antibodies in serum alone will only reflect 
the presence of B cells actively secreting antibody and may not reflect the overall B cell 
sensitisation status, such as the potential presence of memory B cells. Although such 
cells are very rare in the circulation; a more sensitive approach would be to identify 
circulating HLA-specific B cells as a method of assessing B cell alloreactivity between 
recipient–donor pairs. 
 
Method:  
Peripheral whole blood was collected from HLA-A*0201 sensitised renal transplant 
recipients a minimum of one year post-transplant. Non-sensitised healthy males 
served as controls. PBMCs were prepared by Ficoll-Hypaque separation and CD19
+ 
cells 
isolated by positive selection.  A minimum of 10
6 
CD19
+
 cells were stained with anti-
human CD19 followed by Luminex Single HLA Antigen HLA-A*0201 beads (One 
Lambda) and analysed by flow cytometry. All cells with a staining intensity higher than 
the upper limit
 
obtained using the non-sensitised control were considered positive. 
6 
 
 
Results:  
Sensitised renal transplant recipients known to have HLA-A*0201 antibody (MFI 
>1000) as previously defined by Luminex technology were tested for the presence of 
HLA-A2 specific B cells. Using beads coated with HLA-A*0201 it is possible to show the 
presence of a small population of B cells capable of binding to the beads as assessed by 
flow cytometry. The data shows a significantly higher proportion of CD19
+
 cells which 
bind HLA-A2 beads in sensitised (n=5) compared to non-sensitised subjects (n=5; 0.124 
± 0.049% and 0.042 ± 0.008%; p=0.007 sensitised patients and non-sensitised controls 
respectively).  
 
Conclusion:  
This preliminary data shows differences in B cell reactivity in sensitised patients 
compared to controls which can be effectively demonstrated using a simple technique. 
This method can detect and quantify HLA-specific B cells which could provide useful 
information for predicating the B cell response to donor antigens and be a valuable 
tool in both the pre- and post-transplant setting. 
 
